var title_f35_56_36736="Gram stain skin lesion 2 answer";
var content_f35_56_36736=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pasteurella multocida",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of purulent drainage from a wound on the finger following a cat bite (x1000) shows inflammatory cells and small, Gram negative rods and coccobacilli. Pasteurella multocida grew from this specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_56_36736=[""].join("\n");
var outline_f35_56_36736=null;
var title_f35_56_36737="Thalamic lesion lymphoma";
var content_f35_56_36737=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F62013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F62013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Secondary thalamic lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 390px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This axial FLAIR MRI shows a large right thalamic mass (red arrow) with extensive edema and mass effect on the lateral ventricle, with an associated midline shift (yellow arrow). This mass lesion was shown to be a parenchymal metastasis to the brain in a patient with systemic diffuse large B-cell non-Hodgkin's lymphoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_56_36737=[""].join("\n");
var outline_f35_56_36737=null;
var title_f35_56_36738="Umbilical vein to umbilical artery ratio with SUA";
var content_f35_56_36738=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Umbilical vein to umbilical artery ratio with single umbilical artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic drawing shows the compensatory increase in size of the single umbilical artery. In the normal three-vessel umbilical cord the circulation is theoretically distributed equally in two arteries (left), resulting in an umbilical vein to umbilical artery ratio (UV/UA) greater than 2. In fetuses with single umbilical artery (SUA) the size increase of the artery results in a UV/UA ratio lower than 2.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_56_36738=[""].join("\n");
var outline_f35_56_36738=null;
var title_f35_56_36739="Atypical nevus";
var content_f35_56_36739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atypical nevus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clinically atypical nevus with irregular borders and irregular pigmentation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_56_36739=[""].join("\n");
var outline_f35_56_36739=null;
var title_f35_56_36740="Lateral approach to popliteal nerve block";
var content_f35_56_36740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F52188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F52188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Lateral approach to popliteal nerve block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 550px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    For the lateral approach using a nerve stimulator, the patient remains in the supine position. The needle is directed to the femur between the vastus lateralus and the biceps femoris. It is then withdrawn to the skin, reoriented and reinserted while looking for nerve response. Local anesthetic is then injected. A lateral approach using an ultrasound can be performed with the patient in the supine or lateral positions, with the linear probe placed parallel to the popliteal crease and directing the needle towards the hyperechoic nerve before it divides.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_56_36740=[""].join("\n");
var outline_f35_56_36740=null;
var title_f35_56_36741="Benzphetamine: Drug information";
var content_f35_56_36741=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Benzphetamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/35/3637?source=see_link\">",
"    see \"Benzphetamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F140159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Didrex&reg;;",
"     </li>",
"     <li>",
"      Regimex&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F140169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anorexiant;",
"     </li>",
"     <li>",
"      Central Nervous System Stimulant;",
"     </li>",
"     <li>",
"      Sympathomimetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F140163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Obesity (short-term adjunct): Oral: Dose should be individualized based on patient response: Initial: 25-50 mg once daily; titrate to 25-50 mg 1-3 times/day; maximum dose: 50 mg 3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F2697288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Obesity (short-term adjunct): Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F140164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15673300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F140151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Didrex&reg;: 50 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Regimex&trade;: 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F140137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F140171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10527006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer without regard to meals. For patients taking a single daily dose, administer midmorning or midafternoon based on patient&rsquo;s eating habits.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F140152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term (few weeks) adjunct to caloric restriction in exogenous obesity",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Pharmacotherapy for weight loss is recommended only for obese patients with a body mass index &ge;30 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     , or &ge;27 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     in the presence of other risk factors such as hypertension, diabetes, and/or dyslipidemia or a high waist circumference; therapy should be used in conjunction with a comprehensive weight management program.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F140167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiomyopathy/ischemic events (with chronic amphetamine use), hypertension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Depression (with withdrawal), dizziness, headache, insomnia, psychosis (rare), restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Skin reactions, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, unpleasant taste, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, overstimulation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F140155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity or idiosyncrasy to benzphetamine or other sympathomimetic amines; advanced arteriosclerosis, symptomatic cardiovascular disease, moderate-to-severe hypertension; hyperthyroidism; glaucoma; agitated states, history of drug abuse; during or within 14 days following MAO inhibitor therapy, concurrent use with other CNS stimulants; women who are or may become pregnant",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F140141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Amphetamines may impair the ability to engage in potentially hazardous activities (eg, driving or operating machinery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Primary pulmonary hypertension (PPH): A rare, frequently fatal disease of the lungs, PPH has been found to occur with increased frequency in patients receiving some anorexigens. Risk increases with therapy &gt;3 months and repeated therapy. Patients experiencing onset/aggravation of exertional dyspnea or unexplained angina, edema (lower extremity), or syncope, should discontinue therapy immediately and be evaluated for presence of pulmonary hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Valvular heart disease: The use of some anorexigens has been associated with the development of valvular heart disease. Risk is increased with long duration of therapy, exceeding recommended dosing, and combination use with other anorexigens. Avoid stimulants in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that could increase the risk of sudden death that these conditions alone carry.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; antidiabetic agent requirements may be altered with anorexigens and concomitant dietary restrictions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution in patients with hypertension and other cardiovascular conditions that might be exacerbated by increases in blood pressure or heart rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tourette's syndrome: Use with caution in patients with Tourette's syndrome; stimulants may unmask tics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anorexigens: Do not use in combination with other weight loss medications, including prescribed, over-the-counter or herbal products. Not recommended for use in patients who have used other anorectic agents within the past year.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution due to risk of causing dependence, hypertension, angina, and myocardial infarction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse potential: Benzphetamine is pharmacologically related to the amphetamines, which have a high abuse potential; prolonged use may lead to dependency. Prescriptions should be written for the smallest quantity consistent with good patient care to minimize possibility of overdose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	Discontinuation of therapy: Discontinue if satisfactory weight loss (&ge;4 pounds) has not occurred within the first 4 weeks of treatment, or if tolerance develops.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F140166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F140145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alkalinizing Agents: May decrease the excretion of Amphetamines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Amphetamines may enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihistamines: Amphetamines may diminish the sedative effect of Antihistamines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Amphetamines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethosuximide: Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal Acidifying Agents: May decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Amphetamines may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Amphetamines may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Amphetamines may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4092263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: St John's wort may decrease benzphetamine levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F140146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4092257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Benzphetamine may cause fetal harm when used during pregnancy. Amphetamines were found to be teratogenic and embryotoxic in animal studies. Use is contraindicated in patients who are or may become pregnant.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F4092259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4092260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Amphetamines are excreted in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F10527005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Most effective when combined with a low calorie diet and behavior modification counseling. May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F140156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Benzphetamine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $131.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Didrex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $263.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Regimex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $152.47",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4092270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cardiac evaluation (baseline), echocardiogram (during and after treatment), blood pressure; weight, waist circumference",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F4092267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adult classification of weight by BMI (kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Underweight: &lt;18.5",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Normal: 18.5-24.9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Overweight: 25-29.9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Obese, class I: 30-34.9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Obese, class II: 35-39.9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extreme obesity (class III): &ge;40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Waist circumference: In adults with a BMI of 25-34.9 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     , high-risk waist circumference is defined as:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Men &gt;102 cm (&gt;40 in)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Women &gt;88 cm (&gt;35 in)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F140157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Didrex (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F140140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Benzphetamine is a sympathomimetic amine with pharmacologic properties similar to the amphetamines. The mechanism of action in reducing appetite appears to be secondary to CNS effects, including stimulation of the hypothalamus to release norepinephrine.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abenhaim L, Moride Y, Brenot F, et al, &ldquo;Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension. International Primary Pulmonary Hypertension Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 335(9):609-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/56/36741/abstract-text/8692238/pubmed\" id=\"8692238\" target=\"_blank\">",
"        8692238",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      August GP, Caprio S, Fennoy I, et al, &ldquo;Prevention and Treatment of Pediatric Obesity: An Endocrine Society Clinical Practice Guideline Based on Expert Opinion,&rdquo;",
"      <i>",
"       J Clin  Endocrinol Metab",
"      </i>",
"      , 2008, 93(12):4576-99.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/56/36741/abstract-text/18782869/pubmed\" id=\"18782869\" target=\"_blank\">",
"        18782869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: Executive Summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults,&rdquo;",
"      <i>",
"       Am J Clin Nutr",
"      </i>",
"      , 1998, 68(4):899-917.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/56/36741/abstract-text/9771869/pubmed\" id=\"9771869\" target=\"_blank\">",
"        9771869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Snow V, Barry P, Fitterman N, et al, &ldquo;Pharmacologic and Surgical Management of Obesity in Primary Care: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2005, 142(7):525-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/56/36741/abstract-text/15809464/pubmed\" id=\"15809464\" target=\"_blank\">",
"        15809464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;U.S. Preventative Services Task Force. Screening for Obesity in Adults: Recommendations and Rationale,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2003, 139(11):933-49",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/56/36741/abstract-text/14644896/pubmed\" id=\"14644896\" target=\"_blank\">",
"        14644896",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8812 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D487AFE9F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_56_36741=[""].join("\n");
var outline_f35_56_36741=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140159\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140169\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140163\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2697288\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140164\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673300\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673301\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140151\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140137\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140171\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527006\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140152\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140167\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140155\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140141\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140166\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140145\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092263\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140146\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092257\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092259\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092260\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527005\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140156\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092270\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092267\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140157\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140140\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8812\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8812|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/35/3637?source=related_link\">",
"      Benzphetamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_56_36742="Pyogenic granuloma collarette";
var content_f35_56_36742=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pyogenic granuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF7AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDr7SzthHnHmS52Jv53H1HtV90RGBh/eJD8igcbn9fwqO25WRkDD5jFAc/d9TUwEbuvlvgbgse4cbQfmP41wJWPYeo6eMrBKiksYowGOOC7H/CuE8RM32SQKcqRsAxkjH+Nd2lyoMqmMFHZpSc8t2GK5HXIS8TjcUJyAD7daUtSqS11L3gGY3WjpGZYZZgquIiSfLA4OR+tW9etGhupHacnaPMAK8t6D6V594b1ttG1dklAMZfJ7ZDcHp1x1rvry9kntmWKCLy36Mx+YgHrWl00ZOLhOxm3F0bXWYym0zzKpZ2+4hxg8Hj0qLxjcRSWllM0jSyKxjZgmVIYYIVf61DeWyXiJIim4ni+bLnAx710n9oyPozwWdskjNbszyBVHl4xkKTz2og7aE1Fsef+GJJGt1ictsjcgA9eDXewtIXlJcZdgCV4U8DiuK0SeNru/wDNRGDSF/l6HPv69q6qG5W3kRCwIypV88EY4/GsnudHSxpSW0bmYSys/wC8CAKcce1RyWUTMTDGdu8oHY8YxUNvLK6RtGiou9ny5wMe571MHj8pVurzOFJCRrwCaWg1cmklebaWuAoYfdXjOO1QpbRoW8yJnYYI3fL19e9JbXjJD5Nraljn5pNuGIHpnoKinnvpFJ3rFu+Y4bk+lSUl2L228RVSGGFI3GPwHf8AOqd8SJQ15eKzDlgvXPYVUa2TaTPfSOT975uh96oSXFrAu3YztnOSc0czNYx7FtpEZlWKGSUgZPPU1FIHhUtKFjH9z1P1qul3vchC3UE4GAPxqleXsZl+f942cbQ2cms2VZlu4vCckHPPKr0496r2gmvZQIcAjLSSMM4HfNQRWsrRK965iiJJRM/MfwrQeSX7L5cAWCFiqhf4j7mmlfcG0tEV7KEQzsHIO45ANR+d9lmkSbJVumBjAqS+KQ3MZiB24wSx64rD8U3RNupjYh89fX0piSu9epBJtfVVfA2kkEmurs8XBUqNqLwOe1cHDdGe1UpxJkKxz93mu707BgTYuD0/+vSe4T8jTVtqkgAHPA6VYTeCVB6Doagt4mc5LD2z3q9sCkt/F2Pp70CuOSNl4yMnGc81ZiDiPHysox1qKJWA+YE+v/66uQspO4nIHAOOPwFJBqS26GQnCoQnzH1+tWJgSZg3zHIfJPWiHJgdiWYiMg57ZPyj8+anMQd3HTOyMfhy1UIcsX72VmDbVkXHHt6VGkJeLIOAUcjPfB60sjNu3pwGYykt2H8Ip54twytlhHt2+7UydhUg5UdiXPPcEDNJ5YVDuOHRY2U+2cf1qVnVZBlsNHAQQf5UkhP73nKpCiliOhJpoH3I/s+6YtggrOV3AcgNUBaSMR5J+WQRyD+8Qcg1oOA7XCxMdxmjXPvSSxZ3goCr3IHX0qiblSFts8YY/L57qCOBgjIpkW6Q2yYLDa68dDzTljzNtLZBuDjjPT3psbBfLUtjCyOBjGOaTdgepSnKpZxlgM+SceuScYpt4G/01Ax+VY1I9RUmGeNiqAYhRCGGRy3UVKIU86cgEhpmxzxtVe/41IFO6hMiPPCArZ3oezBBz+tUJ23XcVypAidPnYDOMnn9a14zvSFBkRJaEEH1J5rMaPMN3aEcwzgqfRSAf50yehxk9nt8Waln/XyRgxYHO7P8jXoejStqGiWs8pYmMeW4DfMT2X14ORXBaxcQx+J4rqRd6YYDB+bOOP1FdDo929jfTRSfu4ZyJ0PbY3J2++cj8aqL3Jqxvr5G7AVe+EbhCANmN3XuRn1zVm8uGhgRj/ECFG7rk55+lZ9ncKXWfAQLulJJ7+n8qt2G+6nO8BVYKvLcjPb+tUQT2MJ+zErlt7r948N3Jz2qV1IUAkrB5rsyhuTtHX8+9SRowlhLgCL7RluM8AdqRY2uRB5rusLyuBt4Lj/Din0C+pmXe57Ysg2iKIKSDySTk1X1GJ7O6Webbh08x0Q5EfQKTWndBZoyVABlnCKqnsPb8Kp3YaR5Y2G5Z5BFn1CnqalouLIUl8hTIy8wxEr6F2PWiQeVHMuSXit1iXsAz1XiCiYxSmTaz5GOhQHtVqHdLOPPO4Evctt56DCg0l5g0VCvliZEyWQJarnryPmNWAVaYSEMUlcLtPAKJwP1piwyAQjP71SbiTI9qsW9qot0QBi0zbUz02jkn2yaEDMp4imqHBBdozuAHqefyFatvGonniSNt52vuUdV6YIrNdpBqzxMA5MbITnGTkZ/Kp7e8WO5aIMxZ0KyqByFHTBpx0FK5burqU+WwO/aSkEfYj1Oaz70xRymPzGGOZmJxlj/AA0l3cTyWryR2+yMgrGztkxj1x6msu6eFGhSZyVQfPzn5v8AGhshRE1G5RbaR2QPNImIogM+X2JPviuYgjl1W/sbdVcxKfNnyMqwXgYH+NaOqakYxNJbROLpRlnXGAMYxiofDG5dPlnkmaKW8I4GQ2ztg9Kndmq92N+psXeqxzqUYnykYNIpb73HCjvn1ptxPM7oERxM+ArONqxL6e5qeG0hhxiNXjhfK4Pzuzdi3rmp5yzNKrqxZMM2Ow7BT6+tU7sUbLYyZ7aXf5NzLiFTwkfO5j/F75orQaKS2VRIqR3Eh4D5PkoR1x70VNi7mlb3BDDBQuARGvX5m5P5etStPFC8igqGI8pMt2HU1m2pIcFiY1jUknvzS27C4uIVtYTPOFZjuIIz6mq5hOOpZa4JuoZYA4iIEZGOGx7ms+/jZxIzYLEOPrz61blDrHas8is27JVT9361QuGIWXj5UkJ/CpbKjG5xOt2gsriO5kQ+VjD5Pr/hXT6NeW81gkk0pnu9uwYBCADpx9Kh1WMS2bLPhhnGCO1crotzLY38sUkhUPx/vf4cVUZWQ5xc9Ttbqby3WQFOm3aBwfwqTzZDGEhjLwOPmLEKoHqfYVlzP5kDLwO4x1rP0y+M0U0G/Hl54z2pc9ieS8Svp8iQ6zcp54lUH7yDapx6Z611drMWJACsm7IyOnFcXbW5l1sO5wMZCjoR7111tHtICep+nNK92XJW0LYkZhjcXwdpx2H8qnjvUijkRBGjkgdMnj3qlF9njJN07SndyiHAqSPUItzG1tACpPbOPalqSidbmWV3KJNKzHbnoKe8c2C8ssUSlgMA8jFRyS3kS+ZcI8MO4AlCoP4VTae1UxtMJHPOdx4NJmiRJJcWduC0m+VsE4J4zVUzyysRZ2h/vdOAB7mpDMRGskcASIDduZev50wyz3qZiV5hGvJPyoPYmp8ilpqQG3lkYi6u8JnJ8vofapYrVEcm0i5Q/NK/b3FOkkjiLNcv50y4wi8Rgf1plzO0gUyOBGM7Yx707ESm3uLFPDbzGYuJn3febnH4VQlvXaQSHnJJJqjPKm8jOGzzioXbapYkE56VLNVHS5Zvrxim5vvZziub8SXrNb4VueMe1SajfMAyN8vriuT1y4JI2tkfWtacOYipUVONzpvD7fbLq0CRhUYYf/aI5zXqFuqogAALYFebfDyJ52MzAbQMcV6fap8ucYPAPelU0djKErrmLNr8rxggHPOM/wCeKtqoLfKSVzyfWohEARgcDA+tTRBj2yoqDTRliJcqNowv8WT29KtCFkXfDkDOWJGBj2FRwkFgRtJHc9BV2AKU6bs9SxoQ2yKBnIBj5UvwDj5m7Z9hV1giwl1Ztv8AFzzj+JvqTxVdokeQmI7TwrNjAx6Ad6likk3jKjzAc7T6ep9sUxPUJMbT5hGzO5h6L/CKcuOFmy4T97Jt7t0VaVYIx88YLLJ91XPLOeM49BUcTLtlWWT5YDl27SN/CBVITJEJkhIcA+Y4yT1znOfoBQhaRowvPnzbhkcbV71DFI5STzQRcsSoUcCNe7UsMbsFaP5Ny7UDH7sY6t7ZpAy/AwBjeRsbnaZh32jpSF3LWQZRy/mt6c9BToVadAxGDNhFXHSId/xpJ3DRtIwypJMa92xwuPpVNme5UeSIW0Rk4yZSDnGT0GPxqnc4UNEzElYliUdgxOTVp4RFPbq6pttYjK+Ou7+tVlBVbdSwBIe5YHv6ZqS0NJLyqePLeYKuDgFUH+NIxItjgksImf05Y4qOPP2U7TkRwFhx3Y9vzqQAlxGNxZnEe32XkigGPCOly6OMwyFYmOMYCjJFZs7bdTPD4uItx/2iDkfpVuWVnt2dTkPu/Ascc/hVHWSEuEZG/wCPdznHIwAB1ouQkcJ4/It7m3mBKqhVicfdHeuosrXzI9PjaWH90rhH3ZDKOdp9uc/WsrxpaQTWvmg5bB46qKk0Xz7qysllX5ABKM9XA4yT6Uouza7lyXuxkdNpyt9t3H/UkjqOMdia6pILdIYsLu+Vpj/tfWse3jBtFZNu9sZwOpA5/wAKu2ztHHPHtJCoBu/ixn7prZaHPIdCkheJWiZ0ilb5c8HjNTwskbWxGcpAzn5sgZp88K77iSJj+7TdhflwW61Bc7QLgKhZSAn0RRk4/GqJRCwVPsyuD8itOSy8k4PIqiqGGOAhcbIWmJ64LGp57nETvMzNKI1jQZ3BST2/A1HcRCOG4++Q7pAB7Dk8etZtlooyqZEzEwUwoELdN2TyDUiNvWX7MxHmkRKDx8oNQSSJF5qhS7Id7KvIDnhV/AdacYDHHIWXBWDbGobPPc/WkW/MmuHCxTK7ErIMZzyFU85/HpVe7vZGMUjb0YrtQP8AwjPLcfSlSFWiAhLoCPnJXk4GcE1FOi+RaMAxllOQB1Pq3sKYtLmOjM2uiQuh2RuwUEhTketa0cgs7grGih2AYsp5UD1rKhiabWLdUBQyB9xIxhQOOPbFa0dssF1L5+Z5Xjx83Xce35UovQJkDtc3ckssER2EFUZug5647ms9rRYJXE5d5UOFjUYLvW6808kbFUQpbrtBBxl+mc9yPSsPVJ1gt5XMgEisU3dz/fOf0ptWIT6HMajaz6nqUGn2ilJbmQRbd2MD1J/OuqFosMn2jassFsRHFGR8pbGD+HFY3gmN59VutUdcR2yeVEMZySOSPfFdPp85jt/JuI0aC2JK5PzSO3I+pHSnHa/cc2727DVspEc+T800cZYHaAiMTnP5dKaFjRM3DMy8GMN1kb+99BTmbbZvEXU26DzHGPvPn7pPpTSGRYSf3t9cnEcfaOI96GMhuI0m3+bNuQKJLhyeS39xTRTX2JEIt+VhPQfdJ7ux/lRU3HdorwW53KLhmWNiflzjI9aZNdtBGojKqEG0bRg7T/Oqf2iWWaN1SSX3HQD61M0NvHGktzd75Cx/cwnlR2ye1JLTQv1JHLyJIedpxgn1qvJON+5264RwOxqpJcpvAyQHOAvoajnil2u0iiJSRlXOGJ9cUkWmkOuZ/OOMY/hY/wBa5XV4hHOs0ICuh5NbUkqxTbZWLdiOxHrVHUyrwMRtIHHFVYtSSehJFdMVQ5bBXrWFcXLWGo+amQW6j1q1DJmwBUj5PWoL5RdWYZhtYdx1qlC5k522NVWD3sMqkEvgHtgV0QmBXOdx4BHavO9I1AiQwO4byzkE9a6+3u02buMEDIzS5bE8yZorKzDoFPPfFOa9YAq0pUBMYQAcVlzXChiOxNV5Jo3TAcKF4JB5pWLTNmTUIkJUKNxIIcjc34Ugum3xSxwSqS3Esi7j+A6VjR6s0CFI55F2/wAMYGTVCS8nk2iWd/LZs4zlqfKwuuh1lxqMCZe5hnmdF4+0vjB9gKWXVpryE+a8VrZsoGyPAz9FHJrkhqkMErlEd8gjLjJ/Gq7auCAxUK/JA20OLFdWOmubmzRitqHkYqCZZTyPoBWa9+pZtrcgZrCl1FSPmYn+IDGAPWqz6quDtCoB04xRyD9okbj3ILksQSfmGD/OoZr3glcc8ZrAfVFB+U9etQfbV3lmclewpqkwdaNjXkMe1mkJLVzmpQxHzHOAcZ47GrMmpA5x90frWRfXZdJeQd38NbU4tM461VNNHp/wytTFokTkYMhLZ74r0ixULCoPIHJFcp4Mthb6RaoeGVBnNdWmdpIGDjAGa5ZyvJs6oK0Ui42fswIXALcHuTj9BUscfAweOBk9BSyt/oEAOPmYnA+nrUkROTwP61DLQ+Jdu7pnPGeT+Aq4QQcttUern+gqnEhUZIYD34zV2MYDKSqNkHOOPy6k00NjkjeYb4yVmAwrNxkegFCOrA/J8zHDR/xFv9o9hTwpWdWjyASPnbhvw9KluAk7Y3hJM4LRgsW9iaqwhkhCkESKrg4eUDp/sLTJ1kkeKaFVWZeUgI4Cju1S77iBY/NAgt84DImW/WhlXaxVWETdRuy8v19BQIrWmxvMXcZEZwzD+KR/7v0q822Qu0nEf/LV/wC96Rr6iqcsLKouY/kG3DYOMr6L3/GrFvIJGjaJVLKMRQfwxj+8aFvYGXQ5XfG5CyMoMzDpEnYVGZUeaJzE29/9Uo/hUdAfTNQpIAmM+bCHwx6GZ/XPZRQjS3DukbBVlBM03YKOy+3vVMjl6kCxM6bZADJcuS5DcFR1596iZRLHcyorEzEQR8dBn+VTXLgLvLbVmxFbgjBSMdWqvPcbiqwhkhiXy02nkknG78fepvYtXtoNvHH21oY+VVlTOMD5RyPzpsbGNVnkyZdjzAeueBmrdnakwQ20khZTIeQfugZ3c980yfZHFKzZJuI8Kq9gDhadtBX6FFtruogw+CGYZwpCjJNZcxaSB0C8+UWJHA+Y8fjitNkZg8SfugsZijBHPJGf61Du2ibyipRfmO3qQox/OpHscvdW63GnOJE3nBiLHoxFX/AU0Z05ra5HmMkTQszDO1Vbr7cGi6gFreXMUgALrujH3gWx2+uaq+C4TYXsiXiuI3l/1O7GFYcE/iKUNwqfCzrNGG25VpgVjAMoyMkAf44rTePdIXYvueRG7DhucH8KzVcocx8tuILY6g4BrXZHKySzssUbMSAzYwAMDHtWyOdjV3TSB/MHl7w7KD2BwPrTLsefMpdtkJlk3MT1XuPTHFQxzyMwFjEZOeJDwMKO341HLaqVWS8leUGIkgEAAn0FVcEhqXCZ2WsCPljKSeBgDCjP61DPBJO0LSTBn3HMYyPmPJNTTSwQrGWXdtXCRN1+pFQRi6Lu6xMzKhUyE4Adup+uKzZaIorZEZHdcRkNIyp0IHA/M1PdEpbIFCvIXA2gcZPY/SlRNhKSv5gVQvy9AF9/rTvIJM5jAUpH5jbzgbm6CmkKW5nX0MkaOVV1WMeWSp5IPVsVMFghkhmjIaKOI/MR2PQj39qvGMSSeVuMca/fOMfKOWP1ziqcEZaUW8bhUkzPzkqqj1+vWqehL1Mf5jrenoi4ZCYxkYO4gnrWtOttb6ikxLOLYZmB4+cngYrOZo08Q6YZ3OSGlkcnA3HP/wBap7q4t9zRMmcTfaZHPzfKBwKiL3KlrYWS6ncrBFDztM0m4bVBPQn6deK4PxVdMFRIXd2ZjHExH3lz2HufWuj1W9d43bbjefNlG/A2nhVrnvDds2ueJ2uHj/cWn7xhjjd/CoHqKTfN7pUVyrmZ22m6adI0aysoY1kaNg7MR9+Vh/QVb2hViii2fuSQHwTu/vOaeH82eWS3YuEyEDN827GWb8BxVa53x24km+WJ02nBxtUZwufU1q9EZLXUito1QhCjTCRzJBEOS4z1b0Hes4M1tuO9WvLl9iE8hFzz+FSTzuE8xz5cjr+/cH5kjI4X8axZTLqrP5X7mA/uwwP3V9vc1k5GsY9ehMzrd3Jt7XcbWI4d1/5atnrRWraRpGFiCrFFFH/Cc8f4mikkluNt/ZOZu9RurxWVVdlACARLhc9hnpUJt0iZGv7gJtO0wwfM359Kzpr+J4DHaRS+UG4LOcD+lUp51ES+bMAd5DIgxt/HvWlrkc1lZG3PrFrDAkVlbRW+V5dvndj65NZUt/LPLxlmx8xZuvvmqC6lFbo6W9rCZD0kYbmx7ZrPk1FI2V3YSP0x6iq5Rc9jVuyu0jzi7jp5Y+Ue2e9NUsyc45GMelZQ1BZWIZliUZKnOSfbFVJ9V2qCvHGMng1SgS6pqeckKSxtx6isKLWGj82A425yM9apXV+7sGY8nqBWRdbjKrgkZPSto0jlq17LQtQ3h/tHzEwFY4rqrfUgsYyRtX1rj9OjUyyRzjcr8gjqK0lUAku6g45JPUdj9auVHS5lTxPLozqhfRuMsScDp7VTnuFyCoAX69aw/tEYQKsh3Y7DrVRr1IzgzDcOmRUqgbfWrG/NOGYMoVRjGVOKz573B4m4z03cg1iy6hAQQ7sxP908Vnyajb/MpRuvpVKj3IeK7G1LqrCTictIeOvWoG1h0bYZCu3qeCc1hPqUeMeRnHTNQyahkcRID2zzVeySMnXkzfOsF8fJwD1Peqdxqshb5I0z6nnFYb3spOMgfhUTTO33mquWKM3Um+psPrE5IyyKB6L1pG1m7ySkuB6Y6ViBueaeJKViW29zTfUbqUYeY4HOBxUunCS71G1iaRm8yVVxn3rLRs10HgtA/iWy3AkKxbgegok7JhH3pJH0jpUapBEAARt4/Ctq3jLAYIyKytLDeUmM9OhrctFaNcAMwryWe+tizJuKxxMDtGSOOOasxoACMtkdAOBVdnG8NkAYHOcmnSTfMNx4J4JWpuapXLcQyS2OPY8mrC8NnhW9VG4mqURJA+RTgcFjj9KtQtnAJTb3AO2qTBomAG9GdFX1MrZJ/Cp3uNsIDSEJu+TYmA3071XLKAdn5Rrk/nTQjjlVEbHq8rc49vSqJaLHmiKPczLCnG0uNzmkXcWLWym2ZuskpA3D2FRiVIpnRSoIOQV+djQ5YZaLCO4wC3zOfw7UEj15UnASTGDJMecf7K1DKgtBmPeY5cb1J+aT/CpTE7bWYeXLz+9dsvj0AFQxlUyH+WU/eeT5m+qrQMWbzbpo0YAK42pbxdcD1PYVKfO8tolCJtAWZxghQOig1Daq0ZlWFzGj8Ox++w+vb6VaRCIlWKNt2cQQdTnu7UIlvuVpIds25TtkdckyciNO5I7Z7UkKI8sMEcRBZtyqBjgDhj+pqwLQFSJH3tnM0oOdx7KPU1Fdzx7nEhCSFcMephT+7/vGq2BPoiY5MINuHEcv7lXLfNsH3jjtk1WlMcJdrgq2WDqehCL90Ae9RPeGZVjtk8sdgOTsHQY7e5p8VlMrebI7M8rBTkZwT6ntx6Um77AlbcoeZNI8ckn7tPmlYhvmI7fgKdgQwKCECJtVsdSD8xJ9fSrF5LFFA6ylj5knlrtOSI164+prMxJfyyPKQsQV2KE4P41LK3MvVnaSW2uImZUhkXc7D+8ecD0xVi3ikh1oGY5EqEnIzna3Wk1xoxYTRrxJt6AcKDzj8qrwq7waTdXDhlkAVQRxyCP5rSWjFLY6Z7xpEEUUYfaxAYDnJ7mrSW/mMx1RvM2EL0+Vcc9KgVCZYjbkRQRrvwf4z3qytvB5ILySMxjJMa5+cnjmt7XOe9yKa5VFMdpGz4Xkr0DHpz2qIwXE7hrshY1YKY4j2A6Zq5K6QQsWOxSygpt6ADk1Cd0qrPOyxQujSBB19F/E0ml1LIYhCyyNZxn944RS4ySfY+1TzuVeOK3d/JEwXc5yWfuai3/ZpWlw+y2TaoA4Lngn9amjQwxpGODHF35+dv5VKVguNhhVirDezzSlST0VAcnj6itDy98UQdkQ3TmWViOdo6A+2KqyxBVeOMKWRViBBzkk9fyqzPLHJFeOpYn/AFEW3uB1/wD11aIkZt4hkcP8pN5IRvLY2qOn4YqnI8kd0TbFIpnfYqqP+WYGG4q9cGJ1uTIUEcUIjgwcbmPf61RmtW8mVYQxe2CxGTd1Y8kj60mwRmBdviOxdgH/AHxAO3qqrinXYQ31+mzZHcKqKCvIxyf51GXik1nSHLgKBjGSBu5o1yc22pQGNlDnKbuo+bqR7is47Mt7o5rxBqDPaNEBzLISExxgYCj3rq9E0xvD2hWkESq17OBLO5GWEj8BQfYVz2mWD654mZpQPsOnYdm2/KpH3Qfr1rtUl/eSTSBhIi74hjKgk45z69qqmt5CqS2iiGYRxghExsxHukHAPViPXJqtdyeXL5t2GJgGX3kH94fuqB3xVi7eK13GZ93lL+7UdPM6n8KypI3uts02EtF5APWU/wB6nKXQUUZUsVxqMbJI5js926WQ9ZD6D2HSrUFqqCNcZYABCBxx0wPbqfWraossqxzAhIxukCg/UL7cVdtj5yNLICZG56DCLnjp3qUurNJSdiKC3jaNpeTGjbjuH337fgKKuWuAmZ0JtyAxQZDccZPpmiqM+Y+exqR8rYz4CDp1IqjLqY8xucnO7PWsY3IErY3MG+8FGfzp8yoF+YKpPIyef8K7o0GcEsQXJtQZ8dkA5J7VWa5BO0fNjqPT6Yqr50IjKz3ESjpgnr+VQyX9kpKpOQD1CIeK0VJIwddl9GmOQw27Rxzt3Co1QySHYyN3zuwD9apHWLKJ1Mdu8gHdzmkn8QRyMMREKOirgYq1CJm6jZfCMX+ZkC9xGOlKbRWQ7WyT09ay/wDhIAoISEknuW60xvEDKf3UAUd8v3qtCXJs2PsixBZHY4A4PcU6WWIRlghZT69q5qbWrliCmxfoM1SmvriX/WSsfai6J16mzdTbCxTZgHg+ntWVNd7iTxnPHFUi7FiSxJ96QtUuRauTNMxXHTNRFvXmmk5pmTUjH5J600seaM/jSUAJupM5p4XP/wCql8pyeFP5UWC5HmlBqZbaVuiN+VTw6bPI2Ah/KiwnJFeMjOO9ei/DHTo5mnupATITsjx6d65iz8OTyDLnaB3Ner+BtLFrZQxqANvXjk1hiJcsbHVhIKc+bsd9ok7wRlZu2BjNdFbyOcbQNp5HNZFrbxzRBXQ+vpmtK0PkAIEwvTOO1ebbU9roWvLYgsrY56URtt+SbMgPqcVPE5KDZzj0GKHBLdR+NHLYpO5G2bUqrlDG33WBzV+KYNGACuP9lc5quIYfKIkAbI+8R0rOeaSylw0xktz0CjkUtmXo9Df88hGUGXHHyqNtPCu671t1UA8GQ7jWbHceYisodiOOSTmrcUpACPHsZuQxYg1aZD7EwjkCtGGw3UhExn8aRPNj/wBWhRu+WH8+tOQQbdplJJ4OXJqWB8AhEZVJ+9gLj2yadiSKS2l8v55Dg8lFJVSPrT7WCN/mTdI+cbIVOTj1J6VOU3BjIVKfxfxdPVjVaSY27t5bIRjMirwH+vfNGwWvoi8lusumyhgA6khlC7tnv9arWVykWVYMGYENjlnA9T2FQLO9xF5YQpH/AAqgxu/Dv+NPMaWxDfLhsA55Cn1/+tRfsTyW0ZaWWWSPhfLRfuhTt2j1yep96zoYUJd2YiJG7E/Mf6n3NSzvJdEKDiN2yWPU44z9P0qJmAmSNULRIfnIbOfQE0XBKxYtZLaKVSvlmNPmYKOC2OEHr71Fe6hNKWS1XBAJDEc5PU4/QUsWnXEk3mT7UUOM7OWYnooxwKnmgj0wu6kb4seYpOd8h6AH2pq7XkTeN/Mx1tvKheaXJkUhMbskk9qc8Ab7VluIwiAqOOec1NdzQR5CurOqAhgM7nbqazbmd4YiwjbvkjuPuiptYrVle6dHspmcr50pdmB4wo4B/GsPR5jJ4cuonlAazulljQqSRg5xn05rdvLV4kKCWOSTCwDaM/LjJP4VxulXnlT6xZwxTTXE/wA6xIpYg4wT7Din1Qmm4ux6MjmS52ABw+189Ai1oJeGRtlopdj8mSPlUDvmub8NwyXVlFd6jIGRE2iJCcg/7R9eK6m2+QHy1CxiPeUB49h7GtFqY6IjisCjJdXDm4uPmZAwyo98VKsBKRMxU5ImcHjAz8o/E1oLCyRFUdfMZFXcAcgn0qveIYnaQswjAIUdMgcL+OarlQ73KrBrmdAWVRPMzHA42J0/lTUcpHCrSbpjJ5jFh94AnBH4U59w3L0lVVt4+cYLZyf50soEkUhVAq4EcWBnK5wT+JqQGiaRTHKxVnYGYbuBycAGp9hRHjQhiqLEGxj5m5Yj3xUcW2a4ESjcu/8AeDoNqj/GlL7IkJkKkqzBQcnc3A/SmiWV2SKdowNzK8hZWI5EcYwP1rP82WOdEmH791LFeg3NwD+VabmKQxR2zGWNsRxqh7Dlie/JrJ1lt4aVQSysZmBPQdFBpSVhrc5yctaeIbNIyCTNkDnHpTfGMwtrZ9/y3Hms2xDuCDjFS644XULKSSRFlV4+F42AnGKbqcNrceJLXSY41MfmmeaYsSxUDIP0zWUVujRtXi/U0tEtJNO0aK1YFbm9bzJto5wecn8O1Xpr6OxtF87JcOXZSvLY4Vagvrtpr+5EQdpwiq4Xnb75+mB7U+2sWa6ErkSTAbVVl4Ud9vv71r5IyXdlP7LNPIsl2VQxncEPzBcjJY/pxVtoJEObg48pPNZS33snj6fStCGyWYwIudjv5hHbC+v1NRShrgg45uZuo7Kv86nlSKvdmfCnljMpfen72Q45JJ4B9auvHtQGRVWSQiSTaeijovtmllWFrh/LG6MPxj70rCiUn7J5SLk3DZYquSAOfwweKB3Fy8kwllBHmDc+TnGOg9qKjiwjqA6yzOdhIPGT1yD6CimTY+NJb64fJ37fXaMVWd2f7zE+mTmoy3bNML8V6jbZ4diXdz0prOCagaT3qMvmkOxMW5NJ5lQFgPU0YNIZLv5ppc5poVj0BNTR2k0n3UJoC6I8k80mT6Vq22iXMvRSBWzZ+FZGILdKZLmkckAT2NKI3PRT+VeiW3hZVHKE/hV1PDgHAizQQ6qPMFtpWPEZNSrYTsOExXqA8PAD/V81Zh0BR1TFAvbI8wh0adwMqf5VoWugOxIZenevSo9HXuABViHTo4255FBDqnn8Hh0cZWtCHQBn7ort/sseRgYqZYEXooouR7RnHxaFx9ytWw0DfIqhOtdDHFu4Azj0FZXiLXBp8L2lkwN2ykM4/wCWY/xpOVhwUqklGJU1BIjerYWu0rGQZWB/i9K7fw9biBCQBjAri/DFgzhHLbi3Un+p716VpMSpEoA3DoAa4K0+Zn0WGo+yikatsqOpLjacZ5PWrUbKjlWB3dMKc0yKIxBA3zOeQOuPf6VdigCSKSgyRjcp61hc7kgSKQ4579DVwQZAOwccYzU0adsjJ6q1WFOFOwZOcYPUD2NKwrmcbVgAEbGc8ZpyQqEO9A57g4q6gaVzhs4PA3f402aHBDNgd/uDFFkPzM8ReS4khZtx5K4IwKuLF9rO9tzMOxOafuReGIPsE7U9SFcPEshYnGxQQDRYbY21hktnxHGXUDJJyOParhuUJDKm5+o+Umo1WSeNcom09N7En8qe8DxliwaTAwFXC4P9ataGW+41klclmAjL4PzH5m+gHNNaySPcZhuBGMt1J+n+NW8DZvIKDHJj+UfiaRU8zBtY+OnmP3PsOposmHMzPmzEBlmAA6j7309/wpsRebY6ZJBAHy559PatJLXyG3EM8xz97qfc+lIbYojSxShCPyc+gH9aOUfMQxwxxMTejK/7HQH09zVuP5ZNqxxq20MAGwI09f8AepkUq3XyEBJ0/wCWR6IP73vUSeSreXLDtDnMZJwJD2J9BVLQykWZldCksTNGIxny87gSeAcjuaq3AlR4wGjlRSY1Zhj94eSffAp8iSW+PIZpUzlF/wCekp/iHsKRhhxbLyGzEGJ6H/lo1DZBTcJKqOEQBiZAI/QfKin6mqLBQVWVOA3zZPGFGT+pq/evCCzkDJC4KcFRnK/ko6e9ZXmhTsLFg3DAc8feNS2aRKNwrtbyxKOYwQq+jOetc5ogj0vxVIqpJJLcRFMKcAMD1J9OtdI9x9lvRLMRiZd20dNx+7XNXFhLd+INPRC0Qlk8reOue4H1zUXs0zS2jR1Xhxo/tEsM0mIFlMgYn5cE5wf1rsbVDPgiPYJHwox1X3NYFvYwWEsC2qOVJZDvG4O+eozXRxgyNGUO0xIzHkHJ6c+9bxVtzlb6ocp2ICqkvuLhTx04FQMAquACylh83svJ/WrwQLH1fcgC7sE8gZ/nVa7iZoejFyBGoGO/LGqYJlCcbwu1W3bA7N1JduBn6UkwiW4kRiXEWWO3I2hRgD86sRIkkqAZPmOX56lUGAfzqGCCKSGOAkncxllf+/zwGP8ASoLuRYKyERHcY4wCg6Bj1yanjitoI2YIZJYU5c5PzHgYqfd5zxR28QRZHOCBxtHU/Ws+RVi8ryVPlSuxcs3UA8Z9u1PYTEu45IRKgZSqgJnOCWbr09BWVdyJNJ5MUa7JXESYHG1BnPvVy6MVuIncKxRGdwGzvY8YzVG+Y2ksahVLQRkouM5Zx0/z6VMnccVc5LXXM0NhJMqnMqq+xstgNgZ98Ve0x5L691O8iUST7/s8ZcZCIvOT9e1ZOpRm4hliULmOSOdmb720sAQD3Fd7rMdraX/n2aLFDIqwtGpwGIPy4HsaVNbsqq0kkZ+j2qWrkedkSkebI4+ZieufT6V0FoqxoTt4SN5Dj0bgKKgaGTBlaMR3MS7QVAbJzjkd8/pT0mdHMLx7XVgdoOd2PX2rRKysZN3J2j/dykk744VVFxjk4yP1qG5Rh5vlxfMoW3XgHDdyD61c89JIYnn2iRnMsjbhwB0BNZ4kk8oOqlYBnauect39TSbBFTJFwkcQXacxxu2BsI+82amW2SUnyfMxENinP32PQYp0gNs7oVXdAoAA5yx5x+GamiZ4juBKSJhIVA+8x5LGkkU2ILVbVJSVXEKfZ1JGSzn7xH54oq+0HkMhcM6wEKuRkNKep/8Ar0VViec/P0tk03JPGK2IdHlcfdOfetO08PszYZcfh1r0DxPaI5VYnY9CatW+nTynhTXeWnh1FHKZ/Cty10NVAIUAfSgzdY86t/DsrsCwIzWraeFwM7wT+Feiw6ZEgBOD+FWFtkU8KMfSkZuqzirXwzGoBEfP0rWttAjUD5B+VdIYwOVApw6YNBDm2ZcGlxR/w8/Sr8drGqjao/GrIGQMCnBSRxQTch2YI+UYp20dcU5him5oADSDpzQSM0m0twOaAGnnpSbT+PpRK8UClp5EjUd2OKyLzxLZxkLaRvcv69FpXSLjTlP4UbSRsSOKrX2pWNgp+0zrv/uIdxrlbrVNWvpNjn7NA3RY+OPrVjTvD7Sncw3ZOcmsnVSOyngJPWRFqXiO91Fjb6ajWsXeTHzN/hVSzs3jjkacF5WP3m6t6mu6sPDcYhJZQfQ4wK1rfSLRrVmmRnmHAQcY+tc86t9D1cPh401oij4ctVSzjlc4XOAPU129om0qRgknABHQVx1k0n9pqJQMDCCMDhfT/wDXXcWDBUkLMrPkgDt+dc7d2dvLyouwIFYndyTgH1q/DEzOTtH+56/SqtuVbaeNoGf/AK1aUQzjHzDqCOoFIu5Lg7DkEoOcHqpqSNNwO7bj0PRvx7Gp1ACmTAHOQe5Hr9KekfUBFVzzhhw30piKsn+sUfMgXtIMj8DSBBhSmzOez/0qzGCV3bnRD2bkZpThUGwxs2DjamaB3sLBAdxyW3DLHBB+lTgHesao7YXGC/J96rl3MKgkuWO4jIVVA9amjmCwlgMjOMJwCfTNUQ7seF8hz5W1HI4QDcfrSSlIQdzsbhxnaxyfxx0pg88oyq4jY/wxD+bGrFrHHaIArKkrcEqC7t+NNambdtSmbcsiPNnIPyq+Tn/gI/rVkMVVFYiDjq2Cx+npU8imE7hiLd97PzSEf0qJ8RkKvBb0BLuP6U7WHzXJjFggEbj1ALZZvdj2FNZFyGklAboZCPlT2FMETx58vIY/M8Oc5HuaeJYmRmDokg5Cy8Kn09TTIKeoWu9VEbbHX/V4PJ+p9PaoxcLNAy38JUx5W4KqGHsAe1XWkw5bcEdxlZCPzPsPeqN7sWVZQAIDwAe47ufWltqUrvRkOySCQtFKqDZuBB3CJT2HufWpIsXDLbzxlCEWEHqqk8sT+FUBI9pvQlnsZG8yRCOR6Z/DnFTrK8CMXPmpOCAw6qW4BP4Urj5Ss+9GAdlaNGM6l/8AloAcKPxrLvC0DNFtKMityMYZyece3Na7Mu5H3lhGTLz2jQYXH1NUCVJ3zZYDaoOO55aoepUTMvofJQSy7ZJYpAzKp4wMcCqniyVrbVrG9tg0ZMiTpGDgqCfug1fv8CymkcgLKvUjpk54rK11ZZtJ0vUbvqxTZuPKqpqbWvYpa2bOzhtlt766e+kVZ3IliiiJaNM9R+HGa6Jyu4u8cZinwIyvGAOv1rDv47lUs3uIZCobbuZgdwP8RA5Ax/Kr+nyebYv5pUJGfKUHn5j3X8K6Yu2hx7q5fd23LHGQ6lAFYdApPOfyqO8dtjGJCSq5AAxtZjgUWx2IY0kckBuF5yo+XNVJJP3rW6ssblwXJJbAXhfqT6U2NIUqZZpLa3YAxRiJpcfcHcD1NSPlIHjjUYXCKMYO4jkk9zinWsCQsrq0i7syl2Oeg5J+ppUU5ilk+ZI1MxxkfM3TNTYq4g8seeZNwnjQRIufXvUcqhkubdUii8qMIGYdQRzx3qyIyGt4lGXTMsh6E55wfck1BN++hjkKbXmmJHP3QO5qiWzHv7YQO0Er+YSF8vttJ4x9awL9tyyZk2AEy+aQfmA4C/zrbvke6SQMR5ryquHzuPv9Kx9emSSKWQKYkZhHFEB3WspG8LmNJILfxlCZLYvFJAQsQO44xxXU2enZa1lvXZbxizED5hAD0H1rnPDIjttS0PVJlJMk0kEhPbggD88V3Nu3/E1cDaFjJ8od8k5P4Z6UU1oyKzXMkie2gSGM7GJzOWVzydqjNVbpDIN9z8oEbOrp1Lk9qtCMgIEkFy5ypQ8CMseuarywC2a4W7VFQOkSDOCoHO761qzKJSG9i8U5ClOFQgBee+e9Pncv/qlXfbqctj7zfT0FRTT/AGu7WQKoVTmNHB+bjqfb2rVt4FdoS0DLKzL5gH93/CoRbZRgaN7YQ5k2NzIrH5lbr1/rVmHcIUZgxMasygL36DJPrRqUDSZvY49jSyEBc/fQDkY/lS2twtwiGMbpZHUjrjAHSqRLdy0u5QuRjYSAM/8ALQ8n64FFTK8abyvzrFx04dz/ACoqiT5Yg0tdpygHpV2GwRACQCa0eEwMU7YBjFdx83crxwhOG/SrC4A4JpCDxxx9aAvvSEOJBowfwpPwpRQIXHFOVQKAOKWgBymgtz1pqgY6802VkgRnuJFjQc5Y4oHYc+DTMeuAPUnArEvvEcKfLp8bTv8A3m4Wsq4/tK+dftchjQ8hBwPyFQ5pHRTw05avQ377WrC0JUyedKP4I+f1rFm1rULxitjCIU9QMt+dWLDQ1Vv9WJM9GfgD8P8AGt+DQ3c7MFtgH3elZSqs7qWDind6nIDSZJnDXc7SynnjLE1s2ejBELrEkaNjO45Jx/KuwtdHhhfEhC46iMZK++a3dM02QYNrZqZAMMzjJwe/pXO5s9CFKxxD6C6225UY4G5SwxxW14etkuYVO0+YvynjgV09xp6QsRctvyMBVbOw+n0qpbQy6dfmNQAkgyoYfrWTk7nTGC5S1Z6eAGeQgKPvf7P4UC1VLjKLuD9vUVuWdkZAGZsjPzD0rT/swuflUI2Dj/6x96drhe2h5vfaatlqIlVSokHBY8cnr+FW9Knz58a8qrDaevPetjxLaRT2jhiYwvLHGTjoa5fwwWlEjwNmKElF9XA6nFJ6KxcHc7Ow8wgKTg5zx/Oty0hO0E/Kxzg+jDt+NZGngbUA6sCpBPoMit9F2ruGcYWT8fWkkJvUmySiGNcH76KfyIpVjLFgc4wT15VgeQKdtClgv3cyLngHHWmpIxZWA+VkycnoO5/GgZMUCRuSMtnbx/Ee1VHMnyh2YqeipwHPf8BUhl3gYGAw9fug9vqabI5w3O0AbWYd/wDZFDAWGMTP5kxBjjH3QMIPp6mp7c+eTK2NicoDwif4mqcEbSnEi4VekQOOPVq0FIaJcHuPmPCj2A71SZMiQDeUZSDgYBI/9BWrITYzn5hIepHL49z2FRwLznBGefc/59KtTYKhSpYZzgcLj3q0Yy3sU3cKTt64IxHyT9TUQVoY1Cjk/fVTk/nVmUxs22MYA5IXhBj3ppyVIIG36YT8O5NDGnoMZcIuwLgc7AflH+8e9V7jEmN671bqM/MR7DsvvVkrhhGMf3ljOAF92qtNjBLOdpOC+PmkPoPQUFLyI92GUlmlUnH/AF0YdFHsPWqtwBKxDjewIDBTjc3YD2FWJNyZBcIwXLEdIl9APU1GUVEbeuwKnA7on+JqWaJWILchoWEu7K53AnogPPJ65NVZYZYfMliH7v77RE8KzdMepArRjEaHNwNu1BJKDzj+6g9u9V7qYgpAuBJgyPjtnrn8KTQrmRNNG1k6YJyqqCf4QGJxVd7gu0jvuDnLAAYG9un6U7UYmeUPGpO7MzR8ACMHABpufOiUkYBUyvj1PCis7l2I4bc3Aa5n5QERwx9Fcgc8+mKydV3Hw7CZF8xIZ2VDjPHWt0LIFKhsLDHwOnzN6Vh39sz6Lqal2SWOTGOwGBmkxJ3ep1drcPcCBpjIRMoEcedz9MAnHT/69atogtLuIlCIfL8txjjeFyCfesPSzBY6dCqMnIUySZOXHHQ9etWp7rzEMKbipb5UXOcAcD/65roTsc3LdmnNetbRbUeMSAbcjpj+pyaksYZRExcDzNwKof7zep9cZNQaLAZ4i88au+QigcYJ9K1/MWJt0eZDFvY7v4mbgVSV9RSdtEJLGCxj3BYZH2Ko/hVeT+eKA3mzKGRcSybmX0RelI9oqo0XnYaKMIrd/MPPHrQ9wzwTO5KyxKYSpAyW9R7GqZC12GBky0jrkgNMT3GTgYqndO0cTRhdxhh+77tzzT3Uy3E0ReTEKqCR02gZP61Sa5WWD7ZPMFWU5kjzyUXPB9/apbLUSLUPLs47a5klBuY08xs85Y4AGPSsE2RijgnmKZILQrnhWY9/fnpWln7S8t7e8eY+6OMjovY/gKWYAxv5jBiYWuNmMYJ4T8e+Kz3NdjA0q0e70LWEt8GewuxcDPfGD/MV2Fk6zsbjAZpVXZ8wBG4ZyK5bwnOdN1DUorkjyLlhGkgXILqPmB/A/jWlpjyQ/bIoFXfbMY49x6Rnoc+3PFOD0uRUV5M6m7u1tYkESiSVyrAAfMxUen1rBVjNJ51wzFVGQWHygnqAO57Zq9YWaXToJ95VgQSeGcD+QzzitOG2YxoGT/WsD0BCKPaq1kyVaKM+SzRYgpyssUYmOD82ewPrU8c0qyTzFAsiKqMOxz7djzS3StI4aNg3nzAkeijtn0p8m0RyyyNyZCyKOSG6CmhXuV4nQBvmIaJfLClejE96oyv/AGZO8SgNau2FbHCuRyBWnNYmUfKTDOqEu4IOXPTPYj2qBo0ntEilUBo+JFbu59KbQkRNcKrgKVKwJu2E8O57gdzRVe3Vra/a2mAdoR8rZ+8cEUVNx2PEdowM0pp2OKaa9A+YEpQOKQdadnjmgBppVGacqMxAUVBd39pYnE8gaT/nmnJ/GkxpOWiLKqewzVe7u7azBa5mAb+4OW/KsW51e+vC0dun2eE91+9+dLaaG7DzJ8/N3PLGs5VUjsp4KUtZ6C3GvzTZXT4dg/56Pyfw9Kz10+71F2knZ5T1yx4Fdfpnh4Oobyxhe7cL/wDXro7HSEjAAXcVIYMy8D6CsZVWzvp4WMPhRxOl+H5VUMgVVbhmI6/1rptP8ORwBWkjJkHzAy5UN9BXUxWIwZIx8x6sw6VpwWw7kuWHysQQP8axczqVFnPWunqQ3lwrIjdVC8qfXFWhZE7RMT6gIOmPUV0D2u5BkbSODGo5/SnJb5PlgFNycKgBLexb0qG2zeMEjDW2iRsRRpv7hvmLe49K04YJpdo/eeSRjJO0Yq9DBGMeRGEjbpzuKN6n8amkjhEqfbJS8oOGjB4x6jFIsoJZx+WYwC27j5RgKfc1l7wbsWF3hZScwSep7jNdWgJV0MYSN/lcv/Cf4WxXMeJbWSZTIDtuomI/Edx9aUlbUE7nYWcKW/kxyxFBKhRhjJ3DpVqRvtEewFVLAY9Aw96z9MvV1Lw/aXUQkIg2hwezdCKuhfLG12JX+Mf7JrZGSXcwtcijltTIOoOJEK+nc15/phks/Fksc0YRJE3qN3Ujqce9epQQK63UUoRsHGcctXnPjOYQ3trcCJVuoJD8w6YHBB+tRNW1NKbbdjo9Nj8uYop3J5gIGc4FbqTfudrvn5VwPxrmtIkMQjeQfJKcgjscdK1Gl2xhhhhnt6Cs1K6L5W2aM8vmMfdiDz1Hc017hfLYkEAnJ9gOgrOSZs/MCe5Aq3EAWHmkMAd2OxNF77DtYsW8jSt/dDdT/dH+NaCxD5GJxsHyjr5Y9fqapI6qR5fJ7A9PqauIW2fNgAruyT/48f6CmhPyJWTA+78pOdpPJ/2mNSIcsG5OBjdjv7CmA4iGe5B+Y9fr6n2pVUu7hc5bnj73/wBar0J6aliMFThvlPUAncx/CpJv3hwDtzyfMPI/CkRcIQjAcZxHyfxNTlQoCBFXP/LNep/3jVrYwlLW5DgD5sh+fvtwo+g7mmOx3BWJDZ4bGXP0HapJZQ8u1cuR/EBwPZR/WoG3Fdpxx97ngf7x7n2pDjruNcZ+Ty+CdwQHge7t/So5FYOpU/eOPMPBx32D0p+/KAKnzdQpOP8AgTe1RTOWBZ9xBIGQMF/9lR2FI0irECoGcbUB3EmNW53f7be1G8MdwxIofJXH+uk/wFKJFZZmfgA4cqeo/uL/AFqKR9is6AGdQFRQOIs9v96lcvcSUqQwmIKR/vJmz95z0WsxyVT99kSSfvpz6J2X6mr0/kRuUOTDbcsOvmSHtVVomuD+8bcFO6Yn+JuyfhUyKiVLveyFnG0zENIAPuRjop9Kqkxs7yr8scj5MfTCrwAfrWjI0jbyRud2AIHTPQD8BVW5ttrswyV64XuB3BqGU9CD7QEx55DqWLFl53Beg+lYzTyS2OrImQXYMylc565+lak0caqwYYbgDntjJ/wrEhnV7q/3sv8Aqw4Q8Bj02+9G7SJWzsaGjQXVzHEtup+6AZH9cZAGeldZZqPJjS3mBmZwp+XBBx87MfYVweg3LPbww3EjKI8r0wEGecnufSu50qM+U8caGFJMKjMeQhGWbP4VtBNmEtHY19MSUOBK7KvM20Djjhee2anR/sijzNpVF818NnLHoPeoLaVLlZihbdMRGDs4CDrg/Srs9taXMSTtKRDI5lw3VlQcAe1aK62MG9dSRHWO5VGZSsaByWXkSHsazr5nklimRFM0OZJQDkcdqkSZpbWPeu4zyl+RnCD1/Sq9wVeOMPhIbyTnsRGKbeg0rasYWS8RZ/uM8iuQDjYnbI/pWcIBcTfbGQPbBysaZHOO5qzctGLo/ZifscsxUoPulsYBBqNbcK8kZIeMBEUHjDNyf0FZbmyQ26U3EbDBxGqLwOjMf8KpaheC1d5JAXHmbgmOflGFx7Zq/cXTPNvhUiN/3gJH3tvCj6Vk38DG1jKEmWSPeSRknng+1J+Q0lszIs7ae78NapJCXc294syFOu5V5HtwcV0GnW9vcW9pcwMFWb94gI5wOuD396Z8PGtoNI1+J5lEjTKxcnnkYzUWko1le3NpggKPtNpng7Dw+AfzxSjsmTN3lJdjrLSJWilaB0LgBFz2Hfn61auOZJGG5CuIlx71VslK2tohRVZssxJwCAc81YGZI0UuAJHLkHnFbIxIPLS2nZpCgjhi4HOdxzzSxJtjgSVAYWHmvtOTn1zURTzohGrEm4fLAjoo7/Spxlt5C7Zbj5AT0VV7imMfHh7cs2HEsvCE43DPH+NVr5PKuftUSZMPyvu4EjHt+FLDcDequVCxR5QMD948U+SAh44ZZo0jRfMmGeA/bPv/AIUW0E3YwNckES288hBkjfdOACDlv4T+FFXdSjIiMd46maQHzmHJwB8v4YorOUZX0Li9DwrtSYPoalSI85yAO54rI1fWorBxFABNMRn2Feg3Y+YjFydkaqIxzx+dVrvUbOz4klWST+4hzXNvc3+osQ0pCH+FOBWnp+hl2ywJrOVVLY7qWCcvjILrUr2+BSBfs8Ldl+9j3NT6Z4flmk3OjE4yzGuo07QlQJuUEk8KD1rptM0oM+HIjjU5PHH0Hqa5pVHJ6no0sOorRHPaXoJ8xY7eMyS9AcZx9B/Wugt9BigdTOVluOpQHKr9TXQC38qJYY41hQ8H+85Pqf6VchslhKGbKA/L5f8AGw9T/dFZtnTGnYyLewEhVkUSY5bjCgVZWGGI7cLMeoPQKf61o+U7fIihfL42DgY9zTrW2LynyVDeu/7q/T3qNWbxikVPLZG3zhQ4Hy7xyfoKsosa2x3y/uj97Jyyn+lSTosQUSkAZ64/eA+/oPpTowwffsjtwF6yfxj1FBdhoYQoGCkHoHDfKfr602EGU7Y4uc7imMKcdxVqLyhl44XmiH3mlOMH2qKaaa4YRrukXPyhBhR9TSESiFZUM8suY3+9HCMbcVAbiGMLFBEssw+UMozvB/rVj7A4LG5chhy8CnGR6iq80ltErJbD5f4Sv3lb3qrE3Q9IJJVAmcrHnYwHB9s0+9to0tXIQHjy5uNxHo4qCSd3cF0KM+FkC9c9j7VM8wMP73LMMpJH0zjuaaSsS0yl4UnXTTqmmToTHMhmVe4PfHt0NacVzvihYH5jEcknt/kVzstx9j1+ykYCRuYvmPy7SMc1Q+3/AGK7e3kJPOEfPb0qVKysLlu7rqdTLefZZpcyACQenrzkVwmvwRz22prIT9p2LNHzljg5INXNZ1F3jBjbc4G0dzWHNdk2rywojyOoD5HQ03JPQtRa940fDmpK9tEBtJA3A9c+1bUUo8tRGDk9QO3rXnPhwGyuri3LZkWTKqD69h7V6Bp6+Wg7s3X2rM2n7pqwAod8jAsfmx/IVKAoJ6lfpyarIxYsHAyB1PrVtCcDPJPI9aaMx8BO4OQpcn7vv/hVy3kwu0kMPvZJ4z2+pqpEBhzjOTj5f5CrcIAK4XDEdR/T0oQydcs567jnJzyPr6VchO3YEAyDleM4H0/qarRqU+4AeCSSflH1Pc1Kkny7QCR7cJ9c1aE1dWLu54ZMhxHEfmB6sfah3HlKojwerKT29WP9KqIxwGLcYyJeuPZRUq4IKsvBG7y84P1Y1dzJwJjL8gYklG4AUYLn0HoKhMgH3iuB1P8ACn+Jpd2SCWJyMA9CR6KOw96gk284AG0cEHKp7k9zQEYgTgH5MFjkA+n95j/SoJW6kyEs68Oeqr3fHb2oEoCIMkqW+VP4pG9W9BVe4bDPk7kBxIV6yN2RfapepqkSoUESFeFUnyFbnPq59qZG2I94G9ycQ443E9XNMfPlN5hwpOZdnYdkHr70odo0keUbHIAPfyk9B7mpsNrQrShxLEtvtJJO0k/fbu34c09ovJgCx7m2ttXPO9z3P0p6qxkRsqsrjChuka/409irAeVz/DEPRv71NIGyEpHG5EZBEQ2A+sh7mqcy8+X5ilR+6z2OOSc1ZmZI4yVkbahxGO7uerY9BWXJJGGUFht2kZbqV7n8adidypL+/L4IVWBbI7L/AImubtQi+JpY2QNIISxBOAMY7etdDLIHj+6fOfkL6L0Uf1rltPMUnjOGMl9vkSRl2HLZH+P8qSVmP7L9DU0pA17dRJGWSGbexLYAQ9QPfNdvp/mTO2MIWIVYycj5iCBz9K5RYWN8BI4CFBA2FwDnoT+NdHph+RpJFL+USWwecn5Vx+WataMxk76nUJ+7Sdg5D7WiQhcqAPvHHueKqXbq0TCHh1iS3jXbg7mOTikt3EvlxszKF2owU9hyxHtnrUEtykcySqgkm8w3DgHAHZR7etW3oZKOpdl2ASTlgyogtowvG098+tZlzcNegxRIVWIBFBGCVz/F6ZoiXfJDNM+1xvdiB8q89eep7Zq5Ahie3EiPtciV+5Y9gPb3qd9C+VRRC0CJHJHyJIG3sSPugfdA+pqmsgKRzzxlkct5gUcBjxmtGRDIj/ZvMDXE23k5yemSfzpDFFLc3W0/6GgAcDqSOi/nScbDUivKrW8ckKD94AsSY5Dbuv6cVXvpEtpbi4hUtA8awLnjYehH6VpWP+qjt5QDKjm4hcnnaM4Q/Sse7m8uyfewENzIrOGH+qYknj8BSFe7MjweUNx4ntXAkiaGKRjnACh+efWt3xCrXSC/tYXEsJWON8Y3KO/0INcb4YluI/Eeu2cMTSxz2u6VV+8EDZyPzr0ixNvMtvZQ7THGsfmJnhj0xjrkYopq8LCqu07/ANbEdvKqxzElyki4jVuuCccfQ1e8s/PGFA8pVjXd3Prms2W2WC7dEwsclwRHu/gcgHH0P86vQSfuVRmYOpaRwy56dOfStF5k+g9nSAs4XIRAgI4w3fjv25obdHG2BuaJNoBbPzHt9aS2H2gwEuOSZm49eg+lTJgKnmMr75DIMDHHrTJIJ43fZGoCnAeQgf6sAcAe9TzJFe2ymZJ1Mv7yQxLkMB7+9VpzL5i/umeS4JOFboOwPrxVy5iuZZZ3jmCo6CONRJgIQOfxqkRN7GRqDPJeSt5QhFzEFWN+qqo5NFOaDywr3ThpzEFZt+4L75oqdGUnofJ2panqdzCd8pCHsOBil0WyN1IWfLEg8musTRdqSNImVDYxisxYpNLvEG0rbMeCR0qJVmOng4rZG1p2lKrjI5x+Vddp2nBMfKSex9KpaT5JfJOdygge9dPZsQi4+7jPSsue5uqdh1pZxpy+N3U+tX4ByemUUjJHAPt71Jbxx8vxgMDmp4hLjIT5IWOWI4UHvT1KSBC8Lq0YzOV3gkbiPf609tsYIkJLygHjkk+9KmQwVXAIGfMI++PapgnkgNGPnXOW25LqeuPpTWpRJIryKDMPLdQDGo4DY9algYBQ64AJ4PRYW9vWq4C/KkK+cMfLkng9cZ7055URd1wd4f8A5ZIcBT3B/GhspK42VpGuGaNFaYffZsBceozQsaOx2brtyQEc52oatQ6fPdMr3OIti/KvTcvpT1vbeFXitYt0b8MuPun1zSs3qyeboiRNOllJkuXUzryU6DFMe6ht5DFagzbvvQoOAfc0kgkkVRqVwYlHCqnU+gp9u7NtS0gWAk4ErdTT9CG31KktvcT7DdzCGBvugckexqOFI/8AVW0S+Ymd8jdCKt3Qhgysk0ZlP3x94n/drKN3PvMVmojAGVd/vMKHoNaokuZFCsXKhZPkLfxMw9v0rOeSTzczKURMB1/iYe9K8kdu7OMzXLcFWOT+ArNv5pI/mnZS/GF64HualsqMbkGt3DSRw7UG6Ekrj0z396x9e/0mD7RC2yTbv/H0q1ez7oG2jGcg+prFurwvZFHJVoziovc1jG1jK0vUvOYJK53BsHJouNTW0u54xtEbcgA9K5qVni85Uyr7ty+pqxZzi6t3juCFmcbiO4xWkY2Q5rU2dMVbTWI55DveUdM9PSvQNNcmPB//AF15Xo9y08gEgIlhbj2FemaZMNqE9ccVDViJO5uDkrggADOPerCNkAk9RkVVtwGAeTO3NWU/esMHb/P8PSkhXLUMhKbOP6LWhbsHT5hlR15/mfSs+JFUEcEjkHtVuNhvG3Oegzz+lNF7mgvzLklSo6E8KB7ChlBwiiScEdMYAqBXABLOVI4GfmJpWlfldxC56bufxPpVp9ybPoIfllAaVWZRhAvb2A9anjf5QXBU9SGPH4+ppFnLosJKgE8MBg/RR/WolKhTsXYhOA0nLn6CmLfRliSQMApErE5+VfvN/gKZJIBGFyvH8A4RPcnvVdNgbYhkRm4MYOXb6nsKcyvKNiiNwh5U/wCqj92Pc0ybJEThVBmEpKSfKZAPmkPog/rTZFaKUEBY5EHC5+WFff1Jp4by080yhiTsEpGW+ka/1pjo7TbWTYR8/lE5x/tOfXvSZSdnqIf9ZDjCnrFGe3q7fWopJMruzuRGyPWR/X6USmMsTGXkU43s/WQ/0qFz5jtnLAHaMD/x0UrXHcGkOxyxJJPPqf8AZFNacqpO9FLjlsY8tfao2ZQAxBbLYAXJ59M/5zUDSpCykwb0jxuVj95z6+1UlYzciSaZAm7yygCcLn7iev1NZF5cAIz+WeFBcMO/8K/1q695ul/fJlQ2+ZlH3j2X2ArNv50wrOxMjElVJ6Z7YoaEpWKd3c/unCNIZXOTIR0GOT7c9q5G2vE/4Sq0mAkMYBEhHbjsK2tam8u1aPeMtzIxPt0rB0aQNqVnIsYZhwDuzj8/5UuporcrZ6Q8iXav5UBhxgspPTjjnvWvpMm8pLwc8SgjA3KOPz/pXPWT/MEJyDnc7cZA5Y/nx+FTR3gtLrzJWYwyf6wYx16U27MwirrQ6cyKpZPnMoUQq6fxM3J/wp37lGnV41jXd5ahT8qt3JPc1FbSNLAFRBI6AAAPgbmJwfdjU1rCXW3W72ySG4KeWfu4HU/WqYkyYKC0gfcyhAqMV+VQemB9e9aRiSAvFnNxgQxtnO5iMsfpWfPM620tyuxkNyoUjngHH5Voh0RyqOwiijZ1fjiRjwPxqkKdwhdYI7IEMIPKBlPo3Y/QVWkhFlMoDM9v9o5BH3h/UZrSeEzwXkIkJaCFUXdxlyMkfyrM3q6RWTI4mtfmweT09e/NEtCIO7KupboWFxGSXtsCRSc53n5vyFYXip0itWUS5VjuUkY3AAYrajwwtlYE7y80gPUgdAa5XxAfNsY0Kj9wjEHGT8x71lN6M2gtUQ6POml6v4a11tqwX4azumJ67jjJ/HFdjBHHa+J75pcxxmNpHbPJ6Yx+XFcVa2YvPAkNowVRJIwiPQiXfwa3bu4u9W0a0EasbqZBHI4HMfl/fJPrwPrTi+VETV3+Bt24+3PAXAa3LmWSTnnIO0Z9fpSxF2hzONqt+6UnJ5BGSR2zV9IUZbBLWUyQInb7rEDIIplwnnww4I35LIRkliR3H6Vo09yU+hZafZDcSFlC8RJ329PzpjzLudoyqsqiBM9yaztOuHBignb5lctyQDn0JrStGlmWJ5DF5akuQozuwetCdxNWHiWKK4dntnYRJsBJ4z7U5nhjBM8CoUQt98kBjUcbRpFumdmDsZmyRtVc8fjWXPI15MskqN80mRH2J9x3x6VdyeW5i6rqixXLpCki/aF2QwKd29168HoM96Kbr1sulaxpV6zxzTyymF2/iwRlRjt0xxRUWfULpbHKzWaJBOxXkHNUrzTI57NDNjcVzkDOPoK6K6QEMhxu3kFew+vqax7l4/sqyu/KNjHf/wCtXK0d8TiYZZ9LnmchiiN0Lc7T3ruNIvRNFE24/MMAg1zuu2jTgzW55dCu4D7oo0jfpf8Aodw6liVaKTn94h7iqUdLlSafqenaao2gttOeDz+v4VckGDv+/tO1+6/l3rG0li+DGCUIwwB5NbqhpHQIQ8owS2eCD0x7irWqMW7E0MQjVIzkvgvEcDBHoallXKko4RcfOjfePrj/AA70JEoBiORI2Nu49DnjmpYrcsQbgh5kGGjxj8R601oTzIpjzZUKW0ZhtQ2d7DGw+3oKms4oLZh5Kme6b73dX/wqxcKJEy7P5SjI55x6Goxch08vT18rBDDd0FJod2yW8jJiDXk3lwDlQpyVqmLgmJvsUSwrjBmb+IU1gZ5yHYvcdzkbPx/wq1ZTRpIu6NWvPujHMZ/HpRux25UVoI0jw1urXb8HzXHyrUs0dyUzd3YitznBU4UH0NLPqKQsyoA92DgwxH92P8aop5lxIZJFNzIpJNsvCr7n2o0BXerHq8e1vs0caQBcmSbG4+61XmlWSPNiPLg3c3MvUeoFVruVJvmnH2l0HyLuwkX19cVRnu5JAJJGDKvRgML+VRJpFqLLNxdJbqxtgRL3lYct9PSucupFLkE4Qncc+tW7mfYhkblTyCT29hWbcr5bF524YblRe3u1Zu72NIaEN0XdWII/qaw9RP7iQL1Ybqv3dySrAtkj8M1i3k+1XyQQP6047l2OV1C5xqCM2Rxjp1qQFPKcLnzWbcH9PaoNRwCjfKSGpssvmRF8lWAxx2NdUVcyqS1I7LUzFrqq4O+X93tHRjXrukOY7ePfhnOATXhDyva61bTvICokBJA6Z4r2PRLsyRR4Jqa8bWZzUZOba7HbQlWADH8O1XoiqoQcZAyAOKwrWb1OQD17D6eprUQk8E8HueKxRvY0YyrkbOQPyFWFkwvAbHcLxWTbzeUOSSvv1qy0pfBHfkb/APChlpF4MuBsGf7wTr+dWocxpyFU+ijcxqhGzMmCPlB5wcLVkMiqcsBxj5TtH4mqQMnxh9hbyznnHzOf8KjmO2dXJkRWGFZuXP0UdKZFKjOVhaRxnJWFcD8WNStwNsaqpJwwjO5se79qohvUktolJCvFt/i8uNss3+83arEsqvhUMZQH7p4ij+v94+1U4XHzxIhc5OY4z8v1Zu9SRuA6hhHJKFztPEcfv7mqRnJX1AgpiRfun/lqww7D/ZXsKqXcgiyjeYsf3nXqzn+EMf6VfWZTOfLYlsZE0gz9SPpWVqE6TFYoQRFuz/tP/tZ96RSZC5dYg+3CscZH8XstRO+yLywQZOmAefp/jT9RmKmPypCQiAFwOFPcL/jVBBulLMpwO2cE+w9/WnsS2aVvkwFosF2yBkEbcdX9PYVRnuEiTEaggKVTIwTnq1PmuR5DxFv3andKynG89kX6Vk390rsm3DMM5weDnsB6U2zPqNluR5e1VbryfQ1XnkXO9z80akk96r3ey2UrNMuTjgd//r1Epae3BV8IRzuHesnMdtLnP69exi3kYqWkbpkcisDRJ5RdIeAVYA7T0zW5rFgZ4nO1gzdCO9Yem28kVz8nVMHfjv70o1NdTWyaPTYX3iPIYg4RFGD8o5J/Gr9yiXELkFcDg+rMe/4Vkaa22ONslAwCptAA9zmtkKxRGB4Tkg9Sa0epEPIm8H6n9jvY9OvHXKtmOQ8DHUqf6Gus8tIJbV4pGMAidy5XoSeo9a8+1G1E8CH7sv3yVGDxXoHhPVf+Eg0B7WRo47uBRDICOWH94exFFN391jrLltUW3UWyRJ7K0tFBPmN50mfQVLpyqY7e3nACzymdZs424PQ/pVQsLdbwq535FtC478gFf1NXbqOPyb5toUWkYgRXOMt3+vWtFqjGfZlzLGC1jZifPnMjMcbtq5/TisPVS0kbXcfEouGyynB2Acj6VeM5gkUSMWhsrU5cjJDMMYrPYtFbwxHlhaM7+xY5z+tTN32HTjZ6lW/nWSNbq2barwFVQHOwZAArD1khILxhhSCiexxV5dtqZLZgSkyRsufvbuuM1l64zNbSnHzb3Y5/LFZS2NktbIzdMmuLvQILe3iZpDJJIj9gFOSf0r0DTkt0+xx2Y/d3LfaDLu6gryPz7Vw/ha7L+HtI063kUSy3UyuFGSqbgS3txXb6G8aJ5MBZlsGeOJ+wjP3Sf1rSGyZjUupP1L+k7LeKxRSSfJdl9Mjg8/lSsqS224uso8rPcYOeBUVlIfsts+zDLA7KzdySeQO/FS/KqQvGyllQMFYEA/8A16shENzYgqbiErK6oqbccHnp9RTtOmkm3Q8tOcRjHAVR1NIWYfZ/tTMgy0rqepPXIx+VMa2ZYFl3GIEM6qh+Zuf88UJWZTelmWlkhhnckq0pyEBHyR47D1PepLkW9s89zcRySLbqEG7/AJaOe4FZd1cExCFlbzkAWGEDvnqfXg1PewyzRr9r1GRrm2njWRAMJAP6n3q0Yz6GD44Plq8sRxOHilt0xk+ZjgHPpz+VFYvxNvLi3gmjLq7PMghYAZfIzuz1HFFZ1XaRtSjeN2JKzyRK8I+TPr3+lUdP0qa9upIrgNGpbhmXgKTwxra05I7WW7tU2ieCTCgnJPcH8q0r2/trqHzfPWMhCrA8s2e2OgqFBdTWVSW0SDR7ZfDmoz2F15TSQFZYmdMiRD90gd/SuU8fNbjVoHtYHRbdispODsD8hTjjg5/A4rp9Ymk1DQ7e7yBd2DBR/faE9z7VlatFDfWk0cKOv20eUo/vyKN2T6+mKvdcqM4rlam9yPRJmRcRuwAG9c8Y9RXWaesc7MqnHRo9x4IPVc+ted+G7p7iG3ZVYTR8Op5Jx1r0PSIw4D26F43GRHnHzfxbT6+1ZRNp2RpxYLFSpcYJaM8EH1qSV3ZF8lSwXlZP4lHvVWSVd6OxZlGVEmMMD/tCpZbnYqlmVDjCzRjI+hHerMktSOVNxXzyzzMPlKchj71YhRjEwRDgfegJA/Ws25ubiUKqQrHzuSYkrj8KrvLNKyG6vCNvA2Dg/Wp2NUmzVmu4IcLJtuQw2+VGvT61XlmuLqL7OxMMGOIUXkr7kd6hinRE22kflTdeDuJpHabo00m9v+WCncxHuegFDdwsOMBhjCLbzRhhhcYyfcntUUjBAsUkquOvlWxAwf8AaNUZ5DC2ZHETKduxZcv9fpVDz48gXOdu7/VRf6w/j71JVmWpXt9+1FeeU8DYMBfbHeqt9MsM7i5CyXYxtjXHljjvjr9KqXN/IVaBIxEmcleh+jHqay7meLy22YznBJ+6Pp71NzRRLF5eLCXuJtsl0/RsZRPwrGnnaUO5LHPJfPWmXLIobcxV+gPbFZUsjMMYCoO4OM0NXLih0s65ZAwbjpWZdSbcLuGOuT0PsabPNtfIbd/MVn3k+eD989fpVRiVJpIy9VcOzMCFx8233qJ5/NQZ4bHzDtSXj4hlGAwPes6SXCjqCOK6oROGrUKeq5YE/wB05r0XwXqIk06LnJwAfrXml4+4fMcmum8ASsY3jBHyN3GetVVjeBy4Wp+/a7ns2n3HyKcg54VscZ9hW5b3K+XhmCn361yNllFRdxDHnPWt6zQfedG45y1cNj1GkaKSF+QGxjORxVyGUnqRkjqB/WqWAVyGHQDpk1ZitvlG/jP944/SjUbaLPmOw2qwz3x8xNW7ePbtZ4xkHOZm4P4VXtl8vlQ3p8owPzq4JCuFXYp6Er8zVaWhm2yVSs7E7XmYcnny0A9vWpFeJYTvAkQnkZ2xqf5mqs74UM65BHJmbg89lpBMsgjC5A7MPmY/7o7CqEX9+8Qhs4YcQp8u7/AfWmXqm2aNZdrZOUhj5H0JqABt7JDhGA+bDZyPV2/pUTTDezCQuAdhkxjP+yop3JHTt5N2RcbJT/DGjceuD7Cqb3ReZ5JQBuXHyj8gPSjUZ0MoAKiQkI7JwAB2H9feqpfeWkf5Rj5RjOTnp9fWkMfGTc3KZTEajCqp/M4ou5NsgjQkEEiNM8ID/Fnua0LdI4LNpfNzLxlgc+X2x7k/pWPfyKsTqgUHgk9x6D8arZXMb3ZTvZzIyxx8gEqgx1PrUKWy2YPmnfJJgsegGOlPknW3UyHhgMLnt65rktV1m4uboW1nuMj8E5yfwFckp3ep3YbCupqbV1b2csTGZCADnr0qO2uILIBEYnrkdV9q57XLHWbKxilu7e7QNIVDgfxAdMD0HNZ8etx26x5V5g2D0wSe4xUttPU6/qSqwvB3Oq1ESCMs6eWrc5rmvKCzMTkInzt0FdRqF2mp2YmtwViIBIY52jpz+Nc1d4RH3JnnPXNEdzy46aHW6KjPDG6rlX+VV6jjqa2kQAFlH3OFHq1U9KjYabCzAZMeVH90ep+tbKhFlVowNkCcnHVjXUCEEKkOo3EKFUsOg5qtZXU2haxDqNsNwHySLt4Kk4P+NaDFo4QMcg7zGVyNx6UlzaeZCY9pUoihvxNJp7rctWa5Xszptbliksraex2OisLknPy9eAQO5Jpl7umklcZMrXisQTwRtHFc7ok/+jvplx95RtDsP+WYbJ/EVrWzfZntF+byt0lwQeSRzj+lXzc2pl7Pl07Ekl19tgnKDZ58yKwPU1DqkhzfzAbllZYUwensP0qM7tkLxbFkRXmwP4gTwDVRneRfL3RookLn5funHQj8KlscYpalG6kMxkEa4kVk8onrxn+tZmpXDSWBlk5cI5ZSO+etaMmXdQFAkUIMjrknNZGp5WxlbIVH3Bu5ABrNmsUVPCfm20NskCxpLcXD+ZKfvYxwoHQV22kygajM0nlEvaZAJwMg8Z98V5boF2UtLOcu3/HxnAOeCSM49a7/AESN1klkdZWYqCXdeevHFXDRJGNWOr+Z0dhKzwwMV+QW5GGbGDnOa0xcIoQQJ58/khVQ546dPSsrTY5roJFAAkMaFWnfkIT6VcgdbaF2sx+9CZaTqxHrk9BWy11MGk9i80Zt8tL+8nSDlQRtXPv3rMluXjkmFoxkGACm3IQY6Z9aW8uUfzEe4giUogyWJJHU4WmC5e82x2MWUVz8wwi9MUr3egJPqNG1cNC5luiciQH+HHIx6dhRqMzRwXkh0bUpXdVeb7OMeaB0A9z3FZt8z6dHi03SSON8irgn3I9sVZvftc0zX+n30L2LopiLXAQRLjuD0NXEyqbnB+MYr+51GymvrSS3FxIHCFSFUKoAQH2H9aK6i9nBvtWea9insxFCsMRfO6deWdV7CisqiXNc2pStFIxbcCW/jXMUXnoUZ3PRlPGD24NXLe0Ml4sVuiyOh6/wD/GsayE95pUGqvH5qROGZVGEK+2OvFdugAsYpEAEEzKhn67O4+gp/EXflGaXYKmoy20wMrXSGKQFto56Z9vam6Efsws7eVYy9hPJ5uQcrtPH1zVpm+zFXtHSVIHDCTbnOe9JcvbWHiy4F0jNBdRpdBkb5ge4HtkCrSsZSbdziNa01tG8dahDArrDNi8hHTYr8/zzXWabcxyIjghVkO2TB+5J2cYrjPGGvJN4qtWhlG6NTCF29EJyBn+L61sae6oWlg/eRN8skXdT/WstFJpGyu4ps6m4mLOWmKLOPlbBwJB/jVSO4Ctm3IUjqjcn8KzJZy6jbKWRuhPVfamKEA3O5K9Dt6j3pNlJGyZGZHdW2sBhkYk7qoGZOVj+ZTx5YXcVPtVaW9gg58sykdHduPyobVrqbBh8uALzvVQqj61NzSKZZKzmHOzy4u0krbcf1qNZ4MBbq5eWMdRD8v61k3kuXkV7vcw53IpKn8TVJ7gsR5hHIwWTnH4VNyuW/U05bqFXlSCOMRk4yfmk/AmqdxqawrItuNityzNy+f8AerOuLhI3BRTIR3bis6/mkJ3GTaD0BGfyo1ZSii5d3JYbi6sTyQclqzby+IJQMCcj5COKqz3DS5LkKBxk8E1nTXSopCZDevUmhRNC7cTqMsSfXGcisy6vOpUc57cGqV5dlizMQMDjjms6W6Y8sWJxnA71tGmZydi9cXIWPJcEk8jpzWRc3C4+98zetV7i8JB255NUZZCqgtgenetowsctSvYdMx2dQQxqncOcEA9KZLcAdetUJ5tz7UyznsOTWsYnm1a13YSeXJ6k/hXW/DgM80qkMQTuUDjPrzWZofha81OVWuVMNv1I/iNd/omnxpqEawoFWOPC4GO9Z1Zq1kbYKhPn9q9EdxYER4bbn0UHnPvWtCfNGArEFueckCsq3hZEIXnPBAFa0ChckhgoAziuM9V9zTtflc4z7gYq1EDu+U84IP8AERWdA2ScsMg7cYq8g2gcsCeTtHWmiWWEGQSy7v8AadsY/CpfOJxHGzuF5xCNoP41SeTa2AEDerHOKckrODgtKOcMPl2/SncLF8MIsuIoYsjGZG3HBqxIyhlUSNKNuQkUez8zWZGQw+Uorn+FAXapopWVcMfL3fKzZ+d/b2FMRYRBllkUKQSVgiP8z6VBjfMXyMryzL92MD096SeZXd1jVYY+A7Kck+2e9MjbymT5winOAR91epJ96YileP5uoIFQBUQBVX1/xNTsFiwN+wAfvGXsPQe9VopDcX1xIjOCTgEDovrz3p7EZGFPlhv3aH+I/wB404ky7Gjc7iltErBQI/3ScZUE9W96wdQOGIX5l3bQegJ71pggbt7ZJGZGAzj/AGRWbq/EajgNjhc8IP8AGqmtDC9mcl4huHEm3JBx8ozxU/hLT9JS/iu/ECzyRIc4hGc+zD0rG1uQ5Xdz3x7Zq8LiNLBVQ75HTLjGMH0964k+WV2e7G88PGMXa+mht+LfG9tfpd3IuRYfYh5elWsXyuzEYJdjxjaK8Um1JrrUklY7RkHaOinvWh4kaUAZH7tmOeM81zsQO/cFwAc1uve95nqYTDU8LC8WekeGbppbe/VwWhgG8tj7o/p1q1YA6hfmG0zvuMxoGwcL/nvWckLaPokVixDX14RPcKpz5a/wIT69yPpXS+ENMdpInfCqrq80uM4APQUlG2h83VtKTmtjtoLJ7CHyOZFhVRIw5y3YfSpoFxI7g4MfzEf33/u0szxNdT/ZwTCCRGoz857NT7JJIpnIVX8peDnox6t+FatW2MoEuIwWErAuhLPnj5vTFSW0hXbHnDMd7kjOFpgizh5fuEgjIwW/2jSg7nIGQsmW3Zx8opF2KdzCwaK+hGGMjYGeqjrWrLIJrSa5HDSBYYlwc8kZqO1w9xGZMkYeRwV4UYwKNPX7PdxR3BPlOBIpZujdqnYb1Wg98wyyoGJxshUqPQ9Kp3SyGRp4h8xL5XqT9fWryh4pbcsSqyTNI2euRnA/KqLOXjHXnzDx6UPsJamTnzNjMdqiQIQTz0rI1qICyUyOwG1856cH0rbulJlcHiM8n3OBVLXIB9mmTbgKDu79ah7FX1Rxuh3jy6WqLIgFvuIAXk4bPWvQ9PMlx9rcOywEKxI459BnqTXmtgzNbtAm0L5zptOc4I7e1ejaHM32fT84VQvyjrk461cSKsdWdTK3lWkVuwVo44srsY459fU1E72YWRJIpZZCq5xIcfTFVYm2j9yWYklQo/hNPeaAl1ijaS5DqoIJJX8O9Wc/LYtOLZXYWdpBvLqFZlLAce9RTTpbmEtiS4bcqLDjAPbjFVry5NqfLWOWS9aXcqk8kkdDjpS7HspFRzHLeyqN0xOBFzyv/wBei4WFgiaCdCTtuOTkHAHsKr67DpmnHUHk0a1ngtXjdwxbeylsFj2HPI7VFqQeGONUaQOQVKnk5J5x7e9WLucaeXNzrKfaYIhDODa+aCnUKQfvYNawZhUvc5fVIv8AitL92jjjtpoozEqDACFARkf3uefeio7Ym8v7vUbe8fUV3K8jtFsJA4+Ve2OmKKyluzXZJGppj/2XqLadqNvJbabc7ljQtgxnoyD8efoa29MC2wudHvGZY1VtpPRkP3WHuKpeNDZ6ravM144ljw5Pl7VEoHBA9McE/SsWx8QJewQrcTSJewDyxI65Dg9QT1A9K0dosSvKN/vNAaiLaefT7x08+2J8uROC3oc1U1DWZNREJkdvPtgYzhe3uR1FcX4pnuor5JEUblPzOpzkVXjv5EZJ4pCwI+bac5+tZufQ6I0Lq47xLbPLfw3DbBHux8vGea6fSpzaBVRsIR8rHr9DXM6xMLnTw0YJB5BPA471e0mRpdPQM4yOeTnJqGzRx91XOrE2754yVPcDsfWkMmTuYbW7HPWsWC4lU4LYfHI7Gke6Kkgtx6E5pEcpflmTJzIsZ656g1nyXMYOJGdnP8Kc1Vkuotp3H7nYrk/hUC6jNsP2UyLn5QRGF3D0zTSNE2ty9JLMkSuVMMZyMzt/TrVa41ONVZVk8wEAfJ8gz9Ky78SRANPIqk8hS+8/jis+4uowwIcMQOirsAoUR6M1JLonb5shKjn5vl/DPas6a8Af93hAB/Adxz9TWXNqClSApZQef4qz7nUJSMgBR6kYNWoD5kjRluQWZ2dmb3GBWfPfqgZY9u/ue/51mzXZPDOT7daqTSjJIPzelaKnYzlVSW5ZnunLMTkEe+aovOOSx5NV5bj7xOfc1WVprqURWkTyuegUZrVROGpieiLL3QHYLjpWfcXbM2Ey0nYAcmuo03wPqN3H5t6/kKDjygcuf8K63QvDljp/C24jnH8cvLfnSlUjAzVCrW1eiPO9O8M6nqG15VNvFnq3U/hXT6doEemzKttCJJHH325I9/avQRZDcF3K3GW9FFWrTTjCjEgbmzknv6c1jOu5bHZRwdOnruzH01I0gVY02sgO7I6mi0UxlLgEEBiCB2Ga6D+zR5u6JAJGGNrHNZOn6dcyre27FgFYklRjGfU1hq2dT5baG6sqlon+UKwwaesux+GBBPQiuTN5eQJJBcptkgbc2TgFf6iuh0+ZbhEfBJPIGM4FGvUaib1izFBuzgnOFbpWnGBIDuMmP97B/KsC1d9oGPlDduM1sQzHYu8YXPAfn9aZLjYstmJhhWI6cx8//XqOFCVDMFUZIwI85z+maeXBwrM8RIwpzkZ9aWOQ4YOXO0cgthd3tjrQJD5DskKhpGYDbjAXj3xTN/l+Z82GHyySEYx7AGgK6BVzukzx7k9c1JOhKKXAY54B5Ln1NFwsQxI7KZEHyIMqnf6mlkzJceTuygYF2xjdz0p/CxnJ3FzgZ/jP+FKihJEKZLdFB7t3P0FNCa6kbHdfXImAJDZfaeMDsKJZGLAsAHcYUdNo9arO6iefvCjZLdMn0/Oo2ctuEhJY4MjdceiitEZyi9yZpgNvlqSoOEA58xu5+lVL0b4iZGBj6vJjhj6CpjnzMsQkjDGenlLVW/kHkRkcwLlUToSfXFVuc8kcN4rhkQ+dGpyRnyz0UVycGr+UHjJKMOm7pXoWqrGJGSdDJMV6AkflWBd+GYbtQdp3qvU9SfSolSjI7MLipUVy9DjtXvPPG1pECn+FetVdODvdRG2TJRsgEZyfU+1dMPAz+ZkTYAPK45z9a7Dw94TgslO5cvjMreg9KqMFFWO2rjXOHLfQzPDWgTXRjkmO52O2PI5Lf3q9F0u0ihspoWAS1X5c45cj/OKfYWggCuR5ZIwP+ma+tWoiLe7SRI9zOD5MX91R/E386LJHA5c5NG8ouwxQLO6hY0Yf6pcYGadaom6ZQ5S1wPMIPLY5x+JqGIFpLh3m3qPvzd5W7KK0YIkjkSC7I8uFQ8jDs3YH9KFqO1iOG2fYVMbCaUAjJ+5H7/X1pXiD7CqqqSNsUdxGvU1cTzHaUy7TJMu5znmOOk8sSKxddpdAc9kiHpj1qWguRWyb42XO2S7kC5x/AOpov4FuA3l8iSYJGT/dUcke1LE7CAEAb4Ydi+uWP88U26OyKYKQBboIY2U9WPXik9hdSNJZLs2/nndMxd8HoABiszYyQxlcD90zHjsTWje7QZ2iz+4iWIEdcn0qjd4RrhWGNipHjPcmoZSKrBDuUk5LEAEe1UL077dwSu5go59O1XZQRP8AIchZG4Jz2qlMFeJs8fIuQR3qCmcLo0KJqdwk7AytOQG54Brv9DdYLO2eM8Qh1Jbjp2rhLGHbqd0QQNkykcZ9csa7Tw/H5yA3QCwCZizMeMZ4AHuaqGyJq6u50MCSyIhVvLXIEkmeevAX3q+t1FaJiG1VJQ4UHqz/AEPrUMESyESPi3j8wgAdV7AfWtO2svtB+0zytHEpKIEOWPXJz/DW6uc8mluZ8cX2IM8zRyalKx3OGz5Q/u81TjjiVF3eaS8ZDbunWrkgktGilnV51O/GRkL2yPU0xJI3tchlMgjEaoy5OSe/0oSRNzFuSxlVEdmKDCEnnb3H4CneKr6xW6aObQzeeUgxcGR1aVcfeyOua0brR0a0kgtry3glifcjzcHcaz7+51gW0jx+KtPjwNpLPwp/KqimjOVm1/wTnNG1KBrWaSztFsQ4CC3Vi209+Tzz1ooiE8+qQtd31vfTttEl1E2UfA4wcDp0oqE7GjaRrSTuftASQhnOGHccciuJ8yXTtUZSVCy9QV681um6WM7ydpI4Hf8AOs3WUW6thIjEOPmHHI/GoeqOmEUm13LMyR3CnMYUPkEk8Zri9SgbSmZGLLA5+XHU102mXsQtWUMd6n5sngfSsvWNl7AzMY+hAPekVF8rszBg1QWxNtOx2twp3c1o6BfbHZCQFySAeormpLRZQ4YgSrzkjtVe1vDDMrEkjJDDNXyhKVmekG7JBLkAg8EGop74jceg6E9q5y3vVkJZCSp9O1Pa6VjyxDdiKXKJGqLpmUfLgA4JzkflVGW+MTMrS5A6BTVCa7JyCGZvVT1+tUp7hmUEFUfuOpq4xuKTSLtxdOCr8AMM8Hp9apSXH7wEuS55xndWfPdLs3Mc88ZB61Vl1FfLBEhMhJyOmBWyiYTqpdS88zEuFcbuTtJxwPeqVxcoDu5bjJBPFU45bm8m8uyt5JXPACDNdDpngTVr0B76RLWM8lQdzY/pRdRWrMPaym7QVzm7i6CuQSoJ6Af0qfT9H1XVW/0S0fYf+Wj8AV6tongnTbFVb7MryjrJLhz/APWrrrbT1iONq56DuDWTxC6I0jhZS1mzyzRvh7GwDajK88meUU4Un09a7nT/AAxb2CbY4YbaPPYc/l3rq4tKZzmONsoMsG+UfWpbexL5KAvjJJUZIA/mKxlOUtzop0oU/hVjATTYgdsZJccg9N3tis/VLRU2zsBGFYZ4PFduNNQW4mluYIYm+6rH5wfoKyb6KBFKTbZT0Yrzx61DTNoySehlaRCbp33YcswAGOoreuLTylRmaMgLu2djjsa5/SImtNTUCVmgMm5VzgkH0+ldUVLqEwEy+0nPL4PY+tVGOhFSWuhQaxknYvBu2kgqR8oVvT6YrXfRXt9dtWVVEd7AdgB27WA/iz15/Op4nin3ZDFvMLMFBy+B6CtG/Hm6PAski7raQNG+Ryp/hPetUlYwbdzgNf0pr+Z5UgX7dE3lSxA4Dq3GSf1rjtKludJ1efTLxSJYGwRntXrGuRJOILrbsEn7icx4Chh90+5rz/xppk1xFPq4uYjfWu2KZM4eWHtIOxIrOavsdFKdtHsbUE4k3eWeOgA71et22qV3tg479/TFcj4d1aC6t4wrDK5DHPJ9OK6GBiZRuUfL39fes7mko20NvcHCrho0yNwz37EUq4VlDnKhixz7dKpxTjdk8HpipoH3g7znIP4c1VybFyBTksQRu5Psvp+NTSYDEFsLj5iOw/uj3qqJGIwFGc/KAefapS2FAX5gp4P95j60BYVwM/N8pxzj+Fe2KY7FWCx8Mwwuf4F7k0wsAWYglR3z99vT6VG5LOyu4GRmVx2HoKpCsV5CsZYrkojHH+23rUELOjgAbpSd7eiE9zUwfARwmW5WJcdPc1WCAJIisRGrfv5c9f8AZFUiWiR5EEcgLZiH+sbvIfQe1QTOYgjfKZXGEQ87B2pWYq8Y2AKvMUXt6mqtwJcutu3mTt99j0WqTsZumjLvuJ1iiO+YnLP2zW1YQAJGBlifunHU92qhFboLpIUbfIfvEfxGuljtcNgEbgoTPUIvf8aakDgloVUt0wMDMSE8j+JvatC2jVFaNgN+NzADHJ9fpUoRUkXYoG1dsaHoB/ePvUyQr5ZZifKzhmPWRvaquNRIol8wA/M6A4CkcyH/AAp0iAKVEhHOZZf5KKsYLAF1MbHgbfvEegFSeUUwihRLGNwTqF9Cx9faobuapWIogBNGUj2knFvCfuj/AGjVmzYbZHlbdDESZGXpK4PA+lRR+XMpk8w7RjzJuhb/AGUFSoG5iKjBBIiI/wBWg/ib/apImTLEcbSPtlystwvmzbhjag5AzRKQyhn+5J87AHOyNegpkkmQ8u9me4b5gTkpEP8AGoDL5wEarhpm4xxiNe39abZCu9QT5JIjKDu5uZMcgD+Ee1V1YLDEZCdzBrh8evRcVYbzriBt2Fa8bqBjEa9/pTWRZNsiqPLmkCIScHy1FSyr3IpwViljySWmUscfxY5AFVJ9rO7HlpLgBQPQdauIVlMDYOCzzNk9QOlQQJvaBmOG+aXHp16VLGijJt3hl/56nAHpVPJkViPmBUYP0arcybYYQASQGc4+8MmooowkG8ZDCMlh1xhqkG9Dgb+aOz8ROsuQXwuQmT1PJ9q7zw1ctLZBVyAJ2YZXOMn73+FcTqsIk8T21zLJtjc7OBwQexzXd6Wpgt1B3FElcMi9/wC7k/WqghV7Kx08EQbzxC7II3DEkd+/HrVx3kkdUdGVA5UDHysQO2P61VgV0QJ5sW+YplRyo7k+9XoJJRGnlTR7g7M0hzx2z/8AWrY5XsQR7PKjzFIF/ePt7Z9/aqcdv5j/AGqPCFgEgJxkE8F8enpVrdLeNDbqTHbKW3TsMF/UfU024miFosvy+bHII48DlQOn50wMyS1ubq6kYRyz+USpeMZy30ri/G+garPcmeysrh1fBkVYjxz6fzr0FQ9nphUzOssj5k2nBDe9Zuq2FvawXdxfatqziLCTGLohbuBnoPWhJMzcnFnBabay2DtBcQS20mC4Rl2kdxxRU+vbLC+khSe5uRGqFZblt7OCuQ2fQgjFFYt2djpjqrmXPMocqiKFxjB5P1NV57wiMAMenPNZN9f5GVYKq8HHcVnTXgZMIWJPOQavkNOaxqC5RLgjcQrjjFV3nVpAqksCayzLhN5fJzkDpimz6iI4/l4I71XIyZVLFbUMR6iHU4DcHNUb2EQOZUHXqPam6perImc5PUYqlNqSyWu3A3AYNaxic9SskXrC5UDZx6g56+1XWuAw4PzAc1x0F80cvOMAVZl1PcQ2cEDg4qvZmMMWras3pLs/8A9R2rNnuuSRtA9TVfT4tQ1mYRabbyTP3IGAPcmu40H4etI0cmrSGV85aKPhB9TUScYblKc6z9w4ezgvdTlENhC8zeq8BfxruvD3wzeQJNrEm5P+eUY4/E16fomgQWkSpbQIAvGIxgV0ttpqYYqWuHHzbE4QY9WrGVZy+E1jhorWerOT0fw7aWUZS2t0iQDAHTP4dTWvBphlJUJuU+vyj9a3zamTYSUAUfcRdqKP949aQr5jbSwlb7oXGcD2J4FZO73OmKS2KVpaICqfIqY5WLCnj1Jq3ZxxxMfscQLsfuGPf+p4qYRFZZIxFGHBGVb53P8AQVOqTKuySZmXr5bDace1CRdyN7eVwwnKBkIOJj0Hpgdah2M5KhpXUMRhBjb9B3HtVhtigtE2Tt538MPpTUkMkgMEdzPxhnHyFT70WEQwadDG7SThGBPzBF38epPY0l3a7d7xwny1G3B25Yg/KWA696vQpqETDYIocoWBGNrj396rTzrCqf6QGkU71WJck56gmqsTdt7nOa3Agj+0RFYgvBVF3E89M/WrVk0dxah4kbe65DbT1HUD0p93ZPNGwDIPNyc45qloqziSS1mdyyN8uGx2p3uTaxtw3QVgsKyDcMhSOQeh+orXgkcxp5tsLWCTiX5A3b72OoqhYE29yIwVYvyjddrexrfgZpLcyuHllcHcWGFYev1FVFETsc/qGnJc2RtsKdmWikwRn3965i/06yvHVpEjYiMZjJOCR1B9q7yaJWgw7glGzGV78Vk6vbRf2rBJEiqssJU4z19TUyj1KjJrQ8R1+2g8P+KYDYEfZrgbwgOTGOmK7GO5UpEwf75wR9KyPH9hJdpa2Vs4N9AzSxHYEyM8qWzzx0rH0PWUuY2RnAnjbaQ3Udj+NZyXU7E3KKb6HdrL+83k5BbGO9WLOQ7gCCOuBWTFICEAyOT17Vct5QSu5s7QTjHepEzXik8vcWPI+UDuSamMowUHRByQepqhbtkISfujJPqxqUrtXBIJzlvr6VSIuWDnIwP3mPkXPCj1qGVo9pxykZ7fxtTGZ8EMdrHl2/pVdskqFGGP3V/uj1NMCeQgljIdsm394R0RfQe9VjIoEYCgMc+TEf8A0JqjkmiiVmf5oE6esj/4VJbRPPKxYBpJfm25xsX61SYNdyRYGMUhV+T9+YjOT/dWllsnMONv2e3Y8k/ear0ETbht2sI85Y8IvsPWrbgvHLcoS5jH+sPRc+g709jK5iaTAvnO/l+WinbnqT7V0NqAGbeNmOAo5wPf1NVNLj+TczjzCclz0X6VcUlJP3fBH3S3T/ePvREp6smjjQggxkM33Ih1Pux9KkEC/wB4HZ1f+BB7epqGGXjZ84VvX70n1PYVISzA42BVzgk/Io9AO9W2A6FEGW+cE8AgfO/uPQUrgFDGfLIXqqt8qntuPc+wpwDsQxSRg64LMwQt/gtD5RkYNFsAwH2YVT/sjufeoC7KdmT5gQN+/Un52GBGvqBVz9ykfzDzYC+WkP3p2HYd8VCyiOQRsHCy/ME6yS/U9hU0pkMgwqNdAYVFOFhH1/rTRLVyOffJK32nEZfDSADG1Ow+tVTmSQrEAHnO1fZBVkIjRsCTMCcZ/wCe0n90f7IqEb0aaYuHkbEIKjgnuB7DpSGibcZEZgWKvi2hz2UdTiluFWQFYMbdwgiZhkAfxGlLCIt5Iz5IEEXP8Z6n8KjdxG+I/mit42ijPq5GSaQiCUhkcooIjgKDI6c44+tNmIgSUBmHlQBBz1Y9anY5i8pCNrBIsg/jTJ9irlsDfKW5GeFGBTC5UkQp5qMVJEcakbfU1Wm3I22PIL5V1I6/P29KnWJkhy4JZljcd881BnN0u8sf33Qfwjr/ADqeULnKeMrdLYrc4ACyHaB2GcV0EU6wzLDOshaaEMvPLcZGD9azfG6ifRxsHIi3Mc/xZJzUvh27GpnT5GdPMjj+WQjowXBH4elOKtcmbbimzuIyIL5CrbZQo98kj19ParVuvnPAqZDh2fGOFz3P64rJ064HmxpdEl1OWJPC+3vWofMt0BgO3DkkHqBjpj6VqjJIkWc/JHndAgaX5uC5zxzWfCBOxmuB+6t1LjHdzyBTHu3nREZQhSEqSTjC56j14qC+lCIfJDRxRxKGU9yeuf0ouDRV1m4muLmK33lnfDtgfjzVvWL901WC1u7OIrfQBZI2l2biTwxP8J4FZ9hM0aS3kmPOlOxcrkKBUPiQ6RqRn1K41P7GsoCskkLOysOu3HWiNzOaTaRx3jU31x4ilKW6wtFsiaEHlFUYA/Lv3oqTxLqCXmsxXFmGWELHEruMOyqoUFvc46UVNRamkJNJKx5XPfjcQ/yKeeuc1TfU9hzxx0asG5uGfkEKR6nmqwn5ySSfeupROOeKdzak1J36uSKrPdsWyST+NZrXAGTnjvUTXGeMgeg9apRMHiGy7JcEjGT6Yqq0u0kDge9X9K0PUtVcfZ4NkZ43vwK9C8N+AbeFw9yhup+gMn3V98VEqkYFU6NStrayPO9K0PUdYc/ZIGWMDmVxhQP616B4c+G8O6OTUGe6lJ/1S8LXpWmaPFAh2oW2YGQMKD6+9btjp5Z2WJThRuY9B9Sa55V5S2O6lg4U3d6sytI0S1skWNIo41HG1MYB9Ca6GLS0WJXlAAz8uOg/DqasWcItY0lwGGeHZcrn/Z9TV4PKryB/kLLlnfG/BPr2/Csd9zptbYSGBLdiJo2XPGQfnJ9+y/SpZMFSMKYyML/Co/4D3+tJbLu2sCysvJdhuJ/3V/rVt40jjyymNnGeMO7/AOFPUZAPnYCZlk2r8om4A+gFRXIUzlGMr7R8qAd/5YqRFmkkaOKIqhAPlxndn/ePY1M9l5aBZ22Dqsac4/woGrXsZ+6WSNPLUvGnP7oYx+NSCGUktcuBE4++vzMPbNXJZXEhMTmPd3xkfkKhNqUZJZFYSHvK3yv9AKPQq4yOSFEwkb3GOkyDGDVki+crJ+7t3YZV+8nsRUnni3UM0iZbIAC7QfUEdRVSS6kaGVbW3b7McHMg5iPqO+PenoQ7vYi+w3E5l89trx/MYQeTnuOwrQSO0htc24jzgSb8FmHqDUIspTIGu5fMuI08xDn5XXuM0SXUXnpFpkbOGO5QRhQSOR7j607JESd2Q3zPN5zpAAch8lu3YgVzmsebFLDdQ/8ALT5Gweh7GutjjmRo5ppM3CEgAEAL6AisrV7YTNI8aMlnJuJVh91u4xTAZBcG5t4WaWIIyhsg4w2e9b1reLckTGN3kTCtCPuq3976VwenzpZTyWsrtIz8o+3nn0rpEupEaOS3RgdvlyO/GQfUU1KwnG+h093cBYylxsGeHCLu2GuY1Cd8QyMxYJIY9p6jI5PvmrksixjMx81v4zIdoI7ED0rGvbxZmVZGVgQVJ7cdKUpDhG2iOT8UwRzbLiNCDCxJIb1rgvF9lFZXMOqWW3MoBmCJtCn1/GvSrsqEZCTtkUg+9efayiv51tIw8vHylu5rFuzO2nrt0NLTNVS7toyrfNjArR+0FC7K3KDGPU15toF99lufs0wcOpIx1A9Oa6xLwSSquQo6e5puIJanY2t2Q6FjwATj1NX458Z5DNnp3J965O1ZZHEhY4J6Z9OgrYsplGSD+8YZdj1A9KDOSRozy4iJIBVTnA6u1UTKyrKXfrzI+f0FSyzOYVjRF3s2Ux1HHeqEamV/KA3Rxcl24BaqCK7k8BDypLIPnziOIjIHua3NORvmAUMM5ldvlUn0+lUrPaFOAcEEO5HLnsB7e9a9tMgQghCU6L/Ag7k+poQTlfoWVAbD4L4/ifiMewHemXMP+rhyZJGIG0cbfbFIkxuCv2c72zgsTzjtj0qSOZpr/wCcxuIh5a+R3H1psyVyw+2NQhUExgYwfkT/ABNII2XayO8ijqF+978f1qWRkkUZQOiniNBhfxNKEcMz24O8/wAER4H1anYpMQNG6bAm45+WNDnHuTTnjYOSWCvj5A3zMfovanx/ZpAFlXB/uwcfmTQoktmwh8yMjkQcuB7mmIWRFwiTnZnk/wAUrVIqGNVkd44l2/K8pDEf7qjpUcc0bFRGyW4bnCAvIT9e1RhCVYwwqNp5mnbOD/I0kDF3GPMoPkxyAL50hzK/rtFLKyCDBDR25wRFuzJN9fSmh23PMCspxg3MnCj/AHR3qCWbaDs3ncQUDfedh/EfQUXFYtNvY7HZY5AnzAfdt4/b/aNRLMizfukOIkC28Wc/M3QsPXvVFrnK7VUyJI3VjzJJ6/QU7zzEWMYU+WSA/dpG/i/KhDtYsCUW8u2Qq5gQscHILnrUaADakiZEMZdscZZvWqsODHJn5VY7Qx5+7yT+NOaVmSQhTvd1yDycUrgkXoT5c9uJGAKKZS3TnHFI4GNzgblhLHjuarNN5hm38hRt6e9TTthpzywKDbt7D6+lC1E1YiuZGCsrDBZEBAPWqDOUcHOMyZXjtmtK5Ut5pUiNWaNdvsPT2rOuEJEceFwV3ZBzgZP6mmIxdZjZ7XylXJYMhVvTNZ/gDypJ4raVVkaOXJOcAKDkg/hXQohkmMrjKKD2zlmX/wCtXGWt3JoupziIylWPKIM7s+tOD1FKPNGyPV4Ps7X7SKd8HMYcp19KtwSPERG7YTzNvB5H4+nNc3pN3ItnCxORI6yMxGdhzwDXReYrKyyAFmkJ47ZWrMVsZ2oIjoWjPzBDgZ9DjNZEzF7z7K7AbsGRu20c1tStGsKu5yBGeAcVmSoIrWSS4AM04yD1KrnioK6EE1+4SeCJwsL7Qcjt1H0rS8QTanA9vEPEmlWrOV+WSHk5/wCA8Zrk9QYxSqqMSQchiKt6raWXiSZdRltNbQHDSrb2vmxsR12v2BxVwbMqkErMqeLtOv42uL25vba8lgZEufJGwxH+EsmAMHpkUVm+IvEtnLHqgWCZLu+EdskWfligjIxk9S/GKKc1d6FU9rM+bpZunJNQ+az8Y/Ktuz8OSSH/AEhsMOQqf1qez0dYblPNzt3HGa6nOKPLjh6knsUdN0O7vWXAKKfXnj6V6F4f8FW9uQ80Qlk65I71taJYIzQBVwo4Y/yrt7G3XYcKu5uhWuOpXctEerQwcKWr1Zm6RpiQhQIxhR0966SDT9wU84B4A4z9afa27DZkAHPWuj06GPbmQkkqSBnjPvWFm3qdMnbYz4oCqxKwBDHKgDAzV0QbImM+NoxiIHrz1b61ZWISNHzldmRt49e/YVHFCRbmTggfM2eFYDoPeqsSh5WS4kcgqSoG1ugQeij2qeOMu6XB5Q/KZGXIU+3qaIG3Xscr/NuTBBGAPbH0pWkaS3SNOQGwuOAvPWgPIlQrCzGJgpXrIeWfPp7VLbwqf3mSsLcs+cvn61BBt83b5Zmnj79APoKsNCoPmXMxdDyVU8g/SjcHoh5lUHyrEZcHOUJBP1PekFlKx3ySbcnBRfvk/wBatW6ecu1F8tEHCuNpP4024mSNBEi+Zn3+6fdu9X6mfM72iIkUFsdsRG8Dl15P1YdqpySLOwitVYMeBGpyG9w3anPFJK227kVixH7teA/sCO9OuJoLRCqFdv8AFDj94v0NHSw1o9Nyr5RkhmXyFdweRn5o/wAe9TTz3KPH+7QyKMCRiMOnoaj+1TNGjQIIkPEUrnk+zf8A16rXF4izKqg3UgJMkfRM+1K9th2vuSeS8kRmYMUQ58vONgPXA9OKsSXNpbW8sAkBYkSQrByM+hPXisyZmMqy3lwVglH3Izkj0GKLeRYwyQxKk0Z3LI/Jx6Yoi7ahKNy/9ommKtCkdnbSNkvjOH7Ek1TlkheVWLNJnMcjucqH/vY6VDdXtvlZpd86ydVbja/qAKpPOxLPfuVjTCGMDDMvY+lPmBRMTXrdnVWVyXhI3AHaD78dRU2jauLyEJJIrFBt2ntj+dTSyyXUDiCMrGOT7jtXH6i40i+E8X3X5KD196yk7G8YqWh2r3BMZSWRg6Dbjvisy+uCHIZ1LDBVl5BrMOqrOIzvAyME1SuJ2EZdQSVyp+lK9ylC25dvZ3bIVm+RcgelcnrkYukG8HzFHy571oG7ZmfYxwU5z3rOvLhZbZV+4R3PWqii17pw2pSE3PnEFZM4JFbFtfAwq/3ig+Ws/VWVi8bALIT1rKhneMjY3Kdvat1C6MKlVRlqd/peoBTGWPyKu7B9a6azulyC+MHDNz19BXlOn6liUKXGJGB+mK6uy1MogYAHHr3J6VEoWD2kamx3ykMxYHDOuWb+6PSnwBSQu3MZOEQd/c1h21+rQKpBIJxk9WP+FX7a6yWAO05yzenstQ1YSbNnq43jdIP4QcKtWBKoBICttPPZRWdbzqWIcED+4O31p7SngHDKDwi8gD3qbmsVcvfa8RzbVVwegUbV/wDr1Y0vKgDaNrcnnA/E96y3/fSICvIPfp+VbER342dQOOM//qouVJJI0llTaAzbh0wDtFTNMFXD8AcBWO39Kz1K5K7grD+J+SD36VI75RgWDAevf+pqrmNiydsrD5Wkx2HyqKT7QYwVjdsd0j4HPqarfOyElGdR3f5QKS3PmKV3SOB0VBtX8zRco0GSKVNwaOKTAyEbagHfcepNQxzBgqzRA7CRGZDhF9wP61EqIOQ0cYHQIm8n69qgvZDJDvaNnk6DdJlyf90dqd+pKVy5NLufEeLl0Gd5+WOP2ArPnuvORwcnd/rJWPX2FQGczKqSu7ODxDF1P1NTKCCIpPKHlnhAMxx8fePqam9yrcu5DHP8+8Eq2Nka4+4O5pnm7QNpJQbmBPU+hqN1HOwsGPy8jt6/jSouXUYzltvToBQPcuqA0QTgMAqYA5J706QZOexkwABzx602BmZowR/eckdamgP+rC7VKxmQhemfehEJ2IYyxQKA6th2+uat4OyQoxI8sDOMAe3vUMcZaPhmyI85z6mrstuI0nztXaBGCD1OOtNIGyqSu/lTvLqAO3Sqk0LKojjYgMp3Y9Qegq7tjdi5b5gFIGeMd6IhHDEZZAzOSVjA6YzyfpVIhlJgnlxqMgfIPct0zXIarItr4nMzD5QDkMOG56V17bJEyeDtIx3BBrl9dgb7ILs53GchSepA7UtrFR6rublnmGVJIH3WjuHCnnBxnFb9s5nbf5rKDIzD5eoxXFaFfSOq25w8Y5JLchu/NdTBcL9lRVIBLkkA5xx6VpFnPJcrsSXBWVkjIySqqMHGQTzmqF+5d3DkYChAvoOgFTm4REYiY7gqgEfrVC5dWLInzc53EdfSk0BSv4g0RWReXPzY/ujt+VS65pmvan4nW40uaWTSdi/ZXhuAkcAwMAgHgjnOagnkcRu0pJIOBxXHXSz7L1weH46kc1aZHLcrfFC8gk8bMbeVZwERZpYTw8wUB2H496Kz/H8ltp3jWGKOOKJBZ25KKPlJeIFj+JNFact9RRmkkjXTQNl4pb5QVIAHJrI1jRFiniJDBM4Ixyc16UbZVkXYSzjk5FUNX08yNDLtBAfOBzmuS7O2NkcT4avfsl/9huyVUHKk/wAVei6Oym23KQMHOfasDXvDAvpFe0ASQcq5HH5+tL4cuWia7srhgLmPI2dCKGupTaktNzuLYFowerDn9a1YMLu53McFR6n0rBtbj9zGVbcwGTzjNalqTuTpyCyc/d9qRk9Ua8m1mLjBXytwUDCg+pokPnksxIPk9hwvXpRasjxYK73ZGXZjjjk5qfcA8MroHAThV4A5/WrEnYqlfNjtmYMluMjPQnuasK+2CWGKPZGjblZvvY7cU7yneERysxdF3qvb2zTnX99bzynzBIvlk9gaTVx37jIVIR2QGPZyxzywq7EIYdsip5glGPm5JP8A9eoVfy7uUSZKYALHHQjgU2MDyjbbP3q8oC3fsaEgauWWjeTdHLKduPlHt9aYJ4raHBIQk42DncfpSEkwRzXMgRU5wD09Ris64uoWneOygM7N8wdv4SKL23Ek3oTS3Mkygwr5UbNtIfj5vY9qpC5SMrHb5nnz98dQfQnuKZLFJcqZbyYsG++qnARu3HrToYiqOqAcICyp04PXP+FK7bLskMm8+5kzezFImJ328PZh7U2PKqjIFt4on2GYj5jn2+lXbiS2iDM8scaY3AAEtkjpk9apDdfNI+FhjZP9ZIemOyj/AAosTchlaGL7QgVi7HdHJIMY+gpgkWPy5pVK4JEm843E/wBKZ9pKzwzWcbyTY2tLJjAPqB/jUcjRQS3Bnla7nA3AEfIh7n/61Gw9xwDTmRLSAAM3DudoUe2aolre2cyXxN3KhKugb5PYj1p9/qEtzbq0xKvEBhCMYX2rJMiSsXlcpA44A4OaVxxTLlzq73gAJVGjAUBAAu30wK5rWws0TwkA5+ZW7mrFzPwphAj2fKwHNZcz8SIzfNnK0tWawsnoYlnd/ZJzBMSOcKT3q9c3b/MN3yuMYrH1wGSP7RGf3iHkY4FVbfUvNtUPG9etXGGhpKRcmuwApRumc1k3d4VRVZSecdfWmXV6zBhGwETcdKoSyYBLHLED8K3jAxnUKmoSs7tk5rMkZkODwvY96vXTgqTnOazriTKjJBOK1SPKxE7u5BPKVYMvDDoRW3o+tAhVf7wPP8q5yZsHr1qqWKPuVsEHtV8iaOOFedOV0et2V+rwgKxJU7Vx+tbulXfTJGT0A5/KvIdN1h1UJIxB+tdx4bumu5MBlGBuJPQj046GuWpTaPZoYiFRaHo0LBgxZQATxluvuasxzjeFVsAenArAEqovJQnHGOav6WkkzEnKp2IHWuWTtodkVpc6SwjDIztjJ4BzjitGMrtAB+buR0xWSi7WwN+B7dKvwOWXKZPPbNCJlrqWQcAsflTHOxcfqaUSMpBHnbj3AwcVHz5YC53nrgYNCopbEyhHHUNL/hVJklkbsgtEpzgAu24j8KeZN4xJGWBHBdggH4CqrNHGAM2+SMdzTonUHkROO5Uc/r0qkQyQuBH+7uGYjPyxphV+pqvypXY+7IziAZYn3anzujoAzck4AMm7j0wBUYt5CnzfaWXBKgLtA/A0WBNFKZQAXV0hYfwJlmP1Pan2twHRo5fkCncIgMb/AKmrH2ltwjyUQYG9sIie+AOfxpIrNHLLBKrqvzyXHTIzgKAfU1NnfQ1TVveAZMgJbou9ieRnsKUKBtVyPkTJwehNNKS2+EkRZCzYYKd3TsaltnV0UKckyb2B9un5ULzJeg1Iig4YjA2/8CxnFWvLKiba6lRGvX396rLk3AZCFZmblugqRElijBZch4zznI60ITLxhkj8xXx8oUHbzjPSp5jG0rBxjDqcZ4xTTKVEzBsE7MfWnzyB55BNGOHV27Ej0zWiMytsEkuxTgDOe+QDUt+xlJEIURckBTjgY60joGl2QHYd5yTxx9apKxEKAltxDZDng/jQKxDeYjRvLTYyuefXPSs3xPbltEFuwCuseRjjnOa0pmLhABl2wQPpUOrD7Q7FuSWH6jpSa0bGnqmcv4bQRwJJEreYBiVgK6e31QtEu4DAbhtuSc9c1x+lXUFhqlxayyDY3TPrW6JDEV5yhAIU9KpMmcfedzV+1s8JDBBhQAoQZOD61kXl05Z1AUEnPAp8kgEWz+LbkH0NYt7cssu0Dn1z0obJjC5q2GsXunvM1lIqllw25Ac46dahbxjrnkOTcp8uc/uU/wAKdpFtZXMN7cX7Si0s1VmSI/PIzHAAJ6fWoLqxs7jSZtR0OSV7aI/6Vby4MsHo2R95T61qrnPNRXQ8n8YX93rPiZ72/PmzlVDPsA4UYHA9BRWj8UdLj0vxb5NizLC8EEg3tn5mQMefTJoraN7Gd4roexXG0RO0SsApAyeOakng8yJ2uMlVxxGO3tW+dCie1nSRZVLAurEZJA5yR2qK6nhtbQERIfmVCh6hfrXLyW3O1zXQy7Im5sZofK3OpwFztzjpnHauJ8U6ZJaL/bULq7qwWf7OmIwDxy38677XpQbP+3tI2eZbkLcWoGAUxyce3rWVF4l05NHgh1OJ7jRndlmQEYAcZ3cckA1pGKtZkc0780UYujXpBjjlIwV+VvVT711WnzmWMQsf3i/6skYzg9PfNeQ2l7Lp+rS6dOx8tHLQNzyh+6QfpivQdJvZGtl3NsCkMOP4vUmsJKzsdEY8yujs7GUvODnAc78AZww7VpDzZF2o0aZG9doz1B4x26da5y0uwU3wvkkiQgdh3x71uwhvIJWLdsB2bm2kg8g+4xTiRJNFtHYxR3Ck7QNjqeCPc+1QyZNopV/MVJRwv3QPWqj6iTLvj/eHG11QcZ6dfcVXAleVoJJBFGw6AZOO35UPyEr9TUuZY4/tC3EgUuodAOecVSa7nnljlto8Hbs3nrT4rMeVKGQCSLnMh/QCpbprZWiVpDM7rgqo6egAo33KTRAIszESyNclegHCgn1NSyxbU2vIqLHwdgAyT79ajma4kmbfCIUCjIY7R9cCq8Q81163Dk7ig+VRjuakfS46Vox5nkKZAvyhyuEU+vuaYzTXkzmEllCfPLIcKuPSiadGUrO73EmdqwxHCj1471XuJixLXmI4d2PJHBYAdPahgS2jwRN+6Q3dw0X32HC59qZdvHYmJr9TI8eAId3Y/SqUtzcyowtkFvbn5CduAMnjPdqp3EqQSv5JMs+R++YZP4DtSvYOW71NG/klNkxnHkx7sxQAfM2f5D61kXMm2SaMkKdo+VecfjVS5uJHaVpGcuwyxY8n/Cmoxn2MNyQqMF2GenYetLc0UeVXJXaMLEyt58jKVJ6Kpqi5IILyAFWKnI4ANV9RvTbxMEDKFcNgtzWXfXbXLTlX4KhvpQFm9SxPPEDtdgByhPrXO3mo/OFjJbymx9B61Bf324SKjZyM7j2NYl3dKrv5bfKQMt71rGFy3Zas0L69UeYM7g/DD0rDkKQzMY/uEZ+tVJbrcSCTg/e96ry3JZSCeMcVtFWOapWSL7zBQAGIP3selUp5gSSDn1JPWqUlzgnLHPrVaS4yDWiiefUxPYsyTAZ6VRml6jAwaiebtUDtya0UThnU5hWYFqibFGecd/Sr+naNd30wSNCgPVmGP0qm1HczinPRIr2FlNfTiKBSSOSf7or0DwrFcabP9jK+bI4yHGMfjV/w3pltp2nMqwKXYjdKSd2e/Fak9t5Ewv4Ey6AcMM5/CuWrVvoexhMG6fvPc3tP0xmkD3hwR0QDg1uwRRwqFXYFHIGTxWTo96LqJG3B/l6f0FbAiV1UAPwckA4rk3PQfZlvAdRyo4zyx5qzFIqIBwuB0BOfzqjCGQFd525xtx/nNPaRlcYQqx/ACpsO1zRYgDOAxPo2akFwqrt+VPQCPPP41nGbflYyXkA7AZ/MVat4N5RriQnp8ivyPzpryHbuXIXd5QEG4nhd4Sq15Obd1V1O8nBGFP8AKpsZbyrZSfXdGDt/KkSNLYPIWQzbujRGquSktyKBGUpJKEBI4BmAI/LpUsrLM+CYt3YBGkY/TNNWSOaMu1vEQCfuRnn8RUyCIY8hG+0cgNFLux/wE0CGxW4gYzPatIy8nzsbF/4COtRcfaFKl2ZjucMAv0AFShllkRFjjlc8BSNhye+aRgIJfkJVc8h+qsOOaBptvUS3doZY3RgSMljjOPWlDQyNDlAPlK5Bxz2amoN+DyoD4PPrUHlmHDA70V8kk8rU3KSXUljidViKsJQ2WyP1zU8MmEQoAflbOTx9KjaUK4Nv9zfxg9c0+H/VoSCMhvYE0yZFsSb2YEnmIYBHpU0jIZZS3IKA59cVQ80jZjABjI+mKsiYlFRW+U4JHrxVRZkyVpESZ2JyvDdO1Qu6FiSoIEnHOc5qvJJxtBySpHT0PFQmX93IOMlQwIqibEsJVblGChQhZRz3rPnZir/MMMufyNOaTAdwTuMgJOeoxVW4uNrJu5GSp9s0XKtqcXrMYttcjmJDJJz0rsofLmt4xHgg8ZPrXMeLID9jikjT7p5A5IGeTWho115unwtjGcZx7UIqeqTLUjuh8vqc856Vi6mu8DY3zAn8K2bhfNRtvv8AMD0rFuGZMK33dwANAR11JtE1iXTjKHhS6jmXy54JVLLIucjOOmCODWNp+tXmkatJcWgdX5HlmIsrKeqMO47VvaJrU/h+9W5t2JiOEuIwf9Yv9GHY1ha5458Q2+oSSWusX4s9xCeaoDbe2eMZrWOxhUTu1Y5r4k6+dX137U1stqxijVo1ztUKuBjPNFc94y1S61jU2vdSuGnuZFVTM3UgDCj8qK6EeVWm1KyPrbTllaDdfXH7hMboM7FCY+8T3rIuJvtkl1DpVmWikA3TzHZEg7E+tRXMUksyDU52BDcQoOo78dhT7rUIoYltNMtTPKCRCM7QCe+B94/XiuVS6HruOpkJbS2sqz6gyrEzBJzK3y7CcEKvesWGwTTta1HSEhMlvIPMgnuItzLGc4wB/Ot26tvOt5DfjN04bBwWAI6n0NSa9ZTxWHhnVZZVEMg+yu8bYwDzgk9BxRsmwcle3c4fxpbPc6Zb6lHcSXF1priGVWiCqsPRCuO/sas+H7nz1WPKsSOTng12/wBhW60+axa1T7Peo8IdmBVT95DnqWPIz6V574Ti8iJ45cK6MU25+7zU1F1LoVLprsd/aRIFDFR5YIEiHgrnv9K24NzzrE0pZ4V+RS2AR2x6isaxlLpvfDFVCtjjemeefWrtsQGK+aV8pg8bnsD7VK0CWpqIoRCzJ5Sv/HE3IP09KiW5kJe2lC7wchoxkj059DSNLCHBlQyb/mWRhwfw9KbcTrv2ySAf3TENoI/wqiWOnmlJkW5Kx7U27QTlvSiB3CRvCqpHux5pX/OaoOyW9yFYyvKPuhFGSccetIGuHtS0scUYQ/fnJLfQClcNi3e7PNlee5kmwATtIAz7n09qrteR+YEghWTIwIo2LD/gRqlM8EcitJJJcMy4Xd8oH0HemyX0oHlKvlYG0LGuCfc96L2Kv3JpZr0KJB5Vkmdq7W+b9KpvNbIzeXvnc8B5OcevH+NJLbyRB2mxFtHJnbGM+3Wsxrh5f3duskwA5wDtH1qCk1Ytz37SNk7snnI6YFUJbwu6rGwZ/ugqeOfU1HeC0gL+ezTSKowsR2op9CeprGvNXYoiJtVUGdi8CixUbPY2rp4bdXDyrPIABuBOweoHrWfdX5+YEgBF2qAeAK5281IZCK27JyR71j3Oo7UfzGO5j0qlBsqyWrNzV7+Ng/mMSSvb9KwL3VQsa7m2qUGNvesm71VmDAACM9u5rGluGbG48DpWsaZlPERgrF+61CSXIX5VqhNO2MZwPrVWSYZ6mq0k/GSeK2jA82ti2yw8/vmoHnGOtVGkJbjJye3P6Vs6f4W1fUCjx2/lQvyrycZH0rTRbnJzTqO0dTHeXnvTEDzyhIkd2PAVRkmvSdI+HMCsh1KV5mzgqvArvdJ8N21kAlraRxAj723tWMsRGOx1U8vqS+N2PGdO8E61fEM0H2aMngynn8q6mx+GaIA15LJKevA2ivXLTTA8gwCCM/NWpDpu8jaN2Rwe2axliZPRHXDAUoPXU8rt/CNpDsWO3UbRlSBkj60k2irHMJMPGwwE4HX3r1qPTQvEi4JOMe9MuNGR0YiPdgc9ABWPPN7nVFQjsjyk2F3bMWmjZgWBReBk+4rVPnqgMlpJgjndjJrsNV0fbp4DWxeZiNhL4ZPqPpzUmgot1JBYzHyJXUbTJxvU8cZ/rT30L50ldHnml3Bs9RkRo2S3ds7ivIJ7V3NrcqAWjBOR0HJqe+8PWjm90+/KxXQXfbPICDJz0B71T8OrbsjQlPKuE+Vkf7pwfXtSs0TKcZak/wBoSQ5yF4wVHGPwNSRSDbtDEqeMAY/+tV0mOHcFgUOg2ssgG7HuP4h7ioVSIZeNAoY52xcgH/dNFu4KS6DgQdplAVlHAA2k/j3qcYkYIXwg6/N/jUC4YAblYg5weD/gaWKUKzDbgDggf1X/AAoHuaUexfkVIw3Y52E/iOM03eRIcPdLIcjDLv4qKJUlfqTzn92cEf8AATSsqAs67HVeysVYe+KYhtsrOzOiI3JJ8p9jY+lDupIRdpOThZhhv++hTBuuisMSCYt03AK4PsalhBjjaMgOxwGjnXkY9GoAmjj2ZQt5YI4SQZB9lNMniGMMGXPBB6j3z3pytglQGKDnY3UfQ0yV0ZQxbKjqT1x6GhhG9yAIRhhn5uGGeARSoPOEhBx5qlSue45BouHIBVWy7EBe3IqJS+4EIEyoI9iOtKxa1GxobeONifMGcgj2q1NtKjDHO/OM9AfSk+8rrwQ/zqPcVWlAlw8IGwrkgnoR6UC3ZIrHcAW4Vihz2zT1k4hYj5kbafWqsUwmidc4ZuRn1FO3llYpgkgOPqKaIkupYaQqARyUkIx7VWclcAEA5ZSCfXtRPJlZDz8wDLjoD3qnczMJGJwSQG+lU2QtxGkIjwoOSMY9CKoXk7NIgXPOJBx6U+5m2yFhwuQ34HrVSBj5hkVx8rFBn0NKxotFcNdw9hMuSpxmqPhq4D2K9PlPftV2UiRGjfrtK8+orD0dvInnhQjGSOT2p9Q5bxsdTPICrE8Yb+lZlxIrKcAEcHB7VJLOVUljngGs29lZfmUcZ2n2FUZJWOg8LwH/AImkljBFcaqkStaQygMDz8zKp4LAdBVG+1D4gPIUtoLuaTdgQyWSsp9iCuMflVPSbaGeK+vtRuZ7ewsY1dmt+ZWJbCqvoSe9HiV7+40dtV0TWdSvNJTC3EEspWa2J6bwDgqf7wraGxzVFqed/FyCztfF88FlHDEfLiaeOE5jinKgyKvsGzRVX4paXb6R4lazsxIYfs8E2XOW3OgY8/U0VueZUfvH0DHDJfQC5aVY1XiQMpyTn8zWhp1+iWclpp1ugkcFnmOARz0yaR7eYXMM8rpdWUpMbYbYGbqFIFSfu4Lo7QNpGSipgKemBmuLlse05cysWJtL1C7tjF5sDK6FC8ceFQf7LHqfpU95ozan8O7q0gLSfZFE8Iz94pyQR/OrVmZriZGuA8z7SUZn2xp74Hf2qxb3ZtppIg8ksMhJJXAJOOw961irHPNvp0Mqzu7W/wDDVpczwNvSMOvljnjB47Dv15ry++lsovG179nkCW1x88bgEKD9D+VdTp19JpGuXWjyhzC7mWFAuQM9gO/p7VwHjS/m/t+NrqKONIztARAMgnue5pN3jY2owan6noWkyiVWhkAR14GemD3q/FPIgBbPmxnnj7y+1c3pt0JrdM58xBlW9PY1fWbJyrfN0OaxZqjZ88DClsKfmUk5I+lOivB5bRqp3ZyAOpNZ0cq7ACASOhXkioY3nmnaKLAz0ZiFH4mhCsaj3VwiboRDZhPvO7ncc8dOvFU55rfczTXE9wzdwNoJxzjNQOkUcIaa9UlyQyQqXI9yeBVImLHLoinhZJCWZfwzgUak6F9b/wAlI/JhWL1k+8x/E9PwqL+1pDbPHag5LZbyxlm+p61kT6lpsNsuEkuJEY5MjYXHsorLufE8z2+23by4V5xENo/H1qkmU1c3Lq6ZH867jMucnZI2MntnuayrvVpWjFusjMp+YpEMD2rDfUYyhacSSqeW52jPb3NZt3q8jW7RxukSZGVXg+2R1NNQuF7bm9cXiMW89xGU5IUbi3sK5m9vUR87OPUnnNZU+oMMncy+hY1mXl9uXOT7+matQJddR6mnd6kVbIJP0rHuLtiS27bVK4uy+ADmqUs4I+lbKBw1cW3oi5JNkdyarSTj8frUMCzXcwjto3kkPQIM12egeAJ7nEuqOyg8+TH1P1PanJxhuc8VVrO0UcbCLi7mWO1ieR24AUZrq9C8BX1+4a+byE67FHzY969R0Hw5Z2MaRQxJFkduCfqa6aCwSIHYgPH3j1/CsJ4l/ZO2lgYr49WcPo3g3TtNIMNuCw58yXkn6V1OnaZ8wwAo75HWtqKwLSBmAHQHPtya0obUIpZVK45ye5PpXM5Snuz0IqMFZIyEtVj5C8Y4JGM1cgsyxwFJfhQue2K1ntYxGfM++PuovLcevpmrH2cxrKHj8tY3VzCOfrlqXKDkUre0RCqLiVsbgq/KoI6gk/0q6sHm/MGVo8BhHGCAq98e4qysYDukbKzKQ9uqnI56ioBsSQBmKEZbaucqSfut7VVrE7lhYYov+WaHAGd/JkB7r7irqrEYl2yqLRgVWURglT6OPSspNhMzhSq9SGb5lPqvtSvqDvuS3USSONjbf9XL+HrVRkkRKLexNNHKpjEaqJInWRoQ33lxtO09+DWF4ksBK9vJppmWe2JAEqjD9SVbuTgVtTxk2gjuNssQ42nh4fy6Csi8ils4BIVcqwIF1G3BB7MBSfkCWtzmvEF9ceINNj+yxRx31o+6MB2ZwcY2AHscVzMmtkRrctD9luogI7mJwVZz6/Wuvkmnsb0XwYQTNGY8LGcInQOuOCfrVPVL2O01l5po1u7C8QCZLwbyWxwx9M+1J+ZqtHa2n9aE+makmoxxrJKh6KqMNoA9n9frVmWzdJdgcBlwQknDYPTBHBrllaDT9cKpCkcEwDRRA5VQOo9q6lI47xv+JewiuWH/AB6nlX/3WPT8aFK+gSVrNbMa0EofyZNokHGyTqR14NSRxgqFYjeOkcnUfQ00+Y6SRFDmP70Tn94h9R61NbO2AG2PHnjeDg/j2p2BMnihYsFG4t12sMN+BonC7SAdwH8WMOn1HekEr7QgVj38t+vsVNPaQvsLMVK8b+4Po1KwakinzIvLxEQB1b1/2WqMEyttIL+qt95foe9QYyWPCgcuinB9yKeJF4+Znjzzx88fpmgTJiCsQAIlQHoP9YnrUU9ww/ePg9g5HDL7+9LJKEJCkiUDKsON/wBaoyEzTFuMY3YP3X9vrRcqOpOFIhaWQAlBhQf4hn7w+lSElsg5DJ8656GoGnQHADGMDIXPAUntShsIoAJdRkY7rSAkLfLxnB+dMHuOoquWaOb5cDd8yehPenkMCcEgg5XIxg9waq3IZkymePnQ/wAxQVGzdhXYDewODu3r7juKhN0sUhXP3SDx6GkLGROcfPyD6NUJILK78ZGxx79qpA7Fp51CAMeEJX6g1lTXW0kHkxkj6g1DcyvArHO7nY/sOxqhJOj3WwkguuG44P0p21JUepceR5UAAAbaV4pzNsUsMZZQx47ioxIFUYI3L8wHr61XeYCRQM7cHj2NURe5N55YSnIJGHHv61kqqwasx52NyDT2kMSrySVYqfYGqV/Md0bkbjESDjqVpqJXNY1p3aQAKfl5Geue/FZ93cL8wJI7nNM+3hOOg+8melZN3dF2yQMnII9QapRM2zb0bWzpjXC3NvFeWNyghuLeUkBwDlSCOQQehrKtNfuNEvjd2KIylWilt35jmjPVHHcYqz4dtU1A3M+oCVrSBUDxwf6yWRm2pEuehY9+wBNSTNaXmranpl34bsVSxjZpjZXjG5Cr98xsSVlKjkjHY1tGLOOrUSbOH+I+vR69rzX8Vqtruhij8gNuCBFC8HuOKKx/GNi2k63JZecs8eFlinUYE0TqGRx6ZUjiit0jypyu9D6dsH32wsb5MTJkBuu4g9Cen0NaRd0u1j8seaOUkI+Vl965/WSYbmMRkgKGiHOcKMED866SOR7rRt07F2jYlCeorgex7l9jatLqZkGN63CZ2RgbY4ye5Y+tZl/eNLKWkG64GQdvGPrVd7mae0BmldtqjGT71nXvMAY/eyBmm20hKKepynjL7QLxNRMu8oBxjovcfSuc1uaO8a1uCWdCdpUHIx6V3GvohsnQqu3PTHtXl2SqyKpIVW4APSs3ozrpJctzuLCMWy+SG3LjKtntV4z7MEMB2IHf3zWNYkm0jJJzuHf2q5Iflx2pmbbL4uWVSyk46HBqF7lkQMWIA/MVH2/Cs6TlXBzj60ErUuy6kXBKkbjwexP4Vl3moBExGpbHLBqjnYpD8mAQOuOayY1EtxKZPmIHGTVRRN7DmuXuJWFqpctyVXt+NZc92YZDtKhD94A5wfrUOoyvE8ojbYoxwvA/KsYs0sbGQknNbQijKdZ3Ll3qI2uBIcE59zWZcX7GRgpCgjqetV73jgdBWe33vwrVJHFUryehM90c88k96glmPXPFRSnCCoLceZchH5X0p8qscsptk0KzXUgjt4nlf0UZrrdF8Cz3RD6g5RCMmOPr+JrqfDljawQKIoI14HQc/nXZWaKkICqBXPWrOOiPQoYONuaWplaHoVhpyIkEAUdeV5P5V1djY/ITtCjqBjk//WplmqhFIHPrW3AMCbFcjk5as9JxUVZILewET84Y8ZY+p71etoUf7qjA5PPYd80qHMmTzz/SrpUYdcfKkQKgduaaVybjYoUVSSUkIXO5uik+g71PLMUlmkiHmNwocjHboBVi6x9pPA/5Z9qqSk+fLJn5xLgH0ptWHvuXLX5wFAW386I7mb5i5z61TmlSN1eRAQQY5lYk596cVDxOW5KqCp9DntReAQQu0YAZ0+YkZJ/OhAlZlZzLGuZcW4jXhcfO6H09aWKVmdvslu0qgYeVxklT3K9qLJBI6SPlnBABY549PpU+qSvAPNhby33YyvFCQXJI9OnlaJruZZECAxsCOnsO+Ks77ezYMPK2spDKjD51H8XPQ+1c2rvtX5m5IPWnpGrs+4Z4J60J26CUb7m9Jd2zMZBcBpFTKSY3Db/dYevvUduLa6nCw5ikbO6JjmFx9e1N+yQItq6xjdICGPXIxV77PEkz2yoBBJF8ydj/AIVcXdkSVloY9xYGCYi0ieJGyDBOAYwfr6HrWNqejLJEkUtp5K4AZY+Q3HUHsK7BmL21mzHJmVkkB6MAOMjpWdeqsUtzDGMRAAheuPpVOKsEJs4m48PWV7pjS7p1mQYU5ztYDjnsOK59bqS1it7hJyoyY5lLZI9ea9FjiR4btWXK5zjtmuPurO3awuZTCu8yEE//AFqhxTsa05PZ7G3but5bpPJMHzyJfvOg/wBodxUqo6Fo8AGQZCk/JIPY+tczoztFawtGxVt+3I9K6WwPmwXayAMoXcBjoc9vSktkTLR6CrKpTGGKA42H7yfjSpuLZZs7uNx6N7expoZjPExOSQQfcUp+8o4ww5HY807BcjdgFAPzHt/eT/61M3sGGCN7dD2f60bj8p4yDt6dqhcfu39uR7VJVwlLMCgDFepUDJT/AOtR80SbQVDMA2VOd59RWgT5MUDRfIxVssOp+prMjYvACxyVbj2p2CMtbCGYKQRkgnIBHT1FTo3zkKOcblPqKpsSLkgdN9OJICgEjDHFIuRbabacseJO5H8VVBO5OeQAc496SU5hmB6ZrPlYhGIPIAptWIj3Jp5RHMFXHly4I/2TUc83GeisNrj+6fWqcxLF9xzgAj2NOblhn+JPm9+KaGyK8YyL8wB3jY+f0Ncu8rjUFBJzHkEnsK25Hby25PI5rA1Mn+1vr1rRIcX0NOSdwgCN0IZcDtTQ7GZl3EjhlPvUFp96P3Vs0z+DHPT+tVYxcuhallBy2MB+D7EVQnlGRLjDgAYP8QqGQnbJyfXrWdM7eYPmPIqkjBzZLeXAVG2nAU7lz/KqYnQKTIcZ7ehqrOSZFySeDWdcMcsM9hWqijCdVp2O38H62kElxaS3NvazSyw3NtNM2IhcRMSqueysCRnscVd/soaff3F9Z6FqenXBWQpc6jcRiwst4IaTzBzIAGO0dT715XesQuM8Gsq5LMuGZmVRwpYkD6CtUrHFUqNmt411O21LXC2nlm0+1gis7Z3GGkSNQocjtuOWx2zRWA3eiqOc/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pyogenic granuloma: the epithelial \"collarette\" can be seen at the base of the lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_56_36742=[""].join("\n");
var outline_f35_56_36742=null;
var title_f35_56_36743="Oxaprozin: Pediatric drug information";
var content_f35_56_36743=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oxaprozin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?29/58/30632?source=see_link\">",
"    see \"Oxaprozin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/29/24021?source=see_link\">",
"    see \"Oxaprozin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Daypro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F204389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Oxaprozin&reg;;",
"     </li>",
"     <li>",
"      Daypro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Non-narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/58/30632?source=see_link\">",
"      see \"Oxaprozin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Use lowest effective dose; dose may be divided if patient does not tolerate once daily dosing; Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-16 years: JIA: Dose according to body weight.",
"     <b>",
"      Note:",
"     </b>",
"     Doses greater than 1200 mg have not been evaluated:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     22-31 kg: 600 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     32-54 kg: 900 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;55 kg: 1200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Osteoarthritis or Rheumatoid arthritis: Usual: 1200 mg once daily; titrate to lowest effective dose; patients with low body weight should start with 600 mg daily; a one-time loading dose of 1200 mg to 1800 mg or 26 mg/kg (whichever is lower) may be given if needed; maximum daily dose: 1800 mg or 26 mg/kg (whichever is lower) in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Chronic administration of doses &gt;1200 mg/day should be reserved for adult patients &gt;50 kg with severe disease, low risk for peptic ulcer disease, and normal hepatic and renal function; ensure that patient tolerates lower doses before advancing to larger dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Severe renal impairment or patients on dialysis: Initial: 600 mg once daily; may increase dose if needed to 1200 mg once daily with close monitoring",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Use with caution in patients with severe hepatic dysfunction (dosage reduction is not required in patients with well compensated cirrhosis)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F204364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral: 600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Daypro&reg;: 600 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 600 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F204348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088580.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088580.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to food; administer with food or milk to decrease GI distress",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1054550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); protect from light; keep bottle tightly closed",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of the signs and symptoms of osteoarthritis; adult and juvenile idiopathic arthritis(JIA)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F204421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Oxaprozin may be confused with oxazepam",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F204419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, depression, dizziness, headache, sedation, sleep disturbance, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distress, abdominal pain, anorexia, constipation, diarrhea, dyspepsia, flatulence, gastrointestinal ulcer, gross bleeding with perforation, heartburn, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, bleeding time increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Dysuria, renal function abnormal, urinary frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening (effects reported with oxaprozin or other NSAIDs): Acute interstitial nephritis, acute renal failure, agranulocytosis, alopecia, anaphylaxis, angioedema, anxiety, aplastic anemia, appetite changes, arrhythmia,  asthma, blurred vision, bruising,  coma, conjunctivitis, cystitis, death, diaphoresis, dream abnormalities, drowsiness, dyspnea, eosinophilia, eructation, erythema multiforme, esophagitis, exfoliative dermatitis, fever, gastritis, GI bleeding, glossitis, hallucinations, hearing decreased, heart failure, hematemesis, hematuria, hemolytic anemia, hemorrhoidal bleeding, hepatitis, hyperglycemia, hypersensitivity reaction, hyper-/hypotension, infection, insomnia, jaundice, leukopenia, liver failure, liver function abnormalities, lymphadenopathy, malaise, melena, meningitis, menstrual flow increased/decreased, myocardial infarction, nephrotic syndrome, nervousness, oliguria, palpitation, pancreatitis, pancytopenia, paresthesia, peptic ulcer, photosensitivity, pneumonia, polyuria, proteinuria, pseudoporphyria, pulmonary infection, purpura, rectal bleeding, renal insufficiency, respiratory depression, seizures, sepsis, serum sickness, sinusitis, Stevens-Johnson syndrome, stomatitis, syncope, tachycardia, taste alteration, thrombocytopenia, toxic epidermal necrolysis, tremor, upper respiratory tract infection, urticaria, vasculitis, vertigo, weakness, weight changes, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oxaprozin or any component; history of asthma, urticaria, or allergic-type reaction to aspirin, or other NSAIDs; patients with the \"aspirin triad\" [asthma, rhinitis (with or without nasal polyps), and aspirin intolerance] (fatal asthmatic and anaphylactoid reactions may occur in these patients); perioperative pain in the setting of coronary artery bypass graft (CABG)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe hepatic reactions (rare) may occur. Use with caution in patients with, asthma, dehydration (rehydrate patient before starting therapy), mild-to-moderate renal dysfunction, hepatic dysfunction, coagulation disorders, or those receiving anticoagulants. Safety and efficacy in pediatric patients &lt;6 years of age have not been established. Adverse reactions more frequently reported in patients being treated for JIA (45%) compared to adult rheumatoid arthritis patients (~30%).  May cause photosensitivity reactions; incidence in JIA patients is 30%.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including potentially fatal MI and stroke",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease; carefully evaluate cardiovascular risk profile prior to prescribing; use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk. Use is contraindicated for treatment of perioperative pain in the setting of CABG surgery",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; an increased incidence of MI and stroke was found in patients receiving COX-2 selective NSAIDs for the treatment of pain within the first 10-14 days after CABG surgery. NSAIDs may cause fluid retention, edema, and new onset or worsening of pre-existing hypertension; use with caution in patients with hypertension, CHF, or fluid retention. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     NSAIDs may increase the risk of gastrointestinal inflammation, ulceration, bleeding, and perforation",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . These events, which can be potentially fatal, may occur at any time during therapy, and without warning. Avoid the use of NSAIDs in patients with active GI bleeding or ulcer disease. Use NSAIDs with extreme caution in patients with a history of GI bleeding or ulcers (these patients have a 10-fold increased risk for developing a GI bleed). Use NSAIDs with caution in patients with other risk factors which may increase GI bleeding (eg, concurrent therapy with aspirin, anticoagulants, and/or corticosteroids, longer duration of NSAID use, smoking, use of alcohol, and poor general health). Use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     NSAIDs may compromise existing renal function. Renal toxicity may occur in patients with impaired renal function, dehydration, heart failure, liver dysfunction, and those taking diuretics and ACE inhibitors; use with caution in these patients; monitor renal function closely. NSAIDs are not recommended for use in patients with advanced renal disease. Long-term use of NSAIDs may cause renal papillary necrosis and other renal injury.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Fatal asthmatic and anaphylactoid reactions may occur in patients with the &ldquo;aspirin triad&rdquo; who receive NSAIDs. NSAIDs may cause serious dermatologic adverse reactions including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Avoid use of NSAIDs in late pregnancy as they may cause premature closure of the ductus arteriosus.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F204357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1054564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food may decrease the rate, but not the extent of oral absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F204360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F204373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies oxaprozin as pregnancy category C. NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of an NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians). The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication. A registry is available for pregnant women exposed to autoimmune medications including oxaprozin. For additional information, contact the Organization of Teratology Information Specialists, OTIS Autoimmune Diseases Study, at 877-311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, occult blood loss, liver enzymes, renal function tests; blood pressure, signs and symptoms of GI bleeding",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits prostaglandin synthesis by decreasing the activity of the enzyme, cyclooxygenase, which results in decreased formation of prostaglandin precursors",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maximum effect: Due to its long half-life, several days of treatment are required for oxaprozin to reach its full effect",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into synovial tissues at twice the concentration of plasma and 3 times the concentration of synovial fluid; expected to distribute into breast milk (exact amount not known)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     (apparent): Adults: 11-17 L per 70 kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%, primarily to albumin; protein binding is saturable (nonlinear protein binding)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via microsomal oxidation (65%) and conjugation with glucuronic acid (35%); major conjugated metabolites are ester and ether glucuronide (inactive); small amounts of an active phenolic metabolite is produced (&lt;5%) but has limited contribution to overall activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 41-55 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 2.4-3.1 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Excreted in the urine (5% as unchanged drug, 65% as metabolites) and feces (35% as metabolites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: After adjusting for body weight, no clinically important age-related differences in apparent clearance of unbound drug were identified between adult and pediatric patients &ge;6 years of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not significantly removed by hemodialysis or CAPD due to high protein binding",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/29/24021?source=see_link\">",
"      see \"Oxaprozin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID); NSAIDs may cause serious adverse reactions, especially with overuse; use exactly as directed; do not increase dose or frequency. NSAIDs may increase the risk for heart attack, stroke, or ulcers and bleeding in stomach or intestines; GI bleeding, ulceration, or perforation can occur with or without pain. Notify physician before use if you have hypertension, heart failure, heart or kidney disease, history of stomach ulcers or bleeding in stomach or intestines, or other medical problems. Read the patient Medication Guide that you receive with each prescription and refill of oxaprozin.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     While using this medication, do not use alcohol, excessive amounts of vitamin C, other prescription or OTC medications containing aspirin or salicylate, or other NSAIDs without consulting prescriber. Oxaprozin may cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Notify physician if stomach pain or upset occurs, if swelling or redness occurs in painful area, or if any new symptoms appear. Stop taking medication and report ringing in ears; persistent cramping or stomach pain; unresolved nausea or vomiting; respiratory difficulty or shortness of breath; unusual bruising or bleeding (mouth, urine, stool); skin rash; unusual swelling of extremities; chest pain; palpitations; weight gain; unusual fatigue; or yellow skin.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1054562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An open-label study of oxaprozin (10-20 mg/kg/dose once daily) in 59 JIA patients [3-16 years of age (mean age: 9 years)], reported adverse events in 58% of patients; GI symptoms occurred at a higher incidence than historically reported in adults; 9 of 30 patients (30%) who continued therapy for a total of 19-48 weeks, developed a vesicular rash on sun-exposed areas of skin; 5 of these 9 patients with rash discontinued the drug (Bass, 1985).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bass JC, Athreya BH, Brewer EJ, et al, &ldquo;A Once-Daily Anti-Inflammatory Drug, Oxaprozin, in the Treatment of Juvenile Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       J Rheumatol",
"      </i>",
"      , 1985, 12(2):384-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/56/36743/abstract-text/4032415 /pubmed\" id=\"4032415 \" target=\"_blank\">",
"        4032415",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12963 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-3A7D25EF8E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_56_36743=[""].join("\n");
var outline_f35_56_36743=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709185\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204388\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204389\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054554\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054546\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204364\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204348\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874763\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054557\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054550\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054556\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204421\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204419\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054561\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054545\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054544\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299800\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204357\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054564\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204360\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204373\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054553\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054543\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054559\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054560\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054552\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054562\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12963\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12963|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/58/30632?source=related_link\">",
"      Oxaprozin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/29/24021?source=related_link\">",
"      Oxaprozin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_56_36744="Parathyroid hormone secretion and action";
var content_f35_56_36744=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Parathyroid hormone secretion and action",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/56/36744/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/56/36744/contributors\">",
"     Ghada El-Hajj Fuleihan, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/56/36744/contributors\">",
"     Edward M Brown, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/56/36744/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/56/36744/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/56/36744/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/56/36744/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/56/36744/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parathyroid hormone (PTH) is one of the two major hormones modulating calcium and phosphate homeostasis, the other being calcitriol (1,25-dihydroxyvitamin D) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/1\">",
"     1",
"    </a>",
"    ]. The minute-to-minute regulation of serum ionized calcium is exclusively regulated through PTH, maintaining the concentration of this cation within a narrow range, through stimulation of renal tubular calcium reabsorption and bone resorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. On a more chronic basis, PTH also stimulates the conversion of calcidiol (25-hydroxyvitamin D) to calcitriol in renal tubular cells, thereby stimulating intestinal calcium absorption. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2631?source=see_link\">",
"     \"Chapter 6F: Hormonal regulation of calcium and phosphate balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PTH secretion is, in turn, regulated by serum ionized calcium acting via an exquisitely sensitive calcium-sensing receptor (CaSR) on the surface of parathyroid cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/4\">",
"     4",
"    </a>",
"    ]. The receptor has a long amino terminus, seven transmembrane segments, and a shorter intracellular carboxyl terminus (",
"    <a class=\"graphic graphic_figure graphicRef58478 \" href=\"mobipreview.htm?35/8/35983\">",
"     figure 1",
"    </a>",
"    ). When activated by a small increase in serum ionized calcium, the calcium-receptor complex acts via one or more guanine nucleotide-binding (G) protein through second messengers such as intracellular calcium and inositol phosphates to inhibit PTH secretion. Conversely, the effect of deactivation of the receptor by a small decrease in serum ionized calcium is to stimulate PTH secretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL PTH SECRETION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     PTH synthesis and degradation",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTH is synthesized as a 115- amino acid polypeptide called pre-pro-PTH, which is cleaved within parathyroid cells at the N-terminal portion first to pro-PTH (90 amino acids) and then to PTH (84 amino acids). The latter is the major storage, secreted, and biologically active form of the hormone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The biosynthetic process is estimated to take less than one hour. The N-terminal cleaved pre-sequence is rich in hydrophobic amino acids that are necessary for transport into the endoplasmic reticulum, while the basic pro-peptide directs accurate cleavage of pro-PTH into the mature 1-84 molecule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/6\">",
"     6",
"    </a>",
"    ]. The C-terminal portion of PTH is also essential for the PTH secretory process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/6\">",
"     6",
"    </a>",
"    ]. PTH 1-84 is secreted by exocytosis within seconds after induction of hypocalcemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/5\">",
"     5",
"    </a>",
"    ]. Calcium regulates not only the release but also the synthesis and degradation of PTH, in all its molecular forms as described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to intact PTH, some inactive carboxyl-terminal fragments and small amounts of active amino-terminal fragments of PTH are present in the parathyroid glands. During hypocalcemia, intracellular degradation of PTH decreases, and mostly PTH 1-84 is secreted; in comparison, during hypercalcemia mostly biologically inactive carboxyl-terminal fragments of PTH are secreted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/1,3,7\">",
"     1,3,7",
"    </a>",
"    ]. These carboxy-terminal fragments include long, amino-terminally cleaved species, such as PTH 7-84, which possesses some biological activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/58/21416?source=see_link&amp;anchor=H7#H7\">",
"     \"Parathyroid hormone assays and their clinical use\", section on 'PTH fragments'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Under normocalcemic conditions, PTH 1-84 constitutes 20 percent of total circulating PTH molecules. This proportion increases to 33 percent under hypocalcemic conditions, and decreases to 4 percent in the presence of hypercalcemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/7\">",
"     7",
"    </a>",
"    ]. Once secreted, PTH is rapidly cleared from plasma through uptake principally by the liver and kidney, where PTH 1-84 is cleaved into amino- and carboxyl-terminal fragments that are then cleared by the kidney.",
"   </p>",
"   <p>",
"    Intact PTH has a plasma half-life of two to four minutes. In comparison, the C-terminal fragments, which are cleared principally by the kidney, have half-lives that are 5 to 10 times greater. As a result, circulating immunoreactive PTH in normal subjects comprises:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intact PTH &mdash; 5 to 30 percent",
"     </li>",
"     <li>",
"      C-terminal fragments &mdash; 70 to 95 percent",
"     </li>",
"     <li>",
"      N-terminal fragments &mdash; a small percentage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The currently available PTH assays are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/58/21416?source=see_link&amp;anchor=H2#H2\">",
"     \"Parathyroid hormone assays and their clinical use\", section on 'PTH assays'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     PTH receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTH, in its various molecular forms, acts by binding to and activating one of several types of PTH receptors recognized to date [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/6\">",
"     6",
"    </a>",
"    ]. The classical",
"    <span class=\"nowrap\">",
"     PTH/PTHrP",
"    </span>",
"    receptor, otherwise known as PTH1R, was cloned in 1991 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/8\">",
"     8",
"    </a>",
"    ]. This receptor is heavily expressed in bone and kidney, and is also present in other tissues such as breast, skin, heart, blood vessels, pancreas, and others that are not regarded as classical PTH target tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/6\">",
"     6",
"    </a>",
"    ]. The PTH1R binds intact PTH and biologically active N-terminal hormone fragments of PTH, such as PTH 1-34. It recognizes both PTH and PTH-related protein (PTHrP) due to the substantial degree of homology in the N-terminal parts of these two moieties.",
"   </p>",
"   <p>",
"    Subsequently, a closely related receptor was isolated, named the PTH2 receptor (PTH2R), which selectively binds PTH but not PTHrP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/6\">",
"     6",
"    </a>",
"    ]. It is heavily expressed in the central nervous system, cardiovascular and gastrointestinal systems, as well as lung and testes, and may be involved in the perception of pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/6\">",
"     6",
"    </a>",
"    ]. It binds PTH only weakly in rodents; the physiologically relevant ligand for this wrongly named receptor is TIP39, a distant member of the PTH family. The physiologic TIP39 and its receptor appear to have nothing to do with calcium metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increasing evidence points to the presence of novel PTH receptors (C-PTHRs) with specificity for the carboxyl-terminal region of PTH, a portion of the hormone that was previously thought to be biologically inert but has now been shown to possess hypocalcemic activity. The C-PTHRs are present in various tissues but are most heavily expressed in bone (",
"    <a class=\"graphic graphic_figure graphicRef74939 \" href=\"mobipreview.htm?17/17/17681\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Activation of the PTH1R activates multiple cellular signaling pathways including cAMP, the PLC pathway, PKC, and release of intracellular calcium stores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/6,11-13\">",
"     6,11-13",
"    </a>",
"    ]. The details of how these intracellular signal transduction pathways ultimately stimulate bone resorption, renal tubular calcium reabsorption, or hydroxylation of calcidiol remain to be fully elucidated.",
"   </p>",
"   <p>",
"    The biologic activity of PTH (at least its hypercalcemic effect) resides in its amino-terminus, as demonstrated by the observation that the activities of PTH 1-34 and PTH 1-84 are similar on a molar basis. However, not all N-terminal fragments are equally bio-potent in assays of receptor binding and cAMP activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/14\">",
"     14",
"    </a>",
"    ]. Conversely, an increasing body of evidence supports a hypocalcemic effect of C-terminal fragment of PTH, PTH 7-84, that is reversed by PTH 1-34 and PTH 1-84 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/15\">",
"     15",
"    </a>",
"    ]. The amino terminus of parathyroid hormone-related peptide (PTHrP) is structurally similar to that of PTH; it causes hypercalcemia in patients with PTHrP-secreting tumors by activating the same receptor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Calcium-PTH interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracellular calcium ions regulate numerous biological processes, including intracellular signaling for secretion of many hormones, muscle contraction, and the coagulation cascade. It is therefore important that serum ionized calcium concentrations be maintained within a very narrow range, which is achieved by the close interrelationship between serum ionized calcium and PTH secretion.",
"   </p>",
"   <p>",
"    This relationship is described by an inverse sigmoidal curve, based on studies of PTH secretion both in vivo and in vitro (",
"    <a class=\"graphic graphic_figure graphicRef50252 \" href=\"mobipreview.htm?33/8/33935\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. The midpoint or set-point of the calcium-PTH curve is a key determinant of the serum ionized calcium concentration in vivo, and the steepness of the curve ensures that this concentration varies little. In normal subjects, a decrease in serum ionized calcium of as little as 0.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.025",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    results in a large increase in serum PTH concentration within minutes; conversely, an equally small increase in serum ionized calcium rapidly lowers the serum PTH concentration.",
"   </p>",
"   <p>",
"    The PTH response to hypocalcemia has the following temporal profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seconds to minutes &mdash; exocytosis of PTH from secretory vesicles into the extracellular fluid.",
"     </li>",
"     <li>",
"      Minutes to one hour &mdash; reduction in the intracellular degradation of PTH.",
"     </li>",
"     <li>",
"      Hours to days &mdash; increase in PTH gene expression as a result of stabilization of PTH mRNA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/17\">",
"       17",
"      </a>",
"      ] (also stimulated by low serum calcitriol concentrations, owing to increased transcription of the PTH gene).",
"     </li>",
"     <li>",
"      Days to weeks &mdash; proliferation of parathyroid cells (also stimulated by low serum calcitriol concentrations).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Calcitriol and other ions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parathyroid cells contain vitamin D receptors, and the PTH gene contains a vitamin D-response element. Calcitriol, by binding to the vitamin D receptor, inhibits PTH gene expression and therefore PTH synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/17\">",
"     17",
"    </a>",
"    ]. Calcitriol also inhibits parathyroid-cell proliferation.",
"   </p>",
"   <p>",
"    Magnesium, aluminum, and strontium bind to the CaSR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/3,18\">",
"     3,18",
"    </a>",
"    ]. These ions also regulate PTH secretion in vitro with an apparent affinity that is similar to or somewhat lower than that of calcium. While the concentration of magnesium in serum approaches a level that might modulate receptor activity, the concentrations of aluminum and strontium are normally far below those that activate the CaSR and, therefore, the effects of the latter two on PTH secretion in vivo are negligible.",
"   </p>",
"   <p>",
"    Hyperphosphatemia also stimulates PTH secretion, at least in part by increasing PTH mRNA stability, and parathyroid-cell growth. These responses may be mediated, in part, by the induction of hypocalcemia as the following reaction is driven to the right:",
"   </p>",
"   <p>",
"    &nbsp;Ca++ &nbsp;+ &nbsp;HPO4-- &nbsp; &nbsp;&lt;--&gt; &nbsp; &nbsp;CaHPO4",
"   </p>",
"   <p>",
"    However, small elevations in serum phosphate concentrations may not be sufficient to lower serum calcium concentrations to a level that stimulates PTH secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, there is increasing evidence that hyperphosphatemia (independent of the serum concentrations of calcium and calcitriol) directly stimulates PTH synthesis and secretion, as well as parathyroid cellular proliferation, in patients with advanced renal failure, the most common cause of hyperphosphatemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38474?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\", section on 'Overview of secondary hyperparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other hormones and drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parathyroid cells contain beta-adrenergic and histamine-H2 receptors. However, PTH secretion in humans is not altered by either adrenergic or histaminergic stimulation or blockade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ALTERED CALCIUM-SENSING ON PTH SECRETION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mutations in the calcium receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activating or inactivating mutations in the CaSR result in altered calcium-sensing and therefore inappropriate PTH release with respect to the prevailing serum calcium concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/23-27\">",
"     23-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In familial hypocalciuric hypercalcemia (FHH), serum PTH concentrations are inappropriately normal or high in the presence of mild hypercalcemia.",
"     </li>",
"     <li>",
"      In autosomal dominant hypocalcemia, serum PTH concentrations are inappropriately normal or low despite the presence of mild hypocalcemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These disorders are caused, respectively, by loss-of-function and gain-of-function mutations of the CaSR. An inactivating mutation produces a shift in the calcium-PTH curve to the right and hypercalcemia, since higher concentrations of calcium are required to suppress PTH release [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/23-25\">",
"     23-25",
"    </a>",
"    ], while an activating mutation shifts the curve to the left and causes hypocalcemia (",
"    <a class=\"graphic graphic_figure graphicRef50252 \" href=\"mobipreview.htm?33/8/33935\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19258?source=see_link\">",
"     \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Primary hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with hyperparathyroidism caused by a parathyroid adenoma or hyperplasia, PTH secretion is inappropriately high in relation to the serum calcium concentration (the serum calcium-PTH curve is shifted to the right) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/2\">",
"     2",
"    </a>",
"    ]. The cellular basis for the shift is probably a combination of decreased sensitivity of the parathyroid cells to calcium, possibly due to a decrease in the number of functional CaSRs, or an increase in parathyroid cell mass, or both. The molecular basis of primary hyperparathyroidism is known in only a small fraction of cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30361?source=see_link\">",
"     \"Pathogenesis and etiology of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Secondary hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with kidney failure who have uncontrolled hyperparathyroidism, increased secretion of parathyroid hormone is related not only to gland hyperplasia, but also to reduced expression of calcium-sensing receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. This results in reduced responsiveness to calcium levels, with continued secretion of PTH despite normal or high calcium levels and ultimately, in some cases, in parathyroid autonomy. In patients with secondary hyperparathyroidism from severe vitamin D deficiency, four gland parathyroid hyperplasia constitutes the primary pathophysiology, and such hyperplasia may take months to over a year to reverse to normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38474?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\", section on 'Overview of secondary hyperparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Lithium and PTH secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    (Li) is a mood stabilizer that is used in the management of bipolar disorder. It has been associated with several metabolic complications including nephrogenic diabetes insipidus, hypothyroidism, and hyperparathyroidism.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    affects calcium-sensing in vitro and in vivo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In a study of calcium-PTH dynamics in seven young normocalcemic women who had taken lithium for a mean of 5.2 years, the serum calcium-PTH curve was shifted to the right, as compared with normal subjects, reflecting reduced sensitivity of PTH secretion to inhibition by calcium (",
"    <a class=\"graphic graphic_figure graphicRef66597 \" href=\"mobipreview.htm?12/41/12958\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    also affects renal calcium-sensing by decreasing renal calcium excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/33\">",
"     33",
"    </a>",
"    ], an effect that seems to be independent of PTH levels. This dual effect of lithium at the level of the parathyroid gland and kidney is reminiscent of the pathophysiology of familial hypocalciuric hypercalcemia, and is highly suggestive of altered calcium-sensing at the level of the calcium-sensing receptor. This would also be consistent with the observation that although serum calcium concentrations increase with lithium, they remain within the normal range in most lithium-treated patients.",
"   </p>",
"   <p>",
"    However, from 10 to 25 percent of patients receiving chronic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    therapy develop mild hypercalcemia and slightly high serum PTH concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/33\">",
"     33",
"    </a>",
"    ]. Some of these patients probably have coincidental primary hyperparathyroidism, because the hypercalcemia persists after lithium is discontinued. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30361?source=see_link\">",
"     \"Pathogenesis and etiology of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Calcimimetic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the cloning and sequencing of the CaSR, efforts have focused on synthesizing agonists of the calcium-sensing receptor (calcimimetics) that would inhibit PTH secretion and synthesis and also parathyroid-cell proliferation. Such a drug might be useful for the treatment of patients with primary or secondary hyperparathyroidism, provided that it did not mimic the effects of calcium in other tissues. One such drug (norcalcin or R-568) had been developed, but its effects were very short-lived and its metabolic clearance by the P-450 pathway varied widely among patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. A longer-acting calcimimetic drug,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    , is available for the treatment of secondary hyperparathyroidism associated with renal failure, and for hypercalcemia in parathyroid cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13688?source=see_link\">",
"     \"Parathyroid carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=see_link\">",
"     \"Management of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nonhypercalcemic vitamin D analogues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several calcitriol analogues, oxacalcitriol,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32774?source=see_link\">",
"     paricalcitol",
"    </a>",
"    (19-nor, Zemplar), and 1-alpha-hydroxyvitamin D2 (Hectorol), have been developed that inhibit PTH synthesis and secretion to a greater extent than they stimulate intestinal calcium absorption or bone resorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Such analogues are available for use in patients with chronic renal failure and secondary hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Ectopic PTH secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few patients with hypercalcemia and non-parathyroid tumors that secreted PTH have been reported but, in the vast majority, the hypercalcemia is due to tumor overproduction of PTHrP. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5545?source=see_link\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ACTIONS OF PTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classical effects of PTH on calcium and phosphate homeostasis, namely elevation of serum calcium, phosphaturia, and calcitriol synthesis, are mediated through the",
"    <span class=\"nowrap\">",
"     PTH/PTHrP",
"    </span>",
"    receptor, a G-coupled receptor that is mostly expressed in bone and kidney, but is also present in fetal tissue and growth plate chondrocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/38\">",
"     38",
"    </a>",
"    ]. Loss-of-function mutations of the",
"    <span class=\"nowrap\">",
"     PTH/PTHrP",
"    </span>",
"    receptor result in severe skeletal dysplasia (Blomstrand chondrodysplasia), as well as severe abnormalities in breast and tooth development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Skeletal actions of PTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTH acts on bone, the main reservoir of calcium, to release calcium in two phases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The immediate effect of PTH is to mobilize calcium from skeletal stores that are readily available and in equilibrium with the extracellular fluid.",
"     </li>",
"     <li>",
"      Later, PTH stimulates release of calcium (and also phosphate) by activation of bone resorption.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevailing view has been that osteoblasts, but not osteoclasts, express PTH receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, osteoclast formation requires an interaction with cells of the osteoblastic lineage, which may depend upon cell-cell contact and regulators of osteoclast formation such as RANK (the receptor activator of nuclear factor kappaB), osteoprotegerin, and RANK ligand (RANKL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/42\">",
"     42",
"    </a>",
"    ]. PTH increases osteoclast activity and number indirectly through effects on RANKL and osteoprotegerin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=see_link\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\"",
"    </a>",
"    .) However, increasing evidence suggests a binding of intact PTH, but not PTH 1-34 to osteoclasts, possibly through the novel CPTHRs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'PTH receptors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The net effect of PTH on bone varies according to the severity and chronicity of the PTH excess, ranging from osteopenia to osteitis fibrosa cystica. Trabecular bone volume seems to be preserved at the expense of cortical bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1338?source=see_link\">",
"     \"Clinical manifestations of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Furthermore, while chronic hyperparathyroidism results in bone resorption, intermittent administration of PTH stimulates bone formation more than bone resorption. Thus, administration of PTH subcutaneously once daily results in substantial increments in bone mineral density and a decrease in the risk of both vertebral and non-vertebral fractures in patients with osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. The positive effect of intermittent PTH on bone appears to be mediated through the PTH1R, in view of the equivalence of PTH (1-84) and PTH (1-34) in bone anabolism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link\">",
"     \"Parathyroid hormone therapy for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific elements of the PTH molecule seem essential for bone anabolism. As an example, N-terminal truncation of the first two amino-acids of PTH eliminates most of the cAMP signaling, a pathway that seems important for but not predictive of the anabolic effect of PTH on bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/14,50\">",
"     14,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Renal actions of PTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The kidney plays a major role in mineral ion homeostasis that is largely mediated by the actions of PTH and extracellular calcium ions on their respective receptors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Reabsorption of calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Filtered calcium is reabsorbed along much of the nephron. The mechanisms by which it is reabsorbed and their regulation, however, vary as a function of location along the nephron. Most filtered calcium is reabsorbed passively in the proximal tubule down the favorable electrochemical gradients created by sodium and water reabsorption. In contrast, calcium transport is actively regulated in the distal nephron according to the needs of the organism. This takes place in the cortical thick ascending limb of the loop of Henle (cTAL) as well as in the distal convoluted tubule (DCT) and adjacent connecting segment (a small segment between the distal tubule and cortical collecting tubule) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PTH acts at both cTAL and DCT in the distal tubule to stimulate calcium reabsorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/53\">",
"     53",
"    </a>",
"    ]. Thus, if PTH secretion falls appropriately after an increase in serum ionized calcium, the ensuing fall in tubular calcium reabsorption and increase in calcium excretion will tend to restore normocalcemia. The high serum calcium itself also contributes to the calciuresis, acting via the calcium-sensing receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Reabsorption of phosphate",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTH is the major hormonal determinant of serum phosphate concentrations. It inhibits mostly proximal but also distal tubular reabsorption of phosphorus. This effect is primarily mediated by decreased activity, internalization, and degradation of the sodium-phosphate cotransporter in the luminal membrane of the proximal tubules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Synthesis of calcitriol",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTH stimulates the synthesis of 1-alpha hydroxylase in the proximal tubules and thus conversion of calcidiol to calcitriol. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9462?source=see_link\">",
"     \"Metabolism of vitamin D\"",
"    </a>",
"    .) Approximately 50 percent of patients with primary hyperparathyroidism have high serum calcitriol concentrations as a result of this action of PTH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PTH also decreases the activity of a 24-hydroxylase that inactivates calcitriol. This is a particularly important action of PTH in maintaining calcium homeostasis in states of vitamin D deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other actions of PTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility that PTH acts on other tissues has been raised in attempts to explain certain clinical manifestations of hyperparathyroidism, and some experimental studies have found effects of PTH on the intestine, liver, adipose tissue, cardiovascular function, and neuromuscular function. As an example, impaired glucose tolerance and alterations in lipid metabolism reminiscent of the metabolic syndrome have been described in hyperparathyroidism. Similarly, patients with primary hyperparathyroidism have an increased incidence of hypertension, left ventricular hypertrophy, and neuromuscular abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1338?source=see_link\">",
"     \"Clinical manifestations of primary hyperparathyroidism\"",
"    </a>",
"    .) In addition, chronic excess of PTH has been implicated in the pathogenesis of vascular calcification and hypertension in patients with chronic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    .) These non-classical effects of PTH may be mediated by differing PTH moieties",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    differing PTH receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36744/abstract/6\">",
"     6",
"    </a>",
"    ]. Moreover, the extent to which these abnormalities improve after parathyroidectomy varies considerably, and whether they are actually directly caused by PTH excess is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PTH is synthesized as a 115- amino acid polypeptide called pre-pro-PTH, which is cleaved within parathyroid cells at the N-terminal portion first to pro-PTH (90 amino acids) and then to PTH (84 amino acids). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'PTH synthesis and degradation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Calcium regulates not only the release of PTH but also its synthesis and degradation. In normal subjects, a decrease in serum ionized calcium of as little as 0.1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.025",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      results in a large increase in serum PTH concentration within minutes; conversely, an equally small increase in serum ionized calcium rapidly lowers the serum PTH concentration (",
"      <a class=\"graphic graphic_figure graphicRef50252 \" href=\"mobipreview.htm?33/8/33935\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Calcium-PTH interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PTH 1-84 has a plasma half-life of two to four minutes. Once secreted, PTH is rapidly cleared from plasma through uptake principally by the liver and kidney, where PTH 1-84 is cleaved into amino- and carboxyl-terminal fragments that are then cleared by the kidney. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'PTH synthesis and degradation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PTH acts by binding to and activating one of several types of PTH receptors. The classical PTH receptor is PTH1R, which is heavily expressed in bone and kidney, and is also present in other tissues such as breast, skin, heart, blood vessels, and pancreas. The PTH1R binds PTH 1-84 and biologically active N-terminal hormone fragments of PTH, such as PTH 1-34. It recognizes both PTH and PTH-related protein (PTHrP) due to the substantial degree of homology in the N-terminal parts of these two moieties. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'PTH receptors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Activation of the PTH1R by PTH triggers multiple cellular signaling pathways, which ultimately stimulate bone resorption, renal tubular calcium reabsorption and phosphate excretion,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hydroxylation of calcidiol to calcitriol, which enhances gastrointestinal absorption of calcium. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'PTH receptors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Potts JT, Juppner H. Parathyroid hormone: Molecular biology and regulation. In: Principles of Bone Biology, Bilezikian JP, Raisz LG, Rodan GA (Eds), Academic Press, San Diego 1996. p.325.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/2\">",
"      Brown EM. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 1983; 56:572.",
"     </a>",
"    </li>",
"    <li>",
"     Diaz R, El-Hajj Fuleihan G, Brown EM. Regulation of parathyroid function. In: Handbook of Physiology, Section 7: The Endocrine System, Fray GGS (Ed), Oxford University Press, New York 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/4\">",
"      Brown EM, Pollak M, Seidman CE, et al. Calcium-ion-sensing cell-surface receptors. N Engl J Med 1995; 333:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/5\">",
"      Habener JF, Kemper BW, Rich A, Potts JT Jr. Biosynthesis of parathyroid hormone. Recent Prog Horm Res 1976; 33:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/6\">",
"      Murray TM, Rao LG, Divieti P, Bringhurst FR. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl- terminal ligands. Endocr Rev 2005; 26:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/7\">",
"      D'Amour P, R&auml;kel A, Brossard JH, et al. Acute regulation of circulating parathyroid hormone (PTH) molecular forms by calcium: utility of PTH fragments/PTH(1-84) ratios derived from three generations of PTH assays. J Clin Endocrinol Metab 2006; 91:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/8\">",
"      J&uuml;ppner H, Abou-Samra AB, Freeman M, et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 1991; 254:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/9\">",
"      Gardella TJ, J&uuml;ppner H. Molecular properties of the PTH/PTHrP receptor. Trends Endocrinol Metab 2001; 12:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/10\">",
"      Dobolyi A, Palkovits M, Usdin TB. The TIP39-PTH2 receptor system: unique peptidergic cell groups in the brainstem and their interactions with central regulatory mechanisms. Prog Neurobiol 2010; 90:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/11\">",
"      Dunlay R, Hruska K. PTH receptor coupling to phospholipase C is an alternate pathway of signal transduction in bone and kidney. Am J Physiol 1990; 258:F223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/12\">",
"      Hruska KA, Moskowitz D, Esbrit P, et al. Stimulation of inositol trisphosphate and diacylglycerol production in renal tubular cells by parathyroid hormone. J Clin Invest 1987; 79:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/13\">",
"      Abou-Samra AB, Jueppner H, Westerberg D, et al. Parathyroid hormone causes translocation of protein kinase-C from cytosol to membranes in rat osteosarcoma cells. Endocrinology 1989; 124:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/14\">",
"      Murrills RJ, Matteo JJ, Samuel RL, et al. In vitro and in vivo activities of C-terminally truncated PTH peptides reveal a disconnect between cAMP signaling and functional activity. Bone 2004; 35:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/15\">",
"      J&uuml;ppner H, Potts JT Jr. Immunoassays for the detection of parathyroid hormone. J Bone Miner Res 2002; 17 Suppl 2:N81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/16\">",
"      Haden ST, Brown EM, Hurwitz S, et al. The effects of age and gender on parathyroid hormone dynamics. Clin Endocrinol (Oxf) 2000; 52:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/17\">",
"      Naveh-Many T, Friedlaender MM, Mayer H, Silver J. Calcium regulates parathyroid hormone messenger ribonucleic acid (mRNA), but not calcitonin mRNA in vivo in the rat. Dominant role of 1,25-dihydroxyvitamin D. Endocrinology 1989; 125:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/18\">",
"      El-Hajj Fuleihan G. Strontium ranelate--a novel therapy for osteoporosis or a permutation of the same? N Engl J Med 2004; 350:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/19\">",
"      Adler AJ, Ferran N, Berlyne GM. Effect of inorganic phosphate on serum ionized calcium concentration in vitro: a reassessment of the \"trade-off hypothesis\". Kidney Int 1985; 28:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/20\">",
"      Naveh-Many T, Rahamimov R, Livni N, Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 1995; 96:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/21\">",
"      Slatopolsky E, Finch J, Denda M, et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996; 97:2534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/22\">",
"      Fine A, Cox D, Fontaine B. Elevation of serum phosphate affects parathyroid hormone levels in only 50% of hemodialysis patients, which is unrelated to changes in serum calcium. J Am Soc Nephrol 1993; 3:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/23\">",
"      Cole DE, Peltekova VD, Rubin LA, et al. A986S polymorphism of the calcium-sensing receptor and circulating calcium concentrations. Lancet 1999; 353:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/24\">",
"      Pollak MR, Brown EM, Chou YH, et al. Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 1993; 75:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/25\">",
"      Pollak MR, Chou YH, Marx SJ, et al. Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Effects of mutant gene dosage on phenotype. J Clin Invest 1994; 93:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/26\">",
"      Pollak MR, Brown EM, Estep HL, et al. Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation. Nat Genet 1994; 8:303.",
"     </a>",
"    </li>",
"    <li>",
"     El-Hajj Fuleihan G, Brown EM, Heath H III. Familial benign hypocalciuric hypercalcemia and neonatal primary hyperparathyroidism. In: Principles of Bone Biology, Bilezikian JP, Raisz LG, Rodan GA (Eds), Academic Press, San Diego 2002. p.1031.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/28\">",
"      Yano S, Sugimoto T, Tsukamoto T, et al. Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int 2000; 58:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/29\">",
"      Ca&ntilde;adillas S, Canalejo A, Santamar&iacute;a R, et al. Calcium-sensing receptor expression and parathyroid hormone secretion in hyperplastic parathyroid glands from humans. J Am Soc Nephrol 2005; 16:2190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/30\">",
"      Al-Ali H, Fuleihan GE. Nutritional osteomalacia: substantial clinical improvement and gain in bone density posttherapy. J Clin Densitom 2000; 3:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/31\">",
"      Brown EM. Lithium induces abnormal calcium-regulated PTH release in dispersed bovine parathyroid cells. J Clin Endocrinol Metab 1981; 52:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/32\">",
"      Haden ST, Stoll AL, McCormick S, et al. Alterations in parathyroid dynamics in lithium-treated subjects. J Clin Endocrinol Metab 1997; 82:2844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/33\">",
"      Kallner G, Petterson U. Renal, thyroid and parathyroid function during lithium treatment: laboratory tests in 207 people treated for 1-30 years. Acta Psychiatr Scand 1995; 91:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/34\">",
"      Silverberg SJ, Bone HG 3rd, Marriott TB, et al. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 1997; 337:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/35\">",
"      Goodman WG, Frazao JM, Goodkin DA, et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000; 58:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/36\">",
"      Martin KJ, Gonz&aacute;lez EA, Gellens M, et al. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/37\">",
"      Tan AU Jr, Levine BS, Mazess RB, et al. Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997; 51:317.",
"     </a>",
"    </li>",
"    <li>",
"     Segre GV. Receptors for parathyroid hormone and parathyroid hormone-related protein. In: Principles of Bone Biology, Bilezikian JP, Raisz LG, Rodan GA (Eds), Academic Press, San Diego 1996. p.377.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/39\">",
"      Karperien M, van der Harten HJ, van Schooten R, et al. A frame-shift mutation in the type I parathyroid hormone (PTH)/PTH-related peptide receptor causing Blomstrand lethal osteochondrodysplasia. J Clin Endocrinol Metab 1999; 84:3713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/40\">",
"      Wysolmerski JJ, Cormier S, Philbrick WM, et al. Absence of functional type 1 parathyroid hormone (PTH)/PTH-related protein receptors in humans is associated with abnormal breast development and tooth impaction. J Clin Endocrinol Metab 2001; 86:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/41\">",
"      TALMAGE RV, ELLIOTT JR. Removal of calcium from bone as influenced by the parathyroids. Endocrinology 1958; 62:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/42\">",
"      Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998; 95:3597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/43\">",
"      Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999; 140:3552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/44\">",
"      Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989; 4:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/45\">",
"      Parisien M, Silverberg SJ, Shane E, et al. The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab 1990; 70:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/46\">",
"      Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997; 350:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/47\">",
"      Finkelstein JS, Klibanski A, Schaefer EH, et al. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 1994; 331:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/48\">",
"      Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/49\">",
"      Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/50\">",
"      Mohan S, Kutilek S, Zhang C, et al. Comparison of bone formation responses to parathyroid hormone(1-34), (1-31), and (2-34) in mice. Bone 2000; 27:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/51\">",
"      Friedman PA, Gesek FA. Calcium transport in renal epithelial cells. Am J Physiol 1993; 264:F181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/52\">",
"      van Abel M, Hoenderop JG, van der Kemp AW, et al. Coordinated control of renal Ca(2+) transport proteins by parathyroid hormone. Kidney Int 2005; 68:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/53\">",
"      Gesek FA, Friedman PA. On the mechanism of parathyroid hormone stimulation of calcium uptake by mouse distal convoluted tubule cells. J Clin Invest 1992; 90:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/54\">",
"      Hebert SC. Extracellular calcium-sensing receptor: implications for calcium and magnesium handling in the kidney. Kidney Int 1996; 50:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/55\">",
"      el-Hajj Fuleihan G, Seifter J, Scott J, Brown EM. Calcium-regulated renal calcium handling in healthy men: relationship to sodium handling. J Clin Endocrinol Metab 1998; 83:2366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/56\">",
"      Murer H, L&ouml;tscher M, Kaissling B, et al. Renal brush border membrane Na/Pi-cotransport: molecular aspects in PTH-dependent and dietary regulation. Kidney Int 1996; 49:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/57\">",
"      Pfister MF, Lederer E, Forgo J, et al. Parathyroid hormone-dependent degradation of type II Na+/Pi cotransporters. J Biol Chem 1997; 272:20125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/58\">",
"      Broadus AE, Horst RL, Lang R, et al. The importance of circulating 1,25-dihydroxyvitamin D in the pathogenesis of hypercalciuria and renal-stone formation in primary hyperparathyroidism. N Engl J Med 1980; 302:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/59\">",
"      Neves KR, Graciolli FG, dos Reis LM, et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 2007; 71:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36744/abstract/60\">",
"      Rostand SG, Dr&uuml;eke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999; 56:383.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2050 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-E64CDCC3B7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_56_36744=[""].join("\n");
var outline_f35_56_36744=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL PTH SECRETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PTH synthesis and degradation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PTH receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Calcium-PTH interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Calcitriol and other ions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other hormones and drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ALTERED CALCIUM-SENSING ON PTH SECRETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mutations in the calcium receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Secondary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Lithium and PTH secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Calcimimetic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nonhypercalcemic vitamin D analogues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Ectopic PTH secretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ACTIONS OF PTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Skeletal actions of PTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Renal actions of PTH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Reabsorption of calcium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Reabsorption of phosphate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Synthesis of calcitriol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other actions of PTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2050\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2050|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/8/35983\" title=\"figure 1\">",
"      Structure calcium receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/17/17681\" title=\"figure 2\">",
"      Secretion and metabolism PT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/8/33935\" title=\"figure 3\">",
"      PTH and calcium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/41/12958\" title=\"figure 4\">",
"      Ca-PTH dynamics lithium",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2631?source=related_link\">",
"      Chapter 6F: Hormonal regulation of calcium and phosphate balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1338?source=related_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19258?source=related_link\">",
"      Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=related_link\">",
"      Management of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32681?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9462?source=related_link\">",
"      Metabolism of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13688?source=related_link\">",
"      Parathyroid carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/58/21416?source=related_link\">",
"      Parathyroid hormone assays and their clinical use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=related_link\">",
"      Parathyroid hormone therapy for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30361?source=related_link\">",
"      Pathogenesis and etiology of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=related_link\">",
"      Vascular calcification in chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_56_36745="Muscle enzymes in the evaluation of neuromuscular diseases";
var content_f35_56_36745=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Muscle enzymes in the evaluation of neuromuscular diseases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/56/36745/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/56/36745/contributors\">",
"     Marc L Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/56/36745/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/56/36745/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/56/36745/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/56/36745/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/56/36745/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/56/36745/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The measurement of serum levels of muscle enzymes is a critical part of the evaluation of patients presenting with weakness or myalgias and is important in monitoring the course and response to therapy of certain muscular disorders. Creatine kinase (CK), lactate dehydrogenase (LD), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and aldolase are the serum enzymes that are measured in clinical practice.",
"   </p>",
"   <p>",
"    This topic will review the biochemistry of muscle enzymes and their use in clinical practice. The biochemistry and use of serum enzymes in patients with renal failure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/38/33381?source=see_link\">",
"     \"Serum enzymes in patients with renal failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11701?source=see_link\">",
"     \"Serum cardiac enzymes in patients with renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY OF MUSCLE ENZYMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Creatine kinase",
"    </span>",
"    &nbsp;&mdash;&nbsp;CK is the most widely used enzyme to diagnose and follow muscle disease. It is present in the highest concentrations in serum in response to muscle injury, is the most sensitive indicator of muscle injury, and is the best measure of the course of muscle injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CK is located on the inner mitochondrial membrane, on myofibrils, and in the muscle cytoplasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/2\">",
"     2",
"    </a>",
"    ]. It is involved in cellular energy storage and transfer via two major effects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It catalyzes the production of high energy ATP via transfer of a phosphate from creatine phosphate, which is the major storage reservoir of energy during muscle rest, to ADP (adenosine diphosphate).",
"     </li>",
"     <li>",
"      It participates in the transfer of high energy phosphate from its site of production in the mitochondria into the muscle cell cytoplasm where it is used during muscle contraction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CK is a dimer molecule and occurs in three distinct isoenzyme forms (termed MM, MB, and BB), which can be distinguished electrophoretically. Skeletal muscle has the highest concentration of CK of any tissue. Normal skeletal muscle CK is more than 99 percent MM with small amounts of MB. In comparison, cardiac tissue has the highest concentration of CK-MB, which accounts for approximately 20 percent of cardiac CK [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The concentration of MB in skeletal muscle increases in individuals with inflammatory myopathy or muscular dystrophy, in the resting muscles of well-trained elite athletes, and in many individuals after extreme exercise such as marathon running. This change is probably due to the increased number of regenerating muscle fibers in these conditions. Regenerating muscle fibers revert to the fetal state of increased MB production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/4\">",
"     4",
"    </a>",
"    ]. An increased ratio of serum CK-MB measured in inflammatory myopathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/5\">",
"     5",
"    </a>",
"    ] or in athletes after extreme exertion may be confused with myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/6\">",
"     6",
"    </a>",
"    ]. Troponin I is a more specific marker for myocardial damage than CK-MB since it does not appear to be present in either normal or damaged skeletal muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/7-9\">",
"     7-9",
"    </a>",
"    ], while Troponin T may be present in inflamed or regenerating skeletal muscle paralleling the elevation of CK-MB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Brain tissue CK consists of 90 percent CK-BB with the remainder CK-MM. Smaller amounts of CK are also found in the intestine, lung, and bladder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Macro CK is a term used to refer to CK that has an increased molecular weight. Complexes of CK and immunoglobulin (type 1 macro CK) and CK and an undetermined protein (type 2 macro CK) are more slowly cleared from the circulation than normal CK, leading to elevated levels. Macro CK can be detected by CK isoenzyme electrophoresis, which is usually available in reference clinical laboratories. The two types of macro CK can then be distinguished by protein G affinity chromatography. In those laboratories reporting CK isoenzymes, macro CK will be reported as an increased CK MB fraction, which may cause diagnostic confusion suggesting cardiac injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=see_link&amp;anchor=H20#H20\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\", section on 'CK-MB fraction for diagnosis of AMI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CK levels are elevated in some patients with end stage renal disease on dialysis. Serum cardiac enzymes in patients with renal failure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11701?source=see_link\">",
"     \"Serum cardiac enzymes in patients with renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Aldolase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aldolase is another glycolytic pathway enzyme that is found in all tissues but predominantly in skeletal muscle, liver, and brain. While increased aldolase levels are not as specific or sensitive for muscle disease as CK levels, aldolase concentrations are occasionally elevated in patients with myositis who have normal CK levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lactate dehydrogenase",
"    </span>",
"    &nbsp;&mdash;&nbsp;LD catalyzes the final step of glycolysis, converting pyruvate to lactate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/12\">",
"     12",
"    </a>",
"    ]. It is found in nearly every tissue of the body; as a result, increased serum levels are found in a great variety of disease states. There are five LD isoenzymes, each consisting of tetrameric combinations of M and H chains. The LD1 isoenzyme is more common in cardiac tissue, and, in the setting of cardiac injury, the usual LD2 greater than LD1 ratio is reversed. LD5 predominates in skeletal muscle, but increased LD5 is also seen in hepatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Aminotransferases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aminotransferases (transaminases) catalyze the conversion of the amino acids alanine and aspartate to alpha-ketoglutarate, providing a source of nitrogen for the urea cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/13\">",
"     13",
"    </a>",
"    ]. Both enzymes are found widely in many tissues, and increased serum levels are a nonspecific indicator of disease. Serum concentrations are highest in various hepatic disorders, but increased values are also seen in skeletal muscle, myocardial disease, and hemolysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5446?source=see_link\">",
"     \"Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Rate of enzyme clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with an acute myocardial infarction, the increase in serum CK is short-lived while that of LDH persists. Thus, a patient seen a few days after the event may have elevations in LDH and in troponin but no elevation in the serum CK. It is uncertain if this distinction occurs with skeletal muscle injury. Limited data following exercise suggest that the time course of elevation in muscle enzymes is similar for CK, LDH, and the aminotransferases. Why the response to skeletal and cardiac muscle injury might be different is not known. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/28/28101?source=see_link&amp;anchor=H8#H8\">",
"     \"Biomarkers of cardiac injury other than troponins and creatine kinase\", section on 'Lactate dehydrogenase'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H20\">",
"     'Exercise'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MUSCLE ENZYMES IN THE DIAGNOSIS OF NEUROMUSCULAR DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In clinical practice, the measurement of serum muscle enzymes is most commonly used in the evaluation of the patient presenting with muscle weakness or myalgias in whom myopathy is suspected. In general, marked elevation of serum muscle enzymes is seen in myopathies. Thus serum CK activity &gt;1000",
"    <span class=\"nowrap\">",
"     units/L",
"    </span>",
"    helps to distinguish muscle disease from neurogenic causes of weakness and muscle atrophy. More modest elevation of CK may occur in some primary neurologic disorders, particularly motor neuron disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26694?source=see_link\">",
"     \"Approach to the patient with muscle weakness\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H22\">",
"     'Motor neuron disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This section will review the disorders in which serum muscle enzyme concentrations are elevated either chronically (as in most myopathies) or acutely (as in reversible causes of rhabdomyolysis) (",
"    <a class=\"graphic graphic_table graphicRef69841 \" href=\"mobipreview.htm?33/16/34061\">",
"     table 1",
"    </a>",
"    ). This will be followed by a discussion of settings in which muscle enzymes can be used to follow the course of the disease and the response to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Inflammatory myopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Bohan's original series of 153 patients with inflammatory myopathy (polymyositis and dermatomyositis), only two patients had persistently normal muscle enzymes throughout their clinical course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/14\">",
"     14",
"    </a>",
"    ]. Subsequent reports have confirmed the nearly universal elevation of at least one of the muscle enzymes at some time during the course of active myositis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. CK is the most commonly measured muscle enzyme, although at times aldolase, LDH, or the aminotransferases will be elevated in the absence of an elevated CK [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. It is not known why this occurs.",
"   </p>",
"   <p>",
"    Rarely, clinical muscle disease with weakness and abnormal EMG and muscle biopsy findings occurs in the absence of muscle enzyme elevation. It has been suggested in these cases that an inhibitor of CK is present causing a false negative CK level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/17\">",
"     17",
"    </a>",
"    ]. Slight elevation or normal levels of serum CK activity may be present in patients with inclusion body myositis.",
"   </p>",
"   <p>",
"    In other patients, the rash of dermatomyositis is present without clinical muscle disease or elevated muscle enzymes, termed \"amyopathic dermatomyositis\" or \"dermatomyositis sine myositis\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15735?source=see_link\">",
"     \"Clinical manifestations and diagnosis of inclusion body myositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The degree of CK elevation in dermatomyositis and polymyositis varies greatly, reaching as high as 100 times normal. One report noted a correlation between the height of CK elevation at diagnosis and the severity of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/19\">",
"     19",
"    </a>",
"    ], but this relationship has not been confirmed by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with myopathy presenting with nonspecific arthralgias, myalgias, or constitutional symptoms that may overshadow the presence of muscle weakness are commonly evaluated with a multichannel chemical analyzer in which elevated LD and aminotransferases may first suggest the presence of liver disease. In this setting, a careful assessment of muscle strength and measurement of CK and aldolase should lead to the correct diagnosis of muscle disease and avoidance of an unnecessary liver biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, in juvenile dermatomyositis, at least one of the serum muscle enzymes is elevated at some time in the course of almost all cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/21\">",
"     21",
"    </a>",
"    ]. There are rare patients who have normal enzymes in the presence of muscle weakness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29368?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other exceptions include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Very early disease in which children present with rash and fever but before muscle weakness and enzyme elevation occur",
"     </li>",
"     <li>",
"      Very advanced disease in which there are marked muscle atrophy and normalization of enzymes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Muscle enzyme elevation in patients with other connective diseases including rheumatoid arthritis, systemic lupus erythematosus, Sj&ouml;gren's syndrome, and scleroderma suggests an associated myositis which may be subclinical or marked by mild muscle weakness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The enzyme elevations in these disorders are usually mild [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/22\">",
"     22",
"    </a>",
"    ] and, in a patient with systemic lupus or scleroderma, are suggestive of mixed connective tissue disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/24\">",
"     24",
"    </a>",
"    ] or",
"    <span class=\"nowrap\">",
"     scleroderma/polymyositis",
"    </span>",
"    overlap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/25\">",
"     25",
"    </a>",
"    ]; these disorders are associated with the specific autoantibodies anti-U1 RNP and",
"    <span class=\"nowrap\">",
"     anti-PM/Scl,",
"    </span>",
"    respectively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3447?source=see_link\">",
"     \"Definition and diagnosis of mixed connective tissue disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/61/42968?source=see_link\">",
"     \"Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are a number of other myopathies that are associated with elevated serum muscle enzyme concentrations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A group of disorders classified as",
"      <strong>",
"       localized",
"      </strong>",
"      myositis presents with focal muscle involvement and variable degrees of muscle enzyme elevation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/26\">",
"       26",
"      </a>",
"      ]. Etiologies include infections, focal presentations of polymyositis, insect bites, and idiopathic cases.",
"     </li>",
"     <li>",
"      Serum CK elevations occur in about 80 percent of patients with inclusion body myositis. The elevations are mild, less than 10 times the normal range [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15735?source=see_link\">",
"       \"Clinical manifestations and diagnosis of inclusion body myositis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other inflammatory conditions associated with myositis and elevated muscle enzymes include the systemic vasculitides (polyarteritis nodosa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/28\">",
"       28",
"      </a>",
"      ], Churg-Strauss vasculitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/29\">",
"       29",
"      </a>",
"      ], and granulomatosis with polyangiitis [Wegener&rsquo;s] [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/30\">",
"       30",
"      </a>",
"      ]), polymyositis associated with chronic graft-versus-host disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/31\">",
"       31",
"      </a>",
"      ], Beh&ccedil;et&rsquo;s disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/32\">",
"       32",
"      </a>",
"      ], and sarcoidosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Infectious myopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious myopathies with elevated serum enzyme concentrations can follow viral, bacterial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/34\">",
"     34",
"    </a>",
"    ], spirochetal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/35,36\">",
"     35,36",
"    </a>",
"    ], mycobacterial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/37\">",
"     37",
"    </a>",
"    ], fungal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/38\">",
"     38",
"    </a>",
"    ], and parasitic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/39\">",
"     39",
"    </a>",
"    ] infections. Muscle involvement in these infections may be either localized or generalized. CK elevations in viral myositis may reach levels greater than 1000 times normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9879?source=see_link\">",
"     \"Viral myositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Dystrophinopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated serum muscle enzyme concentrations occur in the sex-linked recessive muscular dystrophies (Duchenne's and Becker's), the limb-girdle dystrophies, facioscapulohumeral dystrophy, and myotonic dystrophy. CK levels are elevated in patients with Duchenne and Becker muscular dystrophy from the newborn period, before any clinical signs of the disease appear. CK levels peak by age two and then progressively fall, often to the normal range, as more and more muscle is replaced by fat and fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/41\">",
"     41",
"    </a>",
"    ]. (See appropriate topic reviews on the muscular dystrophies.)",
"   </p>",
"   <p>",
"    CK levels are increased in approximately 70 and 50 percent of Duchenne and Becker female carriers, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/41\">",
"     41",
"    </a>",
"    ]. The elevations are usually mild, up to three times the upper limit of normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute, massive muscle injury due to trauma, prolonged muscle compression, seizures, electrolyte imbalances, infections or drugs is associated with marked elevations of muscle enzymes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/42\">",
"     42",
"    </a>",
"    ]. The degree of CK elevation correlates with the risk of acute renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/43\">",
"     43",
"    </a>",
"    ]. Unlike chronic myopathies, however, the levels decrease rapidly to normal after the offending stimulus is removed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle enzymes are elevated in various drug-induced myopathies including those due to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    , antimalarials, cholesterol-lowering drugs (statins,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    , nicotinic acid, and clofibrate), cocaine, and alcohol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/44/6856?source=see_link\">",
"     \"Drug-induced myopathies\"",
"    </a>",
"    .) Serum CK concentrations range from mild elevations of three to four times normal with antimalarial neuromyopathy to 10- to 20-fold elevations in colchicine neuromyopathy and to massive elevations and rhabdomyolysis with cocaine use or acute alcoholic myopathy. Massive elevations of CK have also been reported in patients on mechanical ventilators treated with nondepolarizing muscle blocking agents and high dose corticosteroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Neuroleptic malignant syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroleptic malignant syndrome is a drug-induced disorder characterized by a change in mental status and the presence of rigidity, fever, and dysautonomia. Elevation of CK is a variable feature, and otherwise typical cases of NMS have occurred in the absence of CK elevation. This syndrome is most often seen with either traditional or \"atypical\" neuroleptic agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/10/38055?source=see_link\">",
"     fluphenazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    ;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ) and has also occurred in the setting of use of antiemetic drugs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    ); NMS is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Metabolic myopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited disorders of carbohydrate, lipid, and purine metabolism are associated with episodic muscle damage ranging from myalgias and mild muscle enzyme elevation to frank rhabdomyolysis. While these conditions represent a very small percentage of cases of rhabdomyolysis, they should be suspected in cases where no obvious precipitating factors are present, particularly when there is a history of recurrent episodes. The heritable metabolic myopathies are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/36/21065?source=see_link\">",
"     \"Causes of metabolic myopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"     Carnitine",
"    </a>",
"    palmitoyltransferase (CPT) and muscle phosphorylase deficiency are the most common metabolic myopathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Muscle phosphorylase deficiency, or McArdle's Disease, is inherited in an autosomal recessive pattern. Affected individuals typically have a history of exercise intolerance in childhood followed by recurrent cramps, fatigue, and myoglobinuria in adolescence or early adulthood. CK levels do not completely return to normal between episodes of rhabdomyolysis.",
"   </p>",
"   <p>",
"    In contrast, individuals with CPT deficiency have normal CK levels during interictal periods. Thus, serum muscle levels should be measured when the individual is symptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Malignant hyperthermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant hyperthermia is characterized by fever, generalized muscular contraction and rigidity, metabolic acidosis, and rhabdomyolysis, most commonly occurring after the use of inhalational anesthetic agents in susceptible individuals. CK levels may rise several hundred times greater than normal during an episode and may remain persistently elevated in those individuals who recover.",
"   </p>",
"   <p>",
"    Malignant hyperthermia may occur sporadically or may be familial. Affected family members may have an elevated CK when asymptomatic, but muscle enzyme measurement has insufficient sensitivity to be useful as a screening test. Approaches to diagnosis and screening of possibly affected or at-risk family members are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36921?source=see_link\">",
"     \"Susceptibility to malignant hyperthermia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32984?source=see_link\">",
"     \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16007?source=see_link&amp;anchor=H9#H9\">",
"     \"Severe hyperthermia (heat stroke) in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Endocrine myopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothyroidism is frequently accompanied by myalgias, stiffness, mild muscle weakness, and mild to moderate elevations of CK and other muscle enzymes. Rarely, rhabdomyolysis and myoglobinuria occur after vigorous exercise. Muscle enzymes return to normal levels after one to two months of thyroid replacement therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29093?source=see_link\">",
"     \"Hypothyroid myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Muscle enzymes are typically normal in patients with hyperthyroidism. However, rhabdomyolysis and acute renal failure have rarely been reported in association with hyperthyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gradually progressive proximal muscle weakness with or without muscle wasting occurs in some patients with acromegaly. Mild myopathic changes may be seen on muscle biopsy, and mild elevation of muscle enzymes has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/50\">",
"     50",
"    </a>",
"    ]. However, weakness may be a manifestation of peripheral neuropathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7015?source=see_link&amp;anchor=H9#H9\">",
"     \"Rheumatic and bone disorders associated with acromegaly\", section on 'Peripheral neuropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cushing's syndrome, glucocorticoid-induced myopathy, and hyperparathyroidism may all be associated with muscle weakness. However, muscle enzyme levels remain normal in these conditions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/40/23173?source=see_link\">",
"     \"Glucocorticoid-induced myopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1338?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations of primary hyperparathyroidism\", section on 'Classical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diabetic muscle infarction is a rare complication of diabetes mellitus. Patients with poorly controlled type I disease appear to be at highest risk of developing this otherwise rare disorder. The sudden onset of pain and localized swelling in the thigh or calf muscles that characterize muscle infarction must be distinguished from pyomyositis or other causes of localized myositis. The serum CK level may be normal or elevated. The erythrocyte sedimentation rate is usually increased. Gradual resolution of pain and swelling is expected over several weeks to months, but recurrences may occur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1526?source=see_link\">",
"     \"Diabetic muscle infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Periodic paralyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The periodic paralyses are characterized by unpredictable recurrent episodes of muscle weakness lasting generally from a few hours to a few days and then spontaneously resolving. The periodic paralyses have been classified as primary or secondary depending upon whether there is a family history or an underlying condition such as thyrotoxicosis and, on the basis of serum potassium levels during an attack, as hypokalemic, hyperkalemic, or normokalemic. The common mechanism of these conditions appears to be an intermittent unexcitability of the muscle fiber membrane related to electrolyte shifts across the membrane. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9193?source=see_link\">",
"     \"Hypokalemic periodic paralysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/54/871?source=see_link\">",
"     \"Hyperkalemic periodic paralysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/38/22119?source=see_link\">",
"     \"Thyrotoxic periodic paralysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Muscle enzyme levels rise rapidly during an attack and may remain slightly elevated between attacks. The degree of enzyme elevation varies widely among patients with these disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ELEVATED MUSCLE ENZYMES IN THE ABSENCE OF MUSCLE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum muscle enzyme concentrations can be increased in the absence of muscle disease with exercise, muscle trauma, and motor neuron disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum CK concentrations reach peak levels at 8 to 24 hours after exercise, begin to decrease at 24 to 48 hours, and return to baseline levels by 72 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/52\">",
"     52",
"    </a>",
"    ]. The increase in CK levels is related to the intensity and duration of exercise and is greater in untrained than trained individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. In an exercise laboratory setting, for example, repetitive sets of leg extension against resistance for 30 minutes resulted in a greater than threefold increase in CK at 8 to 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/52\">",
"     52",
"    </a>",
"    ]. Serum LD and transaminase levels follow a similar pattern after exercise although the increase is not as great as with CK [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/52,55\">",
"     52,55",
"    </a>",
"    ]. Postexercise elevations in muscle enzymes may be asymptomatic or accompanied by muscle soreness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Iatrogenic muscle injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;CK levels follow the same temporal pattern after an intramuscular injection, major surgery, electromyography, or muscle biopsy. The muscle enzyme elevations in the last two settings may confuse serum muscle enzyme measurements in the evaluation of myopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/1\">",
"     1",
"    </a>",
"    ]. Major surgical procedures, particularly orthopedic and spinal surgery, cause serum enzyme elevation due to direct muscle trauma and to ischemic compression of muscle due to positioning during the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Motor neuron disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one study of 94 patients with motor neuron disease (amyotrophic lateral sclerosis), mild elevations in serum muscle enzymes were found in 75 percent of cases, particularly in the early phases of the disease and more commonly in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/58\">",
"     58",
"    </a>",
"    ]. The highest measured CK concentration was 11 times normal, and the mean CK for the entire group was about twofold greater than normal, possibly leading to misdiagnosis of an inflammatory myopathy or inclusion body myositis.",
"   </p>",
"   <p>",
"    Mild elevations of CK, usually less than twice the upper limit of normal, may occur in the various childhood motor neuron disorders also known as the spinal muscular atrophies. These disorders include Werdnig-Hoffmann disease and Kugelberg-Welander disease. Children with the chronic form of spinal muscular atrophy may present some diagnostic difficulty in distinguishing cases from juvenile polymyositis. However, marked elevations of CK in young children presenting with proximal muscle weakness would exclude the diagnosis of spinal muscular atrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8344?source=see_link\">",
"     \"Spinal muscular atrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Asymptomatic elevations in creatine kinase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disorder characterized by an elevation of muscle enzymes in an individual without muscle weakness, significant myalgias, or an obvious explanation for the serum abnormality (such as vigorous exercise or hypothyroidism) is referred to as asymptomatic hyper-CK-emia. This may occur in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blacks &mdash; CK elevations above the laboratories reference range occur more frequently in black patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      \"Presymptomatic\" myopathies &mdash; These include polymyositis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/61\">",
"       61",
"      </a>",
"      ], distal myopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/62\">",
"       62",
"      </a>",
"      ], mitochondrial myopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/61\">",
"       61",
"      </a>",
"      ], inclusion body myopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/61\">",
"       61",
"      </a>",
"      ], Becker muscular dystrophy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/63\">",
"       63",
"      </a>",
"      ], and myotonic dystrophy type 2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/64\">",
"       64",
"      </a>",
"      ]. In these disorders, weakness eventually develops, and the diagnosis can be established by muscle biopsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Predisposition to malignant hyperthermia &mdash; In one report, 11 of 30 asymptomatic patients with unexplained CK elevations had an abnormal halothane",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      caffeine contracture test on muscle biopsy, a finding predictive of malignant hyperthermia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Certain manual labor occupations &mdash; This is particularly true among those jobs that involve vigorous upper extremity use or constrained postures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Macro CK &mdash; Macro CK usually occurs in healthy individuals without evidence of muscle disease. Type 2 macro CK has been associated with malignancies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Creatine kinase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Idiopathic &mdash; No explanation is found despite thorough investigation, including muscle biopsy, and weakness does not develop during subsequent follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359649809\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of renal failure on creatine kinase, aminotransferases, and other serum enzymes are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11701?source=see_link\">",
"     \"Serum cardiac enzymes in patients with renal failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/38/33381?source=see_link\">",
"     \"Serum enzymes in patients with renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MUSCLE ENZYMES IN MONITORING THE COURSE OF DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring the serum concentration of muscle enzymes can be used to monitor the course of patients with",
"    <span class=\"nowrap\">",
"     dermatomyositis/polymyositis",
"    </span>",
"    or those with rhabdomyolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Dermatomyositis or polymyositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults with dermatomyositis or polymyositis, serum levels of creatine kinase typically decrease by about 50 percent during the first month of high-dose therapy with glucocorticoids, and normalization of muscle enzymes may take up to four months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/14,19,67\">",
"     14,19,67",
"    </a>",
"    ]. Muscle enzyme levels generally decrease before improvement in muscle strength occurs; normalization of muscle enzymes with therapy is predictive of recovery of strength. In one study, for example, good clinical outcomes accompanied 17 of 17 myositis episodes in which muscle enzymes normalized but only 8 of 25 episodes in which muscle enzymes did not normalize [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/68\">",
"     68",
"    </a>",
"    ]. Failure to normalize muscle enzymes after two months should prompt consideration of alternative diagnoses such as inclusion body myositis, muscular dystrophy, or hypothyroidism.",
"   </p>",
"   <p>",
"    However, in some cases of severe disease, serum enzymes will fail to normalize even with aggressive corticosteroid and immunosuppressive therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/22/11626?source=see_link\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13065?source=see_link\">",
"     \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Disease exacerbations are usually preceded by an increase in muscle enzymes. Thus, serial enzyme measurements are generally useful in assessing the disease course in an individual patient. In some cases, the elevations in serum CK or aminotransferase concentrations are within the normal range but are still a harbinger of increased clinical disease activity. If corticosteroids are tapered at the time of a mild increase in CK, a further increase in CK to outside the normal range and relapse of muscle weakness is likely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/68\">",
"     68",
"    </a>",
"    ]. In contrast, recurrence of weakness during corticosteroid treatment with no increase in serum enzymes is more likely to represent steroid myopathy than increased disease activity.",
"   </p>",
"   <p>",
"    Muscle enzymes also tend to parallel disease activity in juvenile dermatomyositis. In one study, AST and LD were found to be better predictors of disease flares than CK [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/69\">",
"     69",
"    </a>",
"    ]. However, this observation must be confirmed before the general practice of monitoring the serum CK concentration is changed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of serum muscle enzyme elevation does not always predict the development of acute renal failure in rhabdomyolysis, although there is a general correlation. In one study, for example, 58 percent of patients developing acute renal failure had peak CK levels greater than 16,000",
"    <span class=\"nowrap\">",
"     units/L",
"    </span>",
"    compared with only 11 percent in those who did not develop acute renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36745/abstract/43\">",
"     43",
"    </a>",
"    ]. The peak CK elevation is usually reached quickly, occurring within the first day after the muscle insult. It then falls rapidly back to the normal range over several days to one week, depending on the maximum peak level. This rapid decline helps to distinguish rhabdomyolysis from more chronic disorders of myopathy such as polymyositis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22632?source=see_link\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The measurement of serum levels of muscle enzymes is a critical part of the evaluation of patients presenting with weakness or myalgias and is important in monitoring the course and response to therapy of certain muscular disorders. Creatine kinase (CK), lactate dehydrogenase (LD), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and aldolase are the serum enzymes that are measured in clinical practice.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CK is the most widely used enzyme to diagnose and follow muscle disease. It is present in the highest concentrations in serum with muscle injury, is the most sensitive indicator of muscle injury, and is the best measure of the course of muscle injury. CK is located on the inner mitochondrial membrane, on myofibrils, and in the muscle cytoplasm, and it is involved in cellular energy storage and transfer. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Creatine kinase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CK is a dimer, which occurs in three distinct isoenzyme forms (termed MM, MB, and BB), which can be distinguished electrophoretically. Normal skeletal muscle CK is over 99 percent MM with small amounts of MB. The concentration of MB in skeletal muscle increases in individuals with inflammatory myopathy or muscular dystrophy, in the resting muscles of elite athletes, and in many individuals after extreme exercise. An increased ratio of serum CK-MB measured in inflammatory myopathies or in athletes after extreme exertion may be confused with myocardial infarction. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Creatine kinase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum aldolase concentrations are occasionally elevated in patients with myositis who have normal CK levels, but increased aldolase levels are not as specific or sensitive for muscle disease as CK levels. LDH and the aminotransferases are present in many tissues and are often elevated with skeletal muscle injury. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Aldolase'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Lactate dehydrogenase'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Aminotransferases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, marked elevation of serum muscle enzymes is seen in myopathies. Thus serum CK activity greater than 1000",
"      <span class=\"nowrap\">",
"       units/L",
"      </span>",
"      helps to distinguish muscle disease from neurogenic causes of weakness and muscle atrophy. More modest elevation of CK may occur in some primary neurologic disorders, particularly lower motor neuron disease. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Muscle enzymes in the diagnosis of neuromuscular disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum levels of muscle enzymes may be elevated in a number of conditions. These include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Inflammatory myopathies (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Inflammatory myopathies'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Infectious myopathies (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Infectious myopathies'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Dystrophinopathies (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Dystrophinopathies'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Rhabdomyolysis (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Rhabdomyolysis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Use of certain medications (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Drugs'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Metabolic myopathies (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Metabolic myopathies'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Malignant hyperthermia (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Malignant hyperthermia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Endocrine myopathies (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Endocrine myopathies'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Periodic paralyses (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Periodic paralyses'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Muscle enzymes may be elevated in the absence of muscle disease under certain conditions, including following exercise, in patients with iatrogenic muscle injury or motor neuron disease, and in several other situations without obvious neuromuscular disease. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Elevated muscle enzymes in the absence of muscle disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The serum concentration of muscle enzymes can be used to monitor the course of patients with",
"      <span class=\"nowrap\">",
"       dermatomyositis/polymyositis",
"      </span>",
"      or of those with rhabdomyolysis.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/1\">",
"      Bohlmeyer TJ, Wu AH, Perryman MB. Evaluation of laboratory tests as a guide to diagnosis and therapy of myositis. Rheum Dis Clin North Am 1994; 20:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/2\">",
"      Bessman SP, Carpenter CL. The creatine-creatine phosphate energy shuttle. Annu Rev Biochem 1985; 54:831.",
"     </a>",
"    </li>",
"    <li>",
"     Neumeier D. Tissue specific and subcellular distribution of creatine kinase isoenzymes. In: Creatine Kinase Isoenzymes, Lang H (Ed), Springer-Verlag, Berlin/Heidelberg 1981. p.85.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/4\">",
"      Wolf PL. Abnormalities in serum enzymes in skeletal muscle diseases. Am J Clin Pathol 1991; 95:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/5\">",
"      Larca LJ, Coppola JT, Honig S. Creatine kinase MB isoenzyme in dermatomyositis: a noncardiac source. Ann Intern Med 1981; 94:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/6\">",
"      Young A. Plasma creatine kinase after the marathon--a diagnostic dilemma. Br J Sports Med 1984; 18:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/7\">",
"      Adams JE 3rd, Bodor GS, D&aacute;vila-Rom&aacute;n VG, et al. Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation 1993; 88:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/8\">",
"      Bodor GS, Porterfield D, Voss EM, et al. Cardiac troponin-I is not expressed in fetal and healthy or diseased adult human skeletal muscle tissue. Clin Chem 1995; 41:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/9\">",
"      Babuin L, Jaffe AS. Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ 2005; 173:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/10\">",
"      Aggarwal R, Lebiedz-Odrobina D, Sinha A, et al. Serum cardiac troponin T, but not troponin I, is elevated in idiopathic inflammatory myopathies. J Rheumatol 2009; 36:2711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/11\">",
"      Galarraga B, Sinclair D, Fahie-Wilson MN, et al. A rare but important cause for a raised serum creatine kinase concentration: two case reports and a literature review. Rheumatology (Oxford) 2003; 42:186.",
"     </a>",
"    </li>",
"    <li>",
"     Rawn JD. Biochemistry, Neil Patterson Publishers, Burlington, NC 1989. p.315.",
"    </li>",
"    <li>",
"     Rawn JD. Biochemistry, Neil Patterson Publishers, Burlington, NC 1989. p.468.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/14\">",
"      Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977; 56:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/15\">",
"      Ram&iacute;rez G, Asherson RA, Khamashta MA, et al. Adult-onset polymyositis-dermatomyositis: description of 25 patients with emphasis on treatment. Semin Arthritis Rheum 1990; 20:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/16\">",
"      Lilley H, Dennett X, Byrne E. Biopsy proven polymyositis in Victoria 1982-1987: analysis of prognostic factors. J R Soc Med 1994; 87:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/17\">",
"      Kagen LJ, Aram S. Creatine kinase activity inhibitor in sera from patients with muscle disease. Arthritis Rheum 1987; 30:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/18\">",
"      Gerami P, Schope JM, McDonald L, et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sin&eacute; myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006; 54:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/19\">",
"      Tymms KE, Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol 1985; 12:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/20\">",
"      Helfgott SM, Karlson E, Beckman E. Misinterpretation of serum transaminase elevation in \"occult\" myositis. Am J Med 1993; 95:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/21\">",
"      Pachman LM. Inflammatory myopathy in children. Rheum Dis Clin North Am 1994; 20:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/22\">",
"      Mir&oacute; O, Pedrol E, Casademont J, et al. Muscle involvement in rheumatoid arthritis: clinicopathological study of 21 symptomatic cases. Semin Arthritis Rheum 1996; 25:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/23\">",
"      Garton MJ, Isenberg DA. Clinical features of lupus myositis versus idiopathic myositis: a review of 30 cases. Br J Rheumatol 1997; 36:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/24\">",
"      Sharp GC, Irvin WS, May CM, et al. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases. N Engl J Med 1976; 295:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/25\">",
"      Reichlin M, Maddison PJ, Targoff I, et al. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. J Clin Immunol 1984; 4:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/26\">",
"      Knowles WO, Falasca GF, Catalano E, et al. Relapsing, localized myositis of the head and neck after a hornet sting. J Clin Rheumatol 1996; 2:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/27\">",
"      Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis. Observations in 40 patients. Brain 1989; 112 ( Pt 3):727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/28\">",
"      Fort JG, Griffin R, Tahmoush A, Abruzzo JL. Muscle involvement in polyarteritis nodosa: report of a patient presenting clinically as polymyositis and review of the literature. J Rheumatol 1994; 21:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/29\">",
"      Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984; 63:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/30\">",
"      Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/31\">",
"      Parker P, Chao NJ, Ben-Ezra J, et al. Polymyositis as a manifestation of chronic graft-versus-host disease. Medicine (Baltimore) 1996; 75:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/32\">",
"      Lingenfelser T, Duerk H, Stevens A, et al. Generalized myositis in Beh&ccedil;et disease: treatment with cyclosporine. Ann Intern Med 1992; 116:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/33\">",
"      Alpert JN, Groff AE, Bastian FO, Blum MA. Acute polymyositis caused by sarcoidosis: report of a case and review of the literature. Mt Sinai J Med 1979; 46:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/34\">",
"      Falasca GF, Reginato AJ. The spectrum of myositis and rhabdomyolysis associated with bacterial infection. J Rheumatol 1994; 21:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/35\">",
"      Johnson WD Jr, Silva IC, Rocha H. Serum creatine phosphokinase in leptospirosis. JAMA 1975; 233:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/36\">",
"      Hoffmann JC, Stichtenoth DO, Zeidler H, et al. Lyme disease in a 74-year-old forest owner with symptoms of dermatomyositis. Arthritis Rheum 1995; 38:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/37\">",
"      Wrzolek MA, Rao C, Kozlowski PB, Sher JH. Muscle and nerve involvement in AIDS patient with disseminated Mycobacterium avium intracellulare infection. Muscle Nerve 1989; 12:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/38\">",
"      Arena FP, Perlin M, Brahman H, et al. Fever, rash, and myalgias of dissseminated candidiasis during antifungal therapy. Arch Intern Med 1981; 141:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/39\">",
"      Gherardi R, Baudrimont M, Lionnet F, et al. Skeletal muscle toxoplasmosis in patients with acquired immunodeficiency syndrome: a clinical and pathological study. Ann Neurol 1992; 32:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/40\">",
"      Konrad RJ, Goodman DB, Davis WL. Tumor necrosis factor and coxsackie B4 rhabdomyolysis. Ann Intern Med 1993; 119:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/41\">",
"      Rosalki SB. Serum enzymes in disease of skeletal muscle. Clin Lab Med 1989; 9:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/42\">",
"      Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine (Baltimore) 1982; 61:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/43\">",
"      Ward MM. Factors predictive of acute renal failure in rhabdomyolysis. Arch Intern Med 1988; 148:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/44\">",
"      Zuckner J. Drug-related myopathies. Rheum Dis Clin North Am 1994; 20:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/45\">",
"      Curry SC, Chang D, Connor D. Drug- and toxin-induced rhabdomyolysis. Ann Emerg Med 1989; 18:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/46\">",
"      Hirano M, Ott BR, Raps EC, et al. Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology 1992; 42:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/47\">",
"      Tonin P, Lewis P, Servidei S, DiMauro S. Metabolic causes of myoglobinuria. Ann Neurol 1990; 27:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/48\">",
"      Bennett WR, Huston DP. Rhabdomyolysis in thyroid storm. Am J Med 1984; 77:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/49\">",
"      Alshanti M, Eledrisi MS, Jones E. Rhabdomyolysis associated with hyperthyroidism. Am J Emerg Med 2001; 19:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/50\">",
"      Khaleeli AA, Levy RD, Edwards RH, et al. The neuromuscular features of acromegaly: a clinical and pathological study. J Neurol Neurosurg Psychiatry 1984; 47:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/51\">",
"      Riggs JE. Periodic paralysis. Clin Neuropharmacol 1989; 12:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/52\">",
"      Tiidus PM, Ianuzzo CD. Effects of intensity and duration of muscular exercise on delayed soreness and serum enzyme activities. Med Sci Sports Exerc 1983; 15:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/53\">",
"      Ross JH, Attwood EC, Atkin GE, Villar RN. A study on the effects of severe repetitive exercise on serum myoglobin, creatine kinase, transaminases and lactate dehydrogenase. Q J Med 1983; 52:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/54\">",
"      Priest JB, Oei TO, Moorehead WR. Exercise-induced changes in common laboratory tests. Am J Clin Pathol 1982; 77:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/55\">",
"      Ohman EM, Teo KK, Johnson AH, et al. Abnormal cardiac enzyme responses after strenuous exercise: alternative diagnostic aids. Br Med J (Clin Res Ed) 1982; 285:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/56\">",
"      Lachiewicz PF, Latimer HA. Rhabdomyolysis following total hip arthroplasty. J Bone Joint Surg Br 1991; 73:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/57\">",
"      Lenke LG, Bridwell KH, Jaffe AS. Increase in creatine kinase MB isoenzyme levels after spinal surgery. J Spinal Disord 1994; 7:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/58\">",
"      Amrit AN, Anderson MS. Serum creatine phosphokinase in amyotrophic lateral sclerosis. Correlation with sex, duration, and skeletal muscle biopsy. Neurology 1974; 24:834.",
"     </a>",
"    </li>",
"    <li>",
"     Gomez MR. Motor neuron diseases in children. In: Myology, Engel AG, Franzini-Armstrong C (Eds), McGraw-Hill, New York 1994. p.1837.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/60\">",
"      Prisant LM, Downton M, Watkins LO, et al. Efficacy and tolerability of lovastatin in 459 African-Americans with hypercholesterolemia. Am J Cardiol 1996; 78:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/61\">",
"      Joy JL, Oh SJ. Asymptomatic hyper-CK-emia: an electrophysiologic and histopathologic study. Muscle Nerve 1989; 12:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/62\">",
"      Galassi G, Rowland LP, Hays AP, et al. High serum levels of creatine kinase: asymptomatic prelude to distal myopathy. Muscle Nerve 1987; 10:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/63\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 22-1998. A 22-year-old man with a cardiac transplant and creatine kinase elevation. N Engl J Med 1998; 339:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/64\">",
"      Merlini L, Sabatelli P, Columbaro M, et al. Hyper-CK-emia as the sole manifestation of myotonic dystrophy type 2. Muscle Nerve 2005; 31:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/65\">",
"      Weglinski MR, Wedel DJ, Engel AG. Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels. Anesth Analg 1997; 84:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/66\">",
"      Brewster LM, de Visser M. Persistent hyperCKemia: fourteen patients studied in retrospect. Acta Neurol Scand 1988; 77:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/67\">",
"      Vignos PJ Jr, Goldwyn J. Evaluation of laboratory tests in diagnosis and management of polymyositis. Am J Med Sci 1972; 263:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/68\">",
"      Oddis CV, Medsger TA Jr. Relationship between serum creatine kinase level and corticosteroid therapy in polymyositis-dermatomyositis. J Rheumatol 1988; 15:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36745/abstract/69\">",
"      Guzm&aacute;n J, Petty RE, Malleson PN. Monitoring disease activity in juvenile dermatomyositis: the role of von Willebrand factor and muscle enzymes. J Rheumatol 1994; 21:739.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5161 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8E53C3882F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_56_36745=[""].join("\n");
var outline_f35_56_36745=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGY OF MUSCLE ENZYMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Creatine kinase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Aldolase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lactate dehydrogenase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Aminotransferases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Rate of enzyme clearance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MUSCLE ENZYMES IN THE DIAGNOSIS OF NEUROMUSCULAR DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Inflammatory myopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Infectious myopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Dystrophinopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Malignant hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Endocrine myopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Periodic paralyses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ELEVATED MUSCLE ENZYMES IN THE ABSENCE OF MUSCLE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Iatrogenic muscle injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Asymptomatic elevations in creatine kinase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H359649809\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MUSCLE ENZYMES IN MONITORING THE COURSE OF DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Dermatomyositis or polymyositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5161\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5161|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/16/34061\" title=\"table 1\">",
"      Causes elevated muscle enzymes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26694?source=related_link\">",
"      Approach to the patient with muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/28/28101?source=related_link\">",
"      Biomarkers of cardiac injury other than troponins and creatine kinase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/36/21065?source=related_link\">",
"      Causes of metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15735?source=related_link\">",
"      Clinical manifestations and diagnosis of inclusion body myositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1338?source=related_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3447?source=related_link\">",
"      Definition and diagnosis of mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1526?source=related_link\">",
"      Diabetic muscle infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/44/6856?source=related_link\">",
"      Drug-induced myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/40/23173?source=related_link\">",
"      Glucocorticoid-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/54/871?source=related_link\">",
"      Hyperkalemic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9193?source=related_link\">",
"      Hypokalemic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29093?source=related_link\">",
"      Hypothyroid myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/22/11626?source=related_link\">",
"      Initial treatment of dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32984?source=related_link\">",
"      Malignant hyperthermia: Clinical diagnosis and management of acute crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29368?source=related_link\">",
"      Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5446?source=related_link\">",
"      Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7015?source=related_link\">",
"      Rheumatic and bone disorders associated with acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11701?source=related_link\">",
"      Serum cardiac enzymes in patients with renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/38/33381?source=related_link\">",
"      Serum enzymes in patients with renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16007?source=related_link\">",
"      Severe hyperthermia (heat stroke) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8344?source=related_link\">",
"      Spinal muscular atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36921?source=related_link\">",
"      Susceptibility to malignant hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/38/22119?source=related_link\">",
"      Thyrotoxic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13065?source=related_link\">",
"      Treatment of recurrent and resistant dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/61/42968?source=related_link\">",
"      Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9879?source=related_link\">",
"      Viral myositis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_56_36746="Factor VIII and factor IX inhibitors in patients with hemophilia";
var content_f35_56_36746=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Factor VIII and factor IX inhibitors in patients with hemophilia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/56/36746/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/56/36746/contributors\">",
"     W Keith Hoots, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/56/36746/contributors\">",
"     Amy D Shapiro, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/56/36746/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/56/36746/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/56/36746/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/56/36746/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/56/36746/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/56/36746/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hemophilias are a group of related bleeding disorders that most commonly are inherited. Inherited bleeding disorders include abnormalities of coagulation factors and platelet function; the most common of these disorders is von Willebrand disease. However, when the term \"hemophilia\" is used, it most often refers to the following two disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Factor VIII deficiency (hemophilia A)",
"     </li>",
"     <li>",
"      Factor IX deficiency (hemophilia B, also called Christmas disease)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with hemophilia, particularly those with severe disease, develop bleeding episodes that are treated with replacement of the missing factor (ie, factor VIII or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8151?source=see_link\">",
"     factor IX concentrates",
"    </a>",
"    ). A complication of hemophilia treatment is the development of an inhibitor, which usually occurs shortly after replacement therapy has been initiated. The inhibitors are antibodies (primarily IgG) directed against the specific deficient factor.",
"   </p>",
"   <p>",
"    Development of inhibitors is typically assessed in relationship to the number of exposure days (ie, days on which the patient has received one or more doses of replacement factor).",
"   </p>",
"   <p>",
"    The pathophysiology, clinical features, and management of inhibitors in patients with hemophilia will be reviewed here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/1\">",
"     1",
"    </a>",
"    ]. Acquired inhibitors of factor VIII, factor IX, and other coagulation factors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24650?source=see_link\">",
"     \"Acquired inhibitors of coagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations and treatment of hemophilia A and B are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/18/1322?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hemophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38442?source=see_link\">",
"     \"Treatment of hemophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INHIBITORS IN HEMOPHILIA A",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of inhibitors is more common in patients with hemophilia A than in those with hemophilia B. Many of the principles that apply to factor VIII inhibitors also apply to factor IX inhibitors. However, the development of inhibitors in factor IX deficiency may be associated with some specific manifestations including anaphylaxis and nephrotic syndrome (see",
"    <a class=\"local\" href=\"#H27\">",
"     'Inhibitors in hemophilia B'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Inhibitors in both hemophilia A and B are more likely to form in patients with severe disease. The degree of response in Bethesda units has been used to further classify patients with factor VIII or IX inhibitors. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Diagnosis and screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       High responders",
"      </strong>",
"      &mdash; Patients who develop titers above five Bethesda units at any time are considered high responders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/2\">",
"       2",
"      </a>",
"      ]. Such patients show an increase in antibody titer after each exposure; this response begins within 2 to 3 days, peaks at 7 to 21 days, and may persist for years in the absence of re-exposure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. Such high inhibitor levels render treatment with factor VIII preparations ineffective, and usually require bypassing the deficient clotting factor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Low responders",
"      </strong>",
"      &mdash; Low responders have persistently low antibody titers (less than five Bethesda units) that do not increase after factor infusion and may disappear [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/3,5\">",
"       3,5",
"      </a>",
"      ]. Such patients may continue to respond to treatment with factor VIII replacement therapy with minimal change in the factor VIII dose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor VIII inhibitors have been reported in approximately 25 to 30 percent of patients with severe hemophilia A [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. They primarily occur early in treatment (eg, within the first 50 exposure days) in young children, and are much less common in patients with moderate and mild hemophilia A (3 to 13 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/7,9,10\">",
"     7,9,10",
"    </a>",
"    ]. These relationships were illustrated in a study in which 95 children who were not previously exposed to factor VIII were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/1/23574?source=see_link\">",
"     recombinant human factor VIII",
"    </a>",
"    ; the median follow-up was 1.5 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/7\">",
"     7",
"    </a>",
"    ]. Factor VIII inhibitors developed in 20 percent of patients after a median of nine days of exposure (which represented 15 months from initial treatment). The frequency of antibody development was 29 percent in the children with severe disease (factor VIII levels &lt;2 percent of normal) and &lt;10 percent in those with moderate to mild disease.",
"   </p>",
"   <p>",
"    In one-half of the patients with inhibitors, the inhibitor titers were or became low or absent despite continued exposure. These inhibitors are termed \"transient\", and are more likely to occur in patients with a low inhibitor titer.",
"   </p>",
"   <p>",
"    The overall risk in patients with severe disease was estimated at 36 percent after 18 days of exposure, a value similar to 38 percent after 25 days of exposure in another recombinant factor VIII trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/11\">",
"     11",
"    </a>",
"    ]. Lower rates have been reported in studies that included previously treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. This result probably represents selection bias; because inhibitors generally develop early, previously treated patients who do not have inhibitors represent a lower risk group.",
"   </p>",
"   <p>",
"    The age-adjusted incidence of new factor VIII inhibitors was analyzed in all UK patients with severe hemophilia A between 1990 and 2009. A total of 315 new inhibitors were reported in 2528 patients (12 percent) followed for a median of 12 years. The incidences of new inhibitors were as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Zero to 5 years:",
"      <span class=\"nowrap\">",
"       64/1000",
"      </span>",
"      patient-years at risk",
"     </li>",
"     <li>",
"      5 to 9 years:",
"      <span class=\"nowrap\">",
"       9.4/1000",
"      </span>",
"      patient-years",
"     </li>",
"     <li>",
"      10 to 59 years:",
"      <span class=\"nowrap\">",
"       5.3/1000",
"      </span>",
"      patient-years",
"     </li>",
"     <li>",
"      60 or more years:",
"      <span class=\"nowrap\">",
"       10.5/1000",
"      </span>",
"      patient-years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results are of interest for two reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They indicate a bimodal risk of factor VIII inhibitor development, in early childhood and in old age. The reason for the latter is poorly understood, apparently resulting from a breakdown of immune tolerance with increasing age.",
"     </li>",
"     <li>",
"      Older patients with factor VIII deficiency may need closer monitoring for the development of inhibitors, which may become important if they need surgery or treatment with",
"      <span class=\"nowrap\">",
"       antithrombotics/anticoagulants",
"      </span>",
"      for age-related disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38442?source=see_link&amp;anchor=H38#H38\">",
"       \"Treatment of hemophilia\", section on 'Treatment of age-related comorbidities'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15594486\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factor VIII alloantibodies that are formed after exposure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/12/198?source=see_link\">",
"     factor VIII concentrates",
"    </a>",
"    are directed against specific epitopes on the factor VIII molecule. Factor VIII consists of a heavy chain with A1 and A2 domains, a connecting region with a B1 domain that is not required for clotting, and a light chain with A3, C1, and C2 domains. Most antibodies are directed against A2",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    C2 domains, although other epitopes may also be involved, whether treated with plasma or recombinant factor VIII [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/15-19\">",
"     15-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Not all antibodies to factor VIII are pathologic, and not all pathologic antibodies are similar in their spectrum. Patients with congenital hemophilia who form inhibitors often produce multiple antibodies that bind distinct epitopes of the infused factor VIII, some of which block its function and dramatically reduce its efficacy in treating bleeding. In contrast, patients with acquired hemophilia are more likely to have a single antibody, often directed against a single domain of factor VIII [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/15\">",
"     15",
"    </a>",
"    ]. Individuals in the general population (ie, without hemophilia) may also produce antibodies to factor VIII that do not affect factor VIII function.",
"   </p>",
"   <p>",
"    Increased understanding of the function of these epitopes helps explain why antibodies in patients with hemophilia A interfere with factor VIII function. The role of the different domains is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22824?source=see_link\">",
"     \"Biology and normal function of factor VIII and factor IX\"",
"    </a>",
"    .) Summarized briefly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The C2 domain binds to the procoagulant phospholipid phosphatidylserine on activated platelets and endothelial cells and to von Willebrand factor. An overlap exists in the epitope for both binding functions. Thus, antibodies to the C2 domain can interfere with binding to phospholipid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/20,21\">",
"       20,21",
"      </a>",
"      ], leading to loss of procoagulant activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/22\">",
"       22",
"      </a>",
"      ], and with binding to von Willebrand factor, leading to more rapid degradation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/16,23\">",
"       16,23",
"      </a>",
"      ]. A different site in the C2 domain appears to contain the binding site for factor Xa, and a thrombin binding site is also present in the C2 domain that is responsible for factor VIII cleavage.",
"     </li>",
"     <li>",
"      The A2 domain is a site of factor IXa binding, the active enzyme in the X-ase pathway. Thus, anti-A2 antibodies interfere with the conversion of factor X to Xa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=see_link&amp;anchor=H16#H16\">",
"       \"Overview of hemostasis\", section on 'Intrinsic pathway'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       A1/A3-C1-C2",
"      </span>",
"      dimer also contributes to factor IXa binding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/25,26\">",
"       25,26",
"      </a>",
"      ], at least part of which occurs within the A3 domain. Inhibitors directed against this site inhibit the generation of factor Xa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15594922\">",
"    <span class=\"h3\">",
"     Proteolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some antibodies have direct proteolytic activity against factor VIII [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/27\">",
"     27",
"    </a>",
"    ]. In one study, significant proteolytic activity against human factor VIII was detected in purified IgG from 13 of 24 patients with severe hemophilia A and factor VIII inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/28\">",
"     28",
"    </a>",
"    ]. The rate of hydrolysis of factor VIII by purified IgG from these patients correlated positively with its factor VIII neutralizing activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Predisposing factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both host and product factors influence the likelihood of inhibitor formation. Research continues to define the best predictors of inhibitor formation, as well as methods to decrease or prevent formation. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15593790\">",
"    <span class=\"h3\">",
"     Severity of hemophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predilection for patients with severe disease is consistent with observations that inhibitors primarily occur in patients with large deletions and stop mutations, compared with small deletions or missense mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. There is a modest increase in antibody formation in patients with gene inversions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/32\">",
"     32",
"    </a>",
"    ]. Information taken from an international electronic database indicates the frequency of inhibitors as a function of mutation type [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Large deletions (&gt;200 bp) &mdash; 38 percent",
"     </li>",
"     <li>",
"      Nonsense mutations &mdash; 36 percent",
"     </li>",
"     <li>",
"      Inversions &mdash; 20 percent",
"     </li>",
"     <li>",
"      Small deletions (&le;86 bp) &mdash; 14 percent",
"     </li>",
"     <li>",
"      Missense mutations &mdash; 7 percent",
"     </li>",
"     <li>",
"      Insertions (&le;13 bp) &mdash; 7 percent",
"     </li>",
"     <li>",
"      Splice site mutations &mdash; 4 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis of data from 5383 patients with severe hemophilia estimated the relative risks of inhibitor development according to their specific factor VIII genotypes. When compared with the risk of inhibitor development in patients with intron 22 inversions, the most common abnormal genotype (the comparator, OR= 1.0), these relative risks were as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Large deletions: OR 3.6 (95% CI 2.3-5.7)",
"     </li>",
"     <li>",
"      Nonsense mutations: OR 1.4 (95% CI 1.1-1.8)",
"     </li>",
"     <li>",
"      Intron 1 inversions: OR 0.9 (95% CI 0.6-1.5)",
"     </li>",
"     <li>",
"      Splice-site mutations: OR 1.0 (95% CI 0.6-1.5)",
"     </li>",
"     <li>",
"      Small",
"      <span class=\"nowrap\">",
"       deletions/insertions:",
"      </span>",
"      OR 0.5 (95% CI 0.4-0.6)",
"     </li>",
"     <li>",
"      Missense mutations: OR 0.3 (95% CI 0.2-0.4)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative risks for developing high titer inhibitors were similar.",
"   </p>",
"   <p>",
"    Of interest, a comprehensive study of one-third of the hemophilia A population in the UK has observed that patients with nonsense mutations have a higher inhibitor risk if their mutation is in the 3' half of the factor VIII gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Presumably, the virtually complete lack of circulating factor VIII in patients with severe disease prevents fetal induction of tolerance and predisposes them to antibody formation after exposure to normal exogenous factor VIII. The concept that self factor VIII, even if altered, contributes to tolerance to factor VIII is supported by the lower frequency and often transient nature of inhibitors in patients with less severe hemophilia A [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/7,9,10\">",
"     7,9,10",
"    </a>",
"    ]. In some of these patients the antibodies are directed only against wild-type factor VIII, not endogenously produced factor VIII [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/10,37\">",
"     10,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence for a familial predisposition in which siblings of patients with hemophilia and factor VIII inhibitors have an increased risk of inhibitors also has been shown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/9,30,38\">",
"     9,30,38",
"    </a>",
"    ]. Specific mutations in the C2 domain (Trp2229--&gt;Cys) or the A2 domain (Arg593--&gt;Cys), perhaps in the setting of surgery and intensive factor VIII exposure, may predispose to inhibitor formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/9,39\">",
"     9,39",
"    </a>",
"    ]. HLA class II antigens also appear to have some role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Polymorphisms of immune response genes, such as the Interleukin-10 gene and the cytotoxic T-lymphocyte associated protein-4 (CTLA-4) gene, which have been associated with autoantibody production in other disorders, may also be associated with inhibitor development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. Similarly, polymorphisms within the tumor necrosis factor alpha (TNFA) gene locus appear to be potential modulators of the immune response to replacement therapy in patients with hemophilia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/41,45\">",
"     41,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15593797\">",
"    <span class=\"h3\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient age at the time of initial replacement treatment, treatment intensity, and the early use of prophylaxis may influence inhibitor formation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of inhibitors in one study was 41, 29, and 12 percent for those starting replacement at &lt;6 months, between 6 and 12 months, and &gt;12 months, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/46\">",
"       46",
"      </a>",
"      ]. Similar results were reported in a second series of 81 consecutive patients with severe hemophilia A [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the CANAL (Concerted action on neutralizing antibodies in severe hemophilia A) cohort study of 366 consecutive previously untreated patients with severe hemophilia A, clinically relevant inhibitor development appeared to be associated with earlier age at first treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/31\">",
"       31",
"      </a>",
"      ]. However, after adjustment for treatment intensity, this association largely disappeared. Patients who were first treated for surgical procedures rather than for bleeding or prophylaxis (relative risk 3.7; 95% CI 2.0-7.1) and patients who received factor VIII on at least five consecutive days at the start of treatment (RR 3.3; 95% CI 2.1-5.3) were at increased inhibitor risk, as were those who had a positive family history of inhibitor development. Regular prophylaxis was associated with a 60 percent lower risk than on-demand treatment (RR 0.4; 95% CI 0.2-0.8).",
"     </li>",
"     <li>",
"      In a small study, delaying exposure to factor VIII during the first two years of life by the use of recombinant factor VIIa did not abrogate the development of an inhibitor, but merely delayed its onset [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a separate report, age of first factor VIII infusion did not correlate with the risk of inhibitor development [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/30\">",
"       30",
"      </a>",
"      ]. Rather, in two subgroup analyses of 25 children who remained inhibitor-free up to the age of 35 months, those who started prophylaxis had a significantly lower risk of developing inhibitors than those treated on demand (adjusted OR 0.2, 95% CI 0.1-0.9) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a case-control study involving 36 subjects with mild or moderate hemophilia A and an inhibitor, and 62 controls with mild to moderate hemophilia A without an inhibitor, treatment with factor VIII for six or more consecutive days during the prior year was significantly associated with inhibitor development in those &ge;30 years of age (OR 12.6; 95% CI 2.8-58) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/49\">",
"       49",
"      </a>",
"      ]. Surgery was the most common indication for intensive factor VIII treatment in 14 of the 17 individuals who were &ge;30 years of age in this study; 79 percent of procedures were orthopedic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is not known whether these observations are a reflection of differences in mutation type, plasma factor VIII concentrations, or age-associated differences in immune function. Ascertainment bias may also explain these results: patients with totally absent factor VIIIC levels (eg, those with large deletions) may have more severe disease than those with other \"severe\" mutations, and therefore be more disposed to early bleeding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment. Modifying genes that influence overall hemostasis may affect predilection for early versus late bleeding, thereby confounding the interpretation of age versus risk for inhibitor development. Additionally, variability in bleeding among individuals with &lt;1 percent activity could be related to difficulty in accurate measurement of levels in the very low range as well as to other modifying individual host factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Race",
"    </span>",
"    &nbsp;&mdash;&nbsp;Race is also a factor in inhibitor development, with inhibitor formation in people of color about twice that of whites. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Malmo International Brother Study of patients with hemophilia A and B, the incidences of inhibitors in whites, blacks, and a heterogenous group consisting of Hispanic, Asian, and Asian Indian subjects were 27, 56, and 50 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cross sectional analysis of 5651 males with severe hemophilia A, the prevalences of high-titer inhibitors in whites, blacks, and Hispanics were 16, 25, and 27 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A partial explanation for this difference may be the use of purified or recombinant factor VIII products that differ from the patient's own factor VIII protein at one or two residues representing common single nucleotide polymorphisms (SNPs) within the factor VIII gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/52\">",
"     52",
"    </a>",
"    ]. SNPs are genetic differences that vary by population and do not affect normal factor VIII function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5112?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of genetic variation\", section on 'Nucleotide substitutions and single nucleotide polymorphisms (SNPs)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, of the six recognized factor VIII haplotypes containing these SNPs, haplotypes H1 and H2 were the only ones found in the 86 white subjects, at prevalence rates of 0.93 and 0.07, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Haplotypes H3, H4, and H5 were found only in the 16 Black subjects, at prevalence rates of 0.22, 0.04, and 0.07, respectively. Haplotype H6 was found only among the 10 Chinese subjects",
"     </li>",
"     <li>",
"      Kogenate and Recombinate, the two full-length recombinant factor VIII products currently approved for use in hemophilia A, correspond to haplotypes H1 and H2, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accordingly, it was estimated that approximately one in four blacks with hemophilia A requiring replacement therapy will receive products that differ from their own factor VIII at one or two residues, thus contributing to the higher incidence of inhibitors among black patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/52\">",
"     52",
"    </a>",
"    ]. A large clinical investigation is ongoing by these investigators to verify whether these interpretations are borne out in a larger cohort of African Americans and Africans; in this ongoing study, the immune response to factor VIII is being individually assessed using advanced immunologic measurements.",
"   </p>",
"   <p>",
"    For patients with severe hemophilia who have a null mutation, the presence or lack of a specific haplotype in the infused factor VIII should not matter, since the patient should not have had circulating factor VIII in utero to induce tolerance to factor VIII. The possibility that the \"null\" mutation encodes for a truncated molecule capable of inducing partial prenatal immune tolerance may explain the discordancy between whites and non-whites in this cohort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15593804\">",
"    <span class=\"h3\">",
"     Replacement product",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor VIII replacement products include plasma-derived and recombinant preparations. These products differ in their composition, purity, and potential contaminants. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38442?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of hemophilia\", section on 'Factor VIII products'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No randomized trials that compare the immunogenicity or incidence of inhibitor formation have been reported, and reviews of this question have come to different conclusions regarding the risk of developing inhibitors from various products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. Current evidence suggests that plasma-derived and recombinant products are equivalent in their association with inhibitor development based on the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of inhibitor development was evaluated prospectively in 574 previously untreated children with severe hemophilia A [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/56\">",
"       56",
"      </a>",
"      ]. Of these, 177 patients (32 percent) developed an inhibitor, 116 (22 percent) of which were high titer (ie, more than five Bethesda units). The risk of inhibitor formation was similar with recombinant and plasma derived products (adjusted hazard ratio [HR] 0.96; 95% CI 0.62-1.49). The amount of von Willebrand factor in the product and switching of products did not increase the risk of inhibitor development. Compared with third generation recombinant products, second generation full-length recombinant products had a higher risk of inhibitor formation (adjusted HR 1.60; 95% CI 1.08-2.37).",
"     </li>",
"     <li>",
"      An observational study of 111 patients with hemophilia A who developed inhibitors found that compared with those who received",
"      <span class=\"nowrap\">",
"       low/intermediate",
"      </span>",
"      purity factor VIII products, those who received high purity plasma derived products had an increased risk of inhibitor development (adjusted HR 2.0; 95% CI 1.1-4.0) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an observational study of 478 Canadian patients who were switched from plasma derived to recombinant factor VIII, there was no increase in inhibitor formation during the year following the switch [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an observational study in which all Irish patients with hemophilia A (113 individuals) were switched from one recombinant factor VIII product to another, only one developed a new inhibitor; this was a one-year-old boy who had only received three doses of the previous product [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An observational study of 316 patients with hemophilia A found no increased risk of inhibitor formation with recombinant versus plasma derived factor VIII, and no increased risk in individuals who switched products [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An additional study (Survey of Inhibitors in Plasma-Product Exposed Toddlers [SIPPET]; NCT01064284) will assess the frequency of inhibitor formation in previously untreated children with severe hemophilia A given recombinant versus plasma-derived factor VIII products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If antibodies form in multiply exposed patients who have been changed to a new product, product-related factors might be responsible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. In this case consideration should be given to the use of the prior product if the patient has had many exposure days in the past, although change to the prior product may not always result in inhibitor disappearance. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H847653\">",
"    <span class=\"h3\">",
"     Immunologic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Development of inhibitors is an immune phenomenon, and some data have suggested that immunologic factors may contribute to inhibitor development. As an example, the Hemophilia Inhibitor Genetics Study (HIGS) evaluated genes involved in immune regulation among 104 sibling pairs with hemophilia A who were discordant in inhibitor status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/65\">",
"     65",
"    </a>",
"    ]. As siblings, these individuals had the same factor VIII mutation. Analysis of single nucleotide polymorphisms (SNPs) demonstrated variations in 13 immune",
"    <span class=\"nowrap\">",
"     response/immune",
"    </span>",
"    modifier genes that correlated with inhibitor development. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5112?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of genetic variation\", section on 'Nucleotide substitutions and single nucleotide polymorphisms (SNPs)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Risk score",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings from a cohort of consecutive previously untreated patients with severe hemophilia A (the CANAL study) were used to develop a risk score for the development of factor VIII inhibitors, which included the following adverse risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/66\">",
"     66",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Family history of inhibitors &mdash; 2 points",
"     </li>",
"     <li>",
"      High-risk gene mutation present &mdash; 2 points",
"     </li>",
"     <li>",
"      Intensive treatment at first bleeding episode &mdash; 3 points",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the training cohort (332 patients), inhibitor incidence was 6, 23, and 57 percent for those with a risk score of zero, 2, or &ge;3 points, respectively. Similar incidences were noted in a validation cohort of 64 patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of factor VIII antibodies in patients with hemophilia A depend in part upon the severity of the disease. In general, the inhibitor does not lead to a marked increase in the frequency of bleeding events except when a moderate or mild deficient patient is converted to a more severe state due to inhibitor development. However, patients with inhibitors have more difficulty in achieving hemostasis and tend to have more musculoskeletal complications; in this setting, the bleeding frequency may increase due to the presence of acute and chronic synovitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inhibitors make the treatment of bleeding episodes more difficult. Thus, an inhibitor should be suspected when any bleeding episode is refractory to usual therapy, particularly in patients with severe hemophilia.",
"   </p>",
"   <p>",
"    On the other hand, bleeding episodes may be induced in patients with mild to moderate disease if the inhibitor causes a fall in factor VIII levels, converting the patient to a more severe phenotype. One series identified factor VIII inhibitors in 26 patients with mild or moderate hemophilia A; most of the inhibitors developed after a period of intensive replacement therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/9\">",
"     9",
"    </a>",
"    ]. Spontaneous bleeding occurred in 22, with a bleeding pattern similar to that of acquired hemophilia in 17. The inhibitor persisted in 10 patients for a median of eight years. It disappeared after a median of nine months in the remaining patients, either spontaneously or after immune tolerance induction. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Immune tolerance induction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diagnosis and screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor VIII inhibitor activity generally is measured by the Bethesda assay, which both establishes the diagnosis of a factor VIII inhibitor and quantifies the antibody titer. In this Bethesda assay, serial dilutions of patient plasma are incubated with pooled normal plasma at 37&ordm;C for two hours; residual factor VIII activity then is measured using a clotting assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/68\">",
"     68",
"    </a>",
"    ]. The reciprocal of the dilution of patient plasma that results in residual 50 percent factor VIII activity is the titer of the inhibitor in Bethesda units (BU). The higher the inhibitor titer, the greater the dilution required to demonstrate residual factor VIII activity.",
"   </p>",
"   <p>",
"    The Nijmegen modification of the Bethesda assay appears to have improved specificity and reliability, especially with lower titer inhibitors, by enhancing the intrinsic buffering effect following serial dilution in the assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/69\">",
"     69",
"    </a>",
"    ]. Initial, limited information has been presented on an immunoassay for anti-factor VIII antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no standardized algorithm for the timing of inhibitor screening and experts vary in their screening protocol. A reasonable approach includes testing for the development of an inhibitor at least annually, and more frequently in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately once every 10 exposure days (ie, days in which the patient has received one or more infusions of factor VIII) for the first 50 exposure days in severely deficient patients.",
"     </li>",
"     <li>",
"      If a patient has a poor clinical response to usual replacement therapy.",
"     </li>",
"     <li>",
"      If a patient develops increased severity or frequency of bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comprehensive Hemophilia Treatment Centers provide expertise for these specialized patients and should be consulted for the development of any treatment plan in a hemophilic patient with an inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/71\">",
"     71",
"    </a>",
"    ]. The two components to therapy are treatment of active bleeding and inhibitor ablation via immune tolerance induction. Advances in these areas have led to an improvement in outcome among patients with hemophilia A and inhibitors. In a review from Finland, for example, the annual death rate among such patients fell from 42 to 5.8 per thousand patient years in the periods 1970-1979 and 1980-1989, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/8\">",
"     8",
"    </a>",
"    ]. Guidelines for such treatment from the UK Haemophilia Centre Doctors' Organization are available, and are revised and updated periodically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While treatment results in a quality of life similar to those without inhibitors, such therapy is expensive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/74\">",
"     74",
"    </a>",
"    ]. In a study of 52 patients with high-responding inhibitors observed over an 18-month period, there were 0.6 bleeding episodes per subject per month, at an average estimated monthly cost of $18,000 per patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Active bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general approach to the treatment of bleeding episodes in patients with hemophilia A and inhibitors requires knowledge of the inhibitor type (high versus low responding):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with usual bleeding episodes involving the joints and muscle who are high responders, inhibitor bypassing products are generally employed regardless of the present inhibitor titer. Bypassing products have included prothrombin complex concentrates (PCCs, or the original factor IX complex concentrates) and their activated counterparts (aPCCs: FEIBA), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/42/30373?source=see_link\">",
"       recombinant human factor VIIa",
"      </a>",
"      (NovoSeven).",
"     </li>",
"     <li>",
"      Plasmapheresis may be useful when active bleeding is present to acutely lower the titer and allow use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/12/198?source=see_link\">",
"       factor VIII concentrates",
"      </a>",
"      in some patients with an inhibitor &gt;10 Bethesda units.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PCCs and aPCCs may be associated with reactions due to activation of the complement and bradykinin systems when infused rapidly, as well as other complications such as frank thromboembolic events, myocardial infarction, and disseminated intravascular coagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/75\">",
"     75",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/42/30373?source=see_link\">",
"     Recombinant human factor VIIa",
"    </a>",
"    (rFVIIa) does not produce an anamnestic antibody response and markedly reduces the risk of disseminated intravascular coagulation and thrombosis due to its mechanism of action, which provides more localized hemostatic control at the site of injury or bleeding. The presently licensed form of rFVIIa has a short half-life, which may require higher or more frequent dosing to achieve the desired hemostatic effect for hemarthroses. In a study comparing rFVIIa and aPCC, data obtained support this concept [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31962?source=see_link\">",
"     \"Therapeutic uses of recombinant coagulation factor VIIa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Perioperative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery in patients with a high-responding inhibitor should be undertaken with great caution. In general, protocols that have been successful for a bleeding episode in such patients should be the ones selected for perioperative management. Options include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recombinant factor VIIa in a bolus dose of 90 to 120",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      every two hours for the first 48 hours.",
"     </li>",
"     <li>",
"      FEIBA in a dose of 200",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per day for the first two to four days for major surgery and in a dose of 150",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per day for three days for minor surgical procedures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     High purity factor VIII concentrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although high purity",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/12/198?source=see_link\">",
"     factor VIII concentrates",
"    </a>",
"    can be used in patients with low inhibitor levels (&lt;10 Bethesda units), their main use is in the treatment of life-threatening hemorrhage or emergency surgery in patients with low inhibitor levels or moderate inhibitor levels that have been reduced by plasmapheresis or immunoadsorption (",
"    <a class=\"graphic graphic_table graphicRef51792 \" href=\"mobipreview.htm?16/16/16652\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/4,77\">",
"     4,77",
"    </a>",
"    ]. In these settings, physiologic factor VIII levels can be attained before the anamnestic response occurs.",
"   </p>",
"   <p>",
"    Dosing of factor VIII in the presence of inhibitors has not been prospectively validated, although the following schedule has been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial loading dose (international units) equal to the patient's body weight(kg) x 80 x (1- hematocrit) x antibody titer (Bethesda",
"      <span class=\"nowrap\">",
"       units/mL)",
"      </span>",
"      is given along with an additional 50 international",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      of body weight.",
"     </li>",
"     <li>",
"      Factor VIII levels should be measured 15 minutes after completion of the bolus, and dose adjustments made to correct for individual variations in response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Porcine factor VIII concentrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Porcine factor VIII had been used primarily to treat patients who are high responders with high human factor VIII inhibitor titers and porcine factor VIII titers less than 10 Bethesda units who have life threatening episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/78-80\">",
"     78-80",
"    </a>",
"    ]. However, plasma-derived porcine factor VIII (Hyate-C) is no longer available, since the earlier generation plasma-derived porcine factor was removed from the market because of problems with contamination with porcine parvovirus.",
"   </p>",
"   <p>",
"    A recombinant porcine factor VIII is currently in phase",
"    <span class=\"nowrap\">",
"     II/III",
"    </span>",
"    trials and has not yet been licensed by the US FDA or the EMA in Europe. However, previous data using the plasma-derived porcine concentrate are illustrative of how the future use of recombinant porcine factor VIII might be utilized in the therapeutic armamentarium for patients with high titer factor VIII inhibitors.",
"   </p>",
"   <p>",
"    In approximately 75 to 80 percent of such patients, the inhibitor cross-reacts with shared epitopes on the porcine molecule; the median crossreactivity is approximately 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/79\">",
"     79",
"    </a>",
"    ]. Thus, before this product can be given, and when available, it is necessary to quantitate the patient's specific titer against porcine factor VIII using the Bethesda assay. The dose of porcine factor VIII is determined by the weight of the patient and the titer of the anti-porcine antibodies; monitoring of factor VIII levels is essential (",
"    <a class=\"graphic graphic_table graphicRef51792 \" href=\"mobipreview.htm?16/16/16652\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78059 \" href=\"mobipreview.htm?41/17/42267\">",
"     table 2",
"    </a>",
"    ). As with most therapies for hemophilia A patients with inhibitors, porcine factor VIII is expensive.",
"   </p>",
"   <p>",
"    The administration of plasma-derived porcine factor VIII was sometimes associated with hypersensitivity reactions (approximately 1 to 2 percent of patients), mostly in those treated with higher doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/79\">",
"     79",
"    </a>",
"    ]. Results with the investigational recombinant porcine factor VIII are awaited with regard to its allergenic potential. With either product, an anamnestic elevation in anti-porcine factor VIII antibodies is not unexpected. For the plasma-derived concentrate, anamnesis was common (marked in 30 percent and intermediate in 40 percent); it typically develops around the seventh to tenth day of use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT WITH AGENTS OTHER THAN FACTOR VIII",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hemophilia A and high levels of inhibitor may require treatment with agents other than factor VIII. These agents include prothrombin complex concentrates and recombinant factor VIIa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Activated prothrombin complex concentrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manufacturers of the prothrombin complex concentrates (PCCs) increased the concentration of active proteases, resulting in production of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/61/37844?source=see_link\">",
"     activated prothrombin complex concentrates",
"    </a>",
"    (aPCCs); FEIBA is the only aPCC available for clinical use. Autoplex, a formerly available preparation, has now been withdrawn from the market [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. In one review of 433 bleeding episodes in 60 patients with inhibitors who were treated with FEIBA, the outcome was judged to be good or excellent in 81 percent, poor in 17 percent, and nonexistent in 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the activated proteases that account for the procoagulant activity of aPCCs are short-lived, initial hemostasis may be followed by breakthrough bleeding between doses that may create difficulty for maintenance of hemostasis. In addition, both PCCs and aPCCs are associated with a risk of thrombosis, including myocardial infarction, which is most likely to occur when large doses are given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/75,84\">",
"     75,84",
"    </a>",
"    ]. Other risk factors include crush injuries, surgery, and liver function abnormalities, leading to a decreased ability to clear activated products.",
"   </p>",
"   <p>",
"    Another problem is that there is no in vitro assay for the PCCs or aPCCs that can be used to correlate with in vivo hemostatic efficacy, and it is not possible to predict the hemostatic efficacy of these products. The net effect is that the therapeutic efficacy for specific hemorrhagic episodes and for specific products in any individual can vary. As a result, an individualized therapeutic plan needs to be established and is best designed by a hematologist experienced in the care of these complicated patients. Certain general guidelines may be utilized for initial treatment and stabilization of these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Effective dosing of aPCCs is within the range of 50 to 100 international",
"      <span class=\"nowrap\">",
"       units/kg;",
"      </span>",
"      daily doses exceeding 200 international",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      have been associated with disseminated intravascular coagulation, and should be avoided.",
"     </li>",
"     <li>",
"      Dosing frequency should be every 8 to 12 hours for up to three doses, since more frequent infusion may increase thrombotic risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, therapy with PCCs or aPCCs is expensive, provides unpredictable hemostasis without the ability to monitor clinical efficacy with a laboratory test, and carries the risk of significant complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/75\">",
"     75",
"    </a>",
"    ]. Experience and expertise in their use help to mitigate these risks and to differentiate the appropriate use of aPCCs from other therapeutic alternatives for patients with inhibitors.",
"   </p>",
"   <p>",
"    A small study has suggested the use of a thrombin generation test to assess the in vivo effectiveness of these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/85\">",
"     85",
"    </a>",
"    ]. However, thrombin generation tests (TGT) are not uniformly available, have historically been difficult to establish and standardize, and have not been definitively demonstrated to correlate with clinical efficacy in the use of bypassing agents in patients with hemophilia and inhibitors.&nbsp;Further research is required to support these initial data and to substantiate the use of TGT tests to monitor clinical efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23392928\">",
"    <span class=\"h3\">",
"     Prophylactic use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prospective, randomized, crossover, multicenter Prophylaxis with Factor Eight Inhibitor Bypassing Activity (Pro-FEIBA) study was designed to compare the efficacy and safety of the aPCC product FEIBA when used either in a prophylactic or &ldquo;on demand&rdquo; setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/86\">",
"     86",
"    </a>",
"    ]. Eligible subjects with hemophilia A were &gt;2 years of age, had high titer inhibitors (ie, &gt;5 Bethesda units), were being treated with bypassing agents, and had &ge;6 episodes of bleeding requiring bypassing agent treatment in the six-month period prior to study enrollment.",
"   </p>",
"   <p>",
"    Participants received either six months of on-demand therapy with FEIBA (85 international",
"    <span class=\"nowrap\">",
"     units/kg)",
"    </span>",
"    or prophylactic therapy with FEIBA (85 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    on three nonconsecutive days each week). After the initial six-month period, and a three-month &ldquo;washout&rdquo; period, subjects crossed over to the alternative treatment program. Results included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/86\">",
"     86",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the 26 subjects completing both treatment periods, and compared with on demand treatment, prophylaxis was associated with significant reductions in all bleeding episodes (62 percent reduction), hemarthroses (61 percent reduction), and target joint bleeding (ie, &ge;3 hemarthroses in a single joint during a six-month period; 72 percent reduction).",
"     </li>",
"     <li>",
"      For the 33 subjects receiving at least one infusion of the study drug, there was one episode of allergic reaction and no thromboembolic events. Three patients had multiple events related to central venous access devices (eg, infection, bleeding, line placement and removal).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional, larger, longer-term studies will be required before prophylactic treatment with an aPCC product (or recombinant factor VIIa, see below) can be recommended for preventing the onset of joint disease or halting the progression of arthropathy in patients with inhibitors and minimal joint damage. There is also a need for improving cost-effectiveness of these interventions because of their exceedingly high costs in patients with inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Recombinant human factor VIIa",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/42/30373?source=see_link\">",
"     Recombinant human factor VIIa",
"    </a>",
"    (Novo-Seven, rFVIIA) produces an excellent or effective response in approximately 90 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/87-91\">",
"     87-91",
"    </a>",
"    ]. Because factor VIIa requires tissue factor to be active, it promotes coagulation only at local sites of hemostasis and should minimize the risk of systemic coagulation seen with PCCs and APCCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/84,87\">",
"     84,87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Initial dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual dose is 90 to 120",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    at two- to three-hour intervals until hemostasis is achieved, with further dosing and lengthening of the interval based upon the patient's clinical circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/1\">",
"     1",
"    </a>",
"    ]. In one study of home treatment of mild to moderately severe joint, muscle, and mucocutaneous bleeding episodes, a mean of 2.2 doses was required to control bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A starting dose of 90 to 120",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    is used in patients undergoing surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/89\">",
"     89",
"    </a>",
"    ]. In a prospective randomized trial, the 90",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    dose was found to be superior to a dose of 35",
"    <span class=\"nowrap\">",
"     mcg/kg.",
"    </span>",
"   </p>",
"   <p>",
"    The use of a bolus dose of rFVIIa followed by continuous infusion has been described in two studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 28 patients with factor VIII inhibitors, a starting dose of 90 to 150",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      (median dose: 100",
"      <span class=\"nowrap\">",
"       mcg/kg)",
"      </span>",
"      was given by bolus infusion for 10 spontaneous bleeding episodes, 11 major surgical procedures, and 14 minor procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/92\">",
"       92",
"      </a>",
"      ]. This was followed by a dose of 16, 17, or 20",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per hour by continuous infusion for spontaneous hemorrhages, minor, and major surgery, respectively. Satisfactory hemostasis was achieved in 30 of the 35 courses (86 percent). Median plasma factor VII:c levels were 25 international",
"      <span class=\"nowrap\">",
"       units/mL",
"      </span>",
"      for patients undergoing major surgery and 12 international",
"      <span class=\"nowrap\">",
"       units/mL",
"      </span>",
"      in the other two groups. In this study, plasma factor VII:c levels did not predict the likelihood of treatment failure.",
"     </li>",
"     <li>",
"      rFVIIa was given in a bolus dose of 90",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      immediately prior to elective major orthopedic surgery in nine patients with inhibitors to factor VIII [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/93\">",
"       93",
"      </a>",
"      ]. This was followed by rFVIIa by continuous infusion at a dose of 50",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per hour for a median of 20 days (range: 7 to 20 days), set to achieve a target factor VII:c level of &gt;30 international",
"      <span class=\"nowrap\">",
"       units/mL.",
"      </span>",
"      There were post-operative bleeding episodes in six patients, which could be controlled with a single bolus dose of 60",
"      <span class=\"nowrap\">",
"       mcg/kg;",
"      </span>",
"      there was a good clinical outcome for all patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No severe thrombotic adverse events were noted in either study. It has been suggested, based on these results, that targeting factor VII:c levels to 30 to 40 international",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    in the immediate post-operative period is likely to provide a margin of safety sufficient for most clinical situations, whereas steady-state levels of 10 international",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    are likely to be inadequate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/87,93-95\">",
"     87,93-95",
"    </a>",
"    ]. A more complete discussion of thrombotic events in patients treated with recombinant factor VIIa can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31962?source=see_link&amp;anchor=H26#H26\">",
"     \"Therapeutic uses of recombinant coagulation factor VIIa\", section on 'Thromboembolic events'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A third study compared continuous infusion dosing with bolus dosing in 24 subjects with hemophilia and inhibitors undergoing surgery. All subjects received an initial bolus dose of 90",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    rFVIIa and were then randomly assigned to receive rFVIIa by bolus dosing (90",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    rFVIIa every two hours during surgery through day 5, then every four hours for days 6 through 10) or by continuous infusion (50",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per hour through day 5, then 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour on days 6 through 10) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/96\">",
"     96",
"    </a>",
"    ]. Hemostatic efficacy and safety of the two treatments were judged to be comparable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     High-dose regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three studies have evaluated the safety and efficacy of high-dose factor VIIa, rather than standard dose factor VIIa, to control bleeding in patients with hemophilia and inhibitors in a home treatment setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/97-99\">",
"     97-99",
"    </a>",
"    ]. One of these studies was a trial of rFVIIa to control joint bleeding in 20 hemophiliacs with inhibitors, and compared doses of 90",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    given every three hours as needed (current standard therapy) to a single dose of 270",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/97\">",
"     97",
"    </a>",
"    ]. The two treatment strategies were equally effective in controlling bleeding and the median amount of rFVIIa ultimately used per successful treatment course was identical (270",
"    <span class=\"nowrap\">",
"     mcg/kg).",
"    </span>",
"    Similar conclusions were reached in the other two studies.",
"   </p>",
"   <p>",
"    Thus, a high-dosage regimen appears to be effective, safe, does not increase consumption of rFVIIa, and requires the administration of a lesser number of doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/100\">",
"     100",
"    </a>",
"    ]. Its convenience is particularly relevant in patients with difficult venous access and in hemorrhages into target joints, where rapid reversal of bleeding is paramount. As a result of these data, the dose of 270",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    of rFVIIa was approved by the European Medicines Agency for home-treatment of mild-to-moderate hemorrhage in hemophilia patients with inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Prophylactic use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic use of rFVIIa was explored in 22 male patients with confirmed high baseline bleeding frequency (ie, &ge;4 bleeds per month), who were randomly assigned to receive daily prophylaxis with either 90 or 270",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    of rFVIIa for 3 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/101\">",
"     101",
"    </a>",
"    ]. Bleeding frequency was reduced by 45 and 59 percent during the period of prophylaxis with 90 and 270",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    doses, respectively. The majority of this reduction in bleeding was maintained during the post-prophylaxis period.",
"   </p>",
"   <p>",
"    Although all types of bleeding were similarly reduced, the effect of prophylaxis was most pronounced for spontaneous joint bleeds. No thromboembolic events were reported during prophylaxis. In a subsequent examination of this cohort, quality of life was assessed and found to be significantly improved both during the period of secondary prophylaxis and, perhaps surprisingly, in the three months following discontinuation of rFVIIa prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Activated PCC versus recombinant factor VIIa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FENOC (FEIBA NovoSeven Comparative) Study was a prospective, open label, randomized, crossover study designed to test the equivalence between an activated prothrombin complex concentrate (aPCC, FEIBA, target dose 85 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    IV given once) and NovoSeven (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/42/30373?source=see_link\">",
"     recombinant human factor VIIa",
"    </a>",
"    , target dose 105",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    IV given twice, two hours apart) for the treatment of bleeding episodes in patients with hemophilia A and inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data for 96 bleeding episodes in 48 participants were analyzed. Although the primary criterion for declaring the two products equivalent at six hours after treatment was not met, they were both associated with an efficacy rate of 80 to 90 percent at some of the evaluated time points. In an exploratory analysis, neither product was superior to the other, either in efficacy or the ability to stop bleeding at any of the time points examined (2 to 48 hours after infusion).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17045677\">",
"    <span class=\"h3\">",
"     Activated PCC plus recombinant factor VIIa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The routine use of two bypassing agents in parallel has been criticized and cautioned in several studies due to an increased risk of thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/1,103\">",
"     1,103",
"    </a>",
"    ]. As an example, a literature review disclosed parallel use of activated PCC and recombinant factor VIIa in 49 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/104\">",
"     104",
"    </a>",
"    ]. Thrombotic events occurred in five of the nine patients with acquired hemophilia (three fatal) and in 5 of the 40 patients with congenital hemophilia (one fatal). While the hemostatic efficacy of this combination appears to be satisfactory, the high incidence of thrombotic complications has led to the conclusion that parallel treatment should be reserved for life-threatening or limb-threatening bleeds, in which other treatment options have failed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     IMMUNE TOLERANCE INDUCTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibitor eradication, also called immune tolerance induction (ITI), requires routine administration of the deficient factor to",
"    <span class=\"nowrap\">",
"     reset/tolerize",
"    </span>",
"    the patient's immune system. A variety of ITI protocols exist utilizing a wide range of dosing regimens either with or without immunosuppressive therapy, or via the use of bypassing agents to suppress bleeding episodes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A now closed international prospective ITI study in good-risk patients compared daily high dose factor VIII (200 international",
"      <span class=\"nowrap\">",
"       units/kg/day)",
"      </span>",
"      with a three times weekly lower dose factor VIII (50 international",
"      <span class=\"nowrap\">",
"       units/kg/day)",
"      </span>",
"      regimen with time to successful ITI as the primary endpoint. The study was closed early for safety by the Data Safety Monitoring Board as patients in the low dose arm experienced significantly higher frequency of bleeding events than those in the high dose arm (86 versus 63 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/106\">",
"       106",
"      </a>",
"      ]. There was no difference in the two arms with regards to successful achievement of immune tolerance (41 versus 39 percent).",
"     </li>",
"     <li>",
"      The presence of von Willebrand factor (VWF) as a carrier protein for factor VIII has been hypothesized to mitigate the effects of neutralizing anti-factor VIII antibodies. Retrospective data suggest that plasma products containing VWF and other plasma proteins may result in fewer inhibitors developing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/107\">",
"       107",
"      </a>",
"      ]. A randomized clinical trial will be investigating this possibility (the SIPPET trial).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several factors affect ITI success:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The titer at start of therapy has shown to be a predictor of success with a titer &lt;10 BU associated with improved outcome.",
"     </li>",
"     <li>",
"      Younger patients and a shorter time from onset of the inhibitor to ITI confer improved outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Available ITI regimens appear to be less successful in patients of color, including blacks, Hispanics and Asian Indians. Although less successful overall, ITI should still be considered and utilized in appropriate patients in these groups. Initiating ITI at a low initial titer, preferably &lt;10 BU, must be balanced against the risk of waiting too long and allowing inhibitors to become memory responses. If the decision to wait to start ITI until a titer of &lt;10 BU is achieved, then the titer should be followed regularly to identify a continued fall or plateau in the titer.",
"   </p>",
"   <p>",
"    Long-term management of hemophilic patients with factor VIII inhibitors is aimed at eliminating the inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/108\">",
"     108",
"    </a>",
"    ]. The primary method used is the attempt at immune tolerance induction (ITI) via the administration of repetitive doses of factor VIII with or without immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/4\">",
"     4",
"    </a>",
"    ]. Many responders have an initial rise in antibody titers caused by the anamnestic response, followed by a progressive reduction to a low or undetectable titer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/4,109\">",
"     4,109",
"    </a>",
"    ]. Immune tolerance usually must be maintained by continued exposure to factor VIII [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    How desensitization works is not completely understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. In one study, desensitization did not change the concentration of antibodies or their ability to inhibit the procoagulant function of factor VIII [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/27\">",
"     27",
"    </a>",
"    ]. The associated reduction in the Bethesda assay to undetectable levels appeared to involve the production of antiidiotypic antibodies that neutralized the inhibitory capacity of the factor VIII antibodies. In another report, tolerant patients had circulating antibodies against factor VIII that, compared with the original inhibitor, differed in specificity, lacked coagulation inhibitory activity, and did not enhance the rate of elimination of factor VIII [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Specific regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of different regimens have been used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/1,4,109,113-116\">",
"     1,4,109,113-116",
"    </a>",
"    ]. The range of results can be illustrated by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, 12 patients were treated with factor VIII at 50",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per day without adjunctive immunosuppressive therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/109\">",
"       109",
"      </a>",
"      ]. The inhibitor became undetectable in nine patients at one to 10 months; these patients required smaller and less frequent infusions. The three nonresponders had the highest inhibitor levels.",
"     </li>",
"     <li>",
"      In a multicenter survey of 158 patients from an international registry, 68 percent had complete tolerance, 7 percent partial tolerance, and 25 percent did not respond [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/113\">",
"       113",
"      </a>",
"      ]. Success was most likely with higher doses (&ge;100",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per day) and low levels of inhibitor (&lt;10 Bethesda units) at the start of therapy, even though most patients were high responders. Once achieved, tolerance was long-lasting, as only 1 of 107 responders relapsed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data on 188 courses of immune tolerance therapy (ITT) were obtained via questionnaire by the North American Immune Tolerance Registry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/115\">",
"     115",
"    </a>",
"    ]. Outcome parameters noted to be predictive of ITT success for hemophilia A included historical peak inhibitor titers pre-ITT and during ITT. As an example, ITT was successful in 83 versus 40 percent of patients with hemophilia A when the pre-ITT titer was &lt;10 or &ge;10 BU, respectively.",
"   </p>",
"   <p>",
"    In a study of 86 patients recruited as part of the Italian Immune Tolerance Induction (ITI) registry (the PROFIT study), factor VIII mutations known to be associated with a high risk of factor VIII inhibitor formation (large deletions, inversions, nonsense and splice site mutations) were found in 81 percent, while lower risk mutations (small",
"    <span class=\"nowrap\">",
"     insertions/deletions,",
"    </span>",
"    nonsense mutations) were found in 19 percent. Although ITI was not performed in a uniform manner or at a uniform time after inhibitor development, the following observations were made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/117\">",
"     117",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The low-risk mutation group showed a significantly higher ITI success rate than those with high-risk mutations (81 versus 41 percent).",
"     </li>",
"     <li>",
"      On multivariate analysis, mutation risk class (odds ratio 6.2), inhibitor titer &lt;5 Bethesda",
"      <span class=\"nowrap\">",
"       units/mL",
"      </span>",
"      at the start of ITI (odds ratio 11.8), and peak titer &lt;100 Bethesda",
"      <span class=\"nowrap\">",
"       units/mL",
"      </span>",
"      during ITI (odds ratio 11.4) were predictors of successful ITI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Use of rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    has been employed in hemophilia patients with high inhibitor levels, with variable degrees of success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/118-122\">",
"     118-122",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     INHIBITORS IN HEMOPHILIA B",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of factor IX inhibitors in hemophilia B is much lower than that seen with factor VIII inhibitors in hemophilia A. The estimated incidence is 3 to 5 percent in patients with severe hemophilia B but is population-dependent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/13,123,124\">",
"     13,123,124",
"    </a>",
"    ]. Some evidence indicates that, as in hemophilia A, inhibitors primarily form in patients with gene deletions, major derangements, or nonsense mutations and who have little or no endogenous factor IX, suggesting that the absence of self factor IX prevents the induction of tolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/125,126\">",
"     125,126",
"    </a>",
"    ]. The lower incidence of inhibitors in hemophilia B may be related to a lower frequency of patients with such severe gene defects because the risk of inhibitors in patients with missense mutations is extremely low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/127,128\">",
"     127,128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, only 2 percent of patients in the International hemophilia B database have developed inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/129,130\">",
"     129,130",
"    </a>",
"    ]. Among these, 23 percent of those with gross deletions and 30 percent of the complete deletion entries have developed inhibitors. In contrast, only 10 inhibitors are represented among the 750 patients with missense mutations. A hemophilia B mutation database is available at",
"    <a class=\"external\" href=\"file://www.factorix.org/\">",
"     www.factorix.org",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in factor VIII deficiency, an inhibitor is suspected in patients with factor IX deficiency when they fail to respond to infusion therapy or when an infusion reaction occurs. The diagnosis should be confirmed in the laboratory with a Bethesda assay for factor IX. The majority of patients with factor IX deficiency and inhibitors are high responders (ie, titer of &gt;5 Bethesda units, increasing titer upon re-exposure to factor IX, and persistence of inhibitor years after exposure to factor IX). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Diagnosis and screening'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A family history of inhibitors in factor IX deficient patients should lead to the utmost caution when treating any newly diagnosed patient. It has been recommended that the first 20 infusions of factor IX be administered where facilities for resuscitation are immediately available in patients with severe disease and a known high-risk mutation or when the mutation is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Comprehensive Hemophilia Treatment Centers provide expertise for these specialized patients and should be consulted for the development of any treatment plan in a hemophilic patient with an inhibitor. The two components to therapy are treatment of active bleeding and inhibitor ablation via immune tolerance induction. Guidelines for such treatment from the UK Haemophilia Centre Doctors' Organization are available, and are revised and updated periodically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Active bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal therapy of active bleeding should be determined by the treatment center. In patients without anaphylaxis, PCCs or APCCs can be given, although they will lead to continued stimulation of antibody production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/81,131\">",
"     81,131",
"    </a>",
"    ]. There is also a risk of thrombosis, including myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/75,132\">",
"     75,132",
"    </a>",
"    ]. In comparison,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/42/30373?source=see_link\">",
"     recombinant human factor VIIa",
"    </a>",
"    (NovoSeven) will not lead to stimulation of the antibody titer and is not associated with a risk of anaphylactoid reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/87,131,133\">",
"     87,131,133",
"    </a>",
"    ]. Thus, NovoSeven is the treatment of choice in patients with a history of infusion therapy reactions. The dosing is as described above for factor VIII inhibitors (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Recombinant human factor VIIa'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Immune tolerance induction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune tolerance induction (ITI), similar to that described above for patients with factor VIII, can be attempted. However, according to the North American Immune Tolerance Registry, this technique has been less successful in patients with factor IX inhibitors (31 percent) than in those with factor VIII inhibitors (70 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/115,126\">",
"     115,126",
"    </a>",
"    ]. ITI may also be associated with the development of nephrotic syndrome that is poorly responsive to corticosteroids, and often requires withdrawal of the antigen, factor IX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/126,129,134\">",
"     126,129,134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further work is needed in this area. The use of non-traditional immunosuppressive agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil) has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Anaphylactoid reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to diminished responsiveness to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8151?source=see_link\">",
"     factor IX concentrates",
"    </a>",
"    , patients with factor IX inhibitors also are at risk for development of allergic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anaphylactic reactions following factor IX infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/126,128,129,136\">",
"     126,128,129,136",
"    </a>",
"    ]. One report evaluated 18 children who developed anaphylaxis or an anaphylactoid reaction after factor IX therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/126\">",
"     126",
"    </a>",
"    ]. All had severe hemophilia B and a factor IX inhibitor; the median number of exposure days was 11. As with inhibitor formation itself, these reactions are limited primarily to patients with gene deletions or major gene rearrangements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/126,136\">",
"     126,136",
"    </a>",
"    ]. The risk of anaphylactoid reactions may be as high as 26 percent in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A registry has been established to gather information on the occurrence and characteristics of patients with inhibitors as well as the incidence of allergic and anaphylactic reactions in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Nephrotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune tolerance induction (ITI)-associated nephrosis is more likely to occur in patients with a history of an anaphylactoid reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/56/36746/abstract/134,138\">",
"     134,138",
"    </a>",
"    ]. Unlike common childhood nephrosis, such patients are steroid resistant. Treatment requires withdrawal of the antigen, specifically the FIX concentrate or ITI therapy. The etiology of nephrosis is unclear, although it is thought to be related to immune complex formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10846052\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Factor VIII inhibitors have been reported in approximately 25 to 30 percent of patients with severe hemophilia A and 3 to 5 percent of patients with severe hemophilia B. They primarily occur early in treatment in young children and are much less common in patients with moderate and mild hemophilia A. The inhibitor does not lead to a marked increase in the frequency of bleeding events except when an individual with moderate or mild factor VIII deficiency is converted to a more severe state due to inhibitor development; however, bleeding episodes may be more difficult to control, and the overall number of bleeding episodes may increase over time due to development of musculoskeletal complications. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Inhibitors in hemophilia A'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factor VIII and factor IX inhibitor activity is measured by the Bethesda assay, which both establishes the diagnosis of an inhibitor and quantifies the antibody titer. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis and screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High purity",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/12/198?source=see_link\">",
"       factor VIII concentrates",
"      </a>",
"      can be used in patients with low responding inhibitor levels (&lt;5 Bethesda units); they may also be utilized in the treatment of life-threatening hemorrhage or emergency surgery in patients with inhibitor levels &lt;10 Bethesda units or moderate inhibitor levels that have been reduced by plasmapheresis or immunoadsorption (",
"      <a class=\"graphic graphic_table graphicRef78059 \" href=\"mobipreview.htm?41/17/42267\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef51792 \" href=\"mobipreview.htm?16/16/16652\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with usual bleeding episodes who are high responders, inhibitor bypassing products are generally employed (eg, prothrombin complex concentrates, their activated counterparts, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/42/30373?source=see_link\">",
"       recombinant human factor VIIa",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_table graphicRef51792 \" href=\"mobipreview.htm?16/16/16652\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment with agents other than factor VIII'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inhibitor eradication (immune tolerance induction, ITI), requires routine administration of the deficient factor to",
"      <span class=\"nowrap\">",
"       reset/tolerize",
"      </span>",
"      the patient's immune system. A variety of ITI protocols exist utilizing a wide range of dosing regimens either with or without immunosuppressive therapy, or via the use of bypassing agents to suppress bleeding episodes. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Immune tolerance induction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/1\">",
"      Kempton CL, White GC 2nd. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 2009; 113:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/2\">",
"      White GC 2nd, Rosendaal F, Aledort LM, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/3\">",
"      Allain JP, Frommel D. Antibodies to factor VIII. V. Patterns of immune response to factor VIII in hemophilia A. Blood 1976; 47:973.",
"     </a>",
"    </li>",
"    <li>",
"     Feinstein DI. Inhibitors in hemophilia. In: : Basic Principles and Practice, 3rd ed, Hoffman R, Benz EJ Jr, Shattil SJ, et al. (Eds), Churchill Livingstone, New York 2000. p.1504.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/5\">",
"      Caram C, de Souza RG, de Sousa JC, et al. The long-term course of factor VIII inhibitors in patients with congenital haemophilia A without immune tolerance induction. Thromb Haemost 2011; 105:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/6\">",
"      Hoyer LW, Scandella D. Factor VIII inhibitors: structure and function in autoantibody and hemophilia A patients. Semin Hematol 1994; 31:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/7\">",
"      Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/8\">",
"      Rasi V, Ikkala E. Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 1990; 76:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/9\">",
"      Hay CR, Ludlam CA, Colvin BT, et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/10\">",
"      Fijnvandraat K, Turenhout EA, van den Brink EN, et al. The missense mutation Arg593 --&gt; Cys is related to antibody formation in a patient with mild hemophilia A. Blood 1997; 89:4371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/11\">",
"      Bray GL, Gomperts ED, Courter S, et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83:2428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/12\">",
"      McMillan CW, Shapiro SS, Whitehurst D, et al. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/13\">",
"      Sultan Y. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group. Thromb Haemost 1992; 67:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/14\">",
"      Hay CR, Palmer B, Chalmers E, et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117:6367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/15\">",
"      Prescott R, Nakai H, Saenko EL, et al. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood 1997; 89:3663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/16\">",
"      Healey JF, Barrow RT, Tamim HM, et al. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood 1998; 92:3701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/17\">",
"      Healey JF, Lubin IM, Nakai H, et al. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem 1995; 270:14505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/18\">",
"      Scandella D, Mattingly M, Prescott R. A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2. Blood 1993; 82:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/19\">",
"      Zhong D, Saenko EL, Shima M, et al. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood 1998; 92:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/20\">",
"      Arai M, Scandella D, Hoyer LW. Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 1989; 83:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/21\">",
"      Scandella D, Gilbert GE, Shima M, et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995; 86:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/22\">",
"      Jacquemin MG, Desqueper BG, Benhida A, et al. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood 1998; 92:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/23\">",
"      Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994; 269:11601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/24\">",
"      Lollar P, Parker ET, Curtis JE, et al. Inhibition of human factor VIIIa by anti-A2 subunit antibodies. J Clin Invest 1994; 93:2497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/25\">",
"      Lamphear BJ, Fay PJ. Factor IXa enhances reconstitution of factor VIIIa from isolated A2 subunit and A1/A3-C1-C2 dimer. J Biol Chem 1992; 267:3725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/26\">",
"      O'Brien LM, Medved LV, Fay PJ. Localization of factor IXa and factor VIIIa interactive sites. J Biol Chem 1995; 270:27087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/27\">",
"      Lacroix-Desmazes S, Moreau A, Bonnemain C, et al. Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat Med 1999; 5:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/28\">",
"      Lacroix-Desmazes S, Bayry J, Misra N, et al. The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N Engl J Med 2002; 346:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/29\">",
"      Schwaab R, Brackmann HH, Meyer C, et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/30\">",
"      Santagostino E, Mancuso ME, Rocino A, et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/31\">",
"      Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109:4648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/32\">",
"      Antonarakis SE, Rossiter JP, Young M, et al. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood 1995; 86:2206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/33\">",
"      Kemball-Cook G, Tuddenham EG, Wacey AI. The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4. Nucleic Acids Res 1998; 26:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/34\">",
"      Goodeve AC, Williams I, Bray GL, Peake IR. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group. Thromb Haemost 2000; 83:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/35\">",
"      Gouw SC, van den Berg HM, Oldenburg J, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012; 119:2922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/36\">",
"      Green PM, Bagnall RD, Waseem NH, Giannelli F. Haemophilia A mutations in the UK: results of screening one-third of the population. Br J Haematol 2008; 143:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/37\">",
"      Jacquemin M, Vantomme V, Buhot C, et al. CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood 2003; 101:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/38\">",
"      Gill JC. The role of genetics in inhibitor formation. Thromb Haemost 1999; 82:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/39\">",
"      Eckhardt CL, Menke LA, van Ommen CH, et al. Intensive peri-operative use of factor VIII and the Arg593--&gt;Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. J Thromb Haemost 2009; 7:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/40\">",
"      Hay CR, Ollier W, Pepper L, et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 1997; 77:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/41\">",
"      Pavlova A, Delev D, Lacroix-Desmazes S, et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost 2009; 7:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/42\">",
"      Astermark J, Oldenburg J, Pavlova A, et al. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107:3167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/43\">",
"      Astermark J, Wang X, Oldenburg J, et al. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/44\">",
"      Lu Y, Ding Q, Dai J, et al. Impact of polymorphisms in genes involved in autoimmune disease on inhibitor development in Chinese patients with haemophilia A. Thromb Haemost 2012; 107:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/45\">",
"      Astermark J, Oldenburg J, Carlson J, et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108:3739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/46\">",
"      Lorenzo JI, L&oacute;pez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001; 113:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/47\">",
"      van der Bom JG, Mauser-Bunschoten EP, Fischer K, van den Berg HM. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost 2003; 89:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/48\">",
"      Rivard GE, Lillicrap D, Poon MC, et al. Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age? Haemophilia 2005; 11:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/49\">",
"      Kempton CL, Soucie JM, Miller CH, et al. In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. J Thromb Haemost 2010; 8:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/50\">",
"      Astermark J, Berntorp E, White GC, et al. The Malm&ouml; International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/51\">",
"      Carpenter SL, Michael Soucie J, Sterner S, et al. Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database. Haemophilia 2012; 18:e260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/52\">",
"      Viel KR, Ameri A, Abshire TC, et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009; 360:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/53\">",
"      Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010; 8:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/54\">",
"      Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/55\">",
"      Franchini M, Tagliaferri A, Mengoli C, Cruciani M. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Crit Rev Oncol Hematol 2012; 81:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/56\">",
"      Gouw SC, van der Bom JG, Ljung R, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/57\">",
"      Mancuso ME, Mannucci PM, Rocino A, et al. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A. J Thromb Haemost 2012; 10:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/58\">",
"      Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 1998; 19:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/59\">",
"      Bacon CL, Singleton E, Brady B, et al. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE&reg;). Haemophilia 2011; 17:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/60\">",
"      Gouw SC, van der Bom JG, Auerswald G, et al. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109:4693.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.clinicaltrials.gov/ct2/show/record/NCT01064284 (Accessed on January 25, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/62\">",
"      Peerlinck K, Arnout J, Di Giambattista M, et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/63\">",
"      Spiegel PC Jr, Stoddard BL. Optimization of factor VIII replacement therapy: can structural studies help in evading antibody inhibitors? Br J Haematol 2002; 119:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/64\">",
"      Iorio A, Puccetti P, Makris M. Clotting factor concentrate switching and inhibitor development in hemophilia A. Blood 2012; 120:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/65\">",
"      Astermark J, Donfield SM, Gomperts ED, et al. The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood 2013; 121:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/66\">",
"      ter Avest PC, Fischer K, Mancuso ME, et al. Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice. J Thromb Haemost 2008; 6:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/67\">",
"      Morfini M, Haya S, Tagariello G, et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/68\">",
"      Kasper CK, Aledort L, Aronson D, et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/69\">",
"      Verbruggen B, Novakova I, Wessels H, et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/70\">",
"      Krudysz-Amblo J, Parhami-Seren B, Butenas S, et al. Quantitation of anti-factor VIII antibodies in human plasma. Blood 2009; 113:2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/71\">",
"      Kulkarni R, Aledort LM, Berntorp E, et al. Therapeutic choices for patients with hemophilia and high-titer inhibitors. Am J Hematol 2001; 67:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/72\">",
"      Hay CR, Baglin TP, Collins PW, et al. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). Br J Haematol 2000; 111:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/73\">",
"      Hay CR, Brown S, Collins PW, et al. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/74\">",
"      Gringeri A, Mantovani LG, Scalone L, et al. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102:2358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/75\">",
"      Lusher JM. Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors--benefits and limitations. Semin Hematol 1994; 31:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/76\">",
"      Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/77\">",
"      Uehlinger J, Button GR, McCarthy J, et al. Immunoadsorption for coagulation factor inhibitors. Transfusion 1991; 31:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/78\">",
"      Hay C, Lozier JN. Porcine factor VIII therapy in patients with factor VIII inhibitors. Adv Exp Med Biol 1995; 386:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/79\">",
"      Hay CR, Lozier JN, Lee CA, et al. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey. Thromb Haemost 1996; 75:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/80\">",
"      Brettler DB, Forsberg AD, Levine PH, et al. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. Arch Intern Med 1989; 149:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/81\">",
"      Negrier C, Goudemand J, Sultan Y, et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/82\">",
"      Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981; 305:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/83\">",
"      Lusher JM, Blatt PM, Penner JA, et al. Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood 1983; 62:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/84\">",
"      Hough RE, Hampton KK, Preston FE, et al. Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors. Br J Haematol 2000; 111:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/85\">",
"      Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 2010; 116:5734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/86\">",
"      Leissinger C, Gringeri A, Antmen B, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/87\">",
"      Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost 1999; 82:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/88\">",
"      Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/89\">",
"      Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/90\">",
"      Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 2002; 42:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/91\">",
"      O'Connell N, Mc Mahon C, Smith J, et al. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors. Br J Haematol 2002; 116:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/92\">",
"      Santagostino E, Morfini M, Rocino A, et al. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 2001; 86:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/93\">",
"      Ludlam CA, Smith MP, Morfini M, et al. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol 2003; 120:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/94\">",
"      Smith MP, Ludlam CA, Collins PW, et al. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Thromb Haemost 2001; 86:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/95\">",
"      Ewenstein BM. Continuous infusion of recombinant factor VIIa: continue or not? Thromb Haemost 2001; 86:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/96\">",
"      Pruthi RK, Mathew P, Valentino LA, et al. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial. Thromb Haemost 2007; 98:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/97\">",
"      Santagostino E, Mancuso ME, Rocino A, et al. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/98\">",
"      Kavakli K, Makris M, Zulfikar B, et al. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006; 95:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/99\">",
"      Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008; 14:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/100\">",
"      Shapiro AD. Single-dose recombinant activated factor VII for the treatment of joint bleeds in hemophilia patients with inhibitors. Clin Adv Hematol Oncol 2008; 6:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/101\">",
"      Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/102\">",
"      Hoots WK, Ebbesen LS, Konkle BA, et al. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 2008; 14:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/103\">",
"      Huth-K&uuml;hne A, Baudo F, Collins P, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009; 94:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/104\">",
"      Ingerslev J, S&oslash;rensen B. Parallel use of by-passing agents in haemophilia with inhibitors: a critical review. Br J Haematol 2011; 155:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/105\">",
"      Teitel J, Berntorp E, Collins P, et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007; 13:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/106\">",
"      Hay CR, DiMichele DM, International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/107\">",
"      Kurth M, Puetz J, Kouides P, et al. The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience. J Thromb Haemost 2011; 9:2229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/108\">",
"      Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/109\">",
"      Ewing NP, Sanders NL, Dietrich SL, Kasper CK. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. JAMA 1988; 259:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/110\">",
"      Reipert BM, van Helden PM, van den Helden PM, et al. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors. Br J Haematol 2007; 136:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/111\">",
"      Waters B, Lillicrap D. The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J Thromb Haemost 2009; 7:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/112\">",
"      Nilsson IM, Berntorp E, Zettervall O, Dahlb&auml;ck B. Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients. Blood 1990; 75:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/113\">",
"      Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee. Thromb Haemost 1994; 72:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/114\">",
"      Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/115\">",
"      DiMichele DM, Kroner BL, North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/116\">",
"      Coppola A, Di Minno MN, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol 2010; 150:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/117\">",
"      Coppola A, Margaglione M, Santagostino E, et al. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost 2009; 7:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/118\">",
"      Dunkley S, Kershaw G, Young G, et al. Rituximab treatment of mild haemophilia A with inhibitors: a proposed treatment protocol. Haemophilia 2006; 12:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/119\">",
"      Chuansumrit A, Husapadol S, Wongwerawattanakoon P, et al. Rituximab as an adjuvant therapy to immune tolerance in a haemophilia A boy with high inhibitor titre. Haemophilia 2007; 13:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/120\">",
"      Alexander S, Hopewell S, Hunter S, Chouksey A. Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis. J Pediatr Hematol Oncol 2008; 30:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/121\">",
"      Collins PW, Mathias M, Hanley J, et al. Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort. J Thromb Haemost 2009; 7:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/122\">",
"      Kempton CL, Allen G, Hord J, et al. Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A. Am J Hematol 2012; 87:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/123\">",
"      Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/124\">",
"      Shapiro AD, Ragni MV, Lusher JM, et al. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B. Thromb Haemost 1996; 75:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/125\">",
"      Giannelli F, Choo KH, Rees DJ, et al. Gene deletions in patients with haemophilia B and anti-factor IX antibodies. Nature 1983; 303:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/126\">",
"      Warrier I, Ewenstein BM, Koerper MA, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997; 19:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/127\">",
"      Ljung RC. Gene mutations and inhibitor formation in patients with hemophilia B. Acta Haematol 1995; 94 Suppl 1:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/128\">",
"      Parquet A, Laurian Y, Rothschild C, et al. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate. Thromb Haemost 1999; 82:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/129\">",
"      DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007; 138:305.",
"     </a>",
"    </li>",
"    <li>",
"     Green P. A database of point mutations and short additions and deletions in the Factor IX gene. Version 13, 2004. Available at: www.kcl.ac.uk/ip/petergreen/haemBdatabase.html (Accessed on August 06, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/131\">",
"      Barthels M. Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors. Thromb Res 1999; 95:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/132\">",
"      Mizon P, Goudemand J, Jude B, Marey A. Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor. Ann Hematol 1992; 64:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/133\">",
"      Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 1998; 4:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/134\">",
"      Dharnidharka VR, Takemoto C, Ewenstein BM, et al. Membranous glomerulonephritis and nephrosis post factor IX infusions in hemophilia B. Pediatr Nephrol 1998; 12:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/135\">",
"      Klarmann D, Martinez Saguer I, Funk MB, et al. Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor. Haemophilia 2008; 14:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/136\">",
"      Thorland EC, Drost JB, Lusher JM, et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 1999; 5:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/137\">",
"      Chitlur M, Warrier I, Rajpurkar M, Lusher JM. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia 2009; 15:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/56/36746/abstract/138\">",
"      Tengborn L, Hansson S, Fasth A, et al. Anaphylactoid reactions and nephrotic syndrome--a considerable risk during factor IX treatment in patients with haemophilia B and inhibitors: a report on the outcome in two brothers. Haemophilia 1998; 4:854.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1308 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-06EB330AA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_56_36746=[""].join("\n");
var outline_f35_56_36746=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10846052\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INHIBITORS IN HEMOPHILIA A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15594486\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15594922\">",
"      - Proteolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Predisposing factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15593790\">",
"      - Severity of hemophilia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15593797\">",
"      - Age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Race",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15593804\">",
"      - Replacement product",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H847653\">",
"      - Immunologic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Risk score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diagnosis and screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Active bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Perioperative management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - High purity factor VIII concentrates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Porcine factor VIII concentrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT WITH AGENTS OTHER THAN FACTOR VIII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Activated prothrombin complex concentrates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23392928\">",
"      - Prophylactic use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Recombinant human factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Initial dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - High-dose regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Prophylactic use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Activated PCC versus recombinant factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17045677\">",
"      - Activated PCC plus recombinant factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      IMMUNE TOLERANCE INDUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Specific regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Use of rituximab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      INHIBITORS IN HEMOPHILIA B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Active bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Immune tolerance induction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Anaphylactoid reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10846052\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1308\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1308|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/16/16652\" title=\"table 1\">",
"      Overview Rx fVIII inhibitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/17/42267\" title=\"table 2\">",
"      Emergency Rx fVIII inhibitor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24650?source=related_link\">",
"      Acquired inhibitors of coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22824?source=related_link\">",
"      Biology and normal function of factor VIII and factor IX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/18/1322?source=related_link\">",
"      Clinical manifestations and diagnosis of hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5112?source=related_link\">",
"      Overview of genetic variation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31962?source=related_link\">",
"      Therapeutic uses of recombinant coagulation factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38442?source=related_link\">",
"      Treatment of hemophilia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_56_36747="Cerebrospinal fluid biochemical markers";
var content_f35_56_36747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cerebrospinal fluid biochemical markers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Marker",
"       </td>",
"       <td class=\"subtitle1\">",
"        Associated malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beta 2 microglobulin",
"       </td>",
"       <td>",
"        Lymphoma, infection, other tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beta glucuronidase",
"       </td>",
"       <td>",
"        Nonspecific",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CEA",
"       </td>",
"       <td>",
"        Colon, ovarian, breast, bladder, lung",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CA-125",
"       </td>",
"       <td>",
"        Ovarian",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CA-15-3",
"       </td>",
"       <td>",
"        Breast",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CA19-9",
"       </td>",
"       <td>",
"        Adenocarcinoma, biliary disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CK -BB",
"       </td>",
"       <td>",
"        Small cell lung cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GFAP",
"       </td>",
"       <td>",
"        Glioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HCG subunit",
"       </td>",
"       <td>",
"        Choriocarcinoma, embryonal and germ cell tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-HIAA",
"       </td>",
"       <td>",
"        Carcinoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgM",
"       </td>",
"       <td>",
"        Myeloma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LDH isoenzyme D",
"       </td>",
"       <td>",
"        Carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PSA",
"       </td>",
"       <td>",
"        Prostate",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alexis Demopoulos, MD, and Jerome Posner, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_56_36747=[""].join("\n");
var outline_f35_56_36747=null;
var title_f35_56_36748="Antidepressant warning";
var content_f35_56_36748=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Class suicidality labeling language for antidepressants - 2007 revisions indicating increased suicidality in young adults and emphasizing that depression itself is the largest risk factor for suicide",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Black box warning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Suicidality and antidepressant drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of",
"        <strong>",
"         [Insert established name]",
"        </strong>",
"        or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         [Insert Drug Name]",
"        </strong>",
"        is not approved for use in pediatric patients. [The previous sentence would be replaced with the sentence, below, for the following drugs:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Prozac: Prozac is approved for use in pediatric patients with MDD and obsessive compulsive disorder (OCD).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Zoloft: Zoloft is not approved for use in pediatric patients except for patients with obsessive compulsive disorder (OCD).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Fluvoxamine: Fluvoxamine is not approved for use in pediatric patients except for patients with obsessive compulsive disorder (OCD).]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        (See Warnings: Clinical Worsening and Suicide Risk, Precautions: Information for Patients, and Precautions: Pediatric Use.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Warnings: Clinical worsening and suicide risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ...The pooled analyses of placebo-controlled trials in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs placebo), however, were relatively stable within age strata and across indications...",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     www.fda.gov/cder/drug/antidepressants/SSRIlabelChange.htm. (January 2, 2009)",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_56_36748=[""].join("\n");
var outline_f35_56_36748=null;
var title_f35_56_36749="Gemcitabine for metastatic pancreatic and biliary tract cancer";
var content_f35_56_36749=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F60330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F60330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Gemcitabine for metastatic pancreatic and biliary tract cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"4\">",
"        Cycle length: 8 weeks for first cycle, then&nbsp;4 weeks.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration schedule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Gemcitabine",
"        </strong>",
"        *",
"       </td>",
"       <td>",
"        1000 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 100 mL normal saline (concentration no greater than 40 mg/mL) and administer over 30 to 60 minutes.",
"       </td>",
"       <td>",
"        Weekly for seven weeks followed by one week of rest in the first cycle, then weekly for three weeks followed by one week of rest in all subsequent cycles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        LOW. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with granulocyte colony stimulating factors not indicated (incidence of neutropenic fever &lt;1 percent",
"        <sup>",
"         [1-4]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        A lower starting dose may be needed for patients with liver impairment. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess basic metabolic panel (including serum creatinine) and liver function tests prior to each cycle and otherwise as indicated during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        This regimen should not be initiated unless the white blood cell count is greater than 3500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelets are greater than or equal to 100,000 cells/mm",
"        <sup>",
"         3[1]",
"        </sup>",
"        . During therapy, the dose of gemcitabine should be decreased by 25 percent if the absolute neutrophil count decreases to &lt;1000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        but &ge;500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        , or the platelets decrease to &lt;100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        and &ge;50,000/mm",
"        <sup>",
"         3[5]",
"        </sup>",
"        . The US FDA approved product information recommends holding gemcitabine for an&nbsp;absolute neutrophil count&nbsp;&lt;500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        or platelets &lt;50,000/mm",
"        <sup>",
"         3[5]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hepatotoxicity:",
"        </strong>",
"        Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear dose recommendations in these patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hemolytic-uremic syndrome (HUS):",
"        </strong>",
"        In clinical trials, HUS was reported in 0.25 percent of patients receiving gemcitabine. Consider diagnosis if the patient develops hemolysis and severe thrombocytopenia, with or without renal failure or central nervous system findings. Discontinue gemcitabine immediately and permanently. Refer to UpToDate topic on \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Pulmonary toxicity:",
"        </strong>",
"        A variety of manifestations of pulmonary toxicity have been reported. Discontinue gemcitabine immediately and permanently. Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count.",
"     <br>",
"      * In the original protocol, the gemcitabine dose could be increased by 25 percent up to, but not exceeding, a dose of 1250 mg/m",
"      <sup>",
"       2",
"      </sup>",
"      after the first cycle, provided the absolute neutrophil count and platelets exceed 1500 cells/mm",
"      <sup>",
"       3",
"      </sup>",
"      and 100,000/mm",
"      <sup>",
"       3",
"      </sup>",
"      , respectively, and nonhematologic toxicity was less than or equal to WHO Grade 1",
"      <sup>",
"       [1]",
"      </sup>",
"      .",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Burris HA, et al. J Clin Oncol 1997; 15:2403.",
"       </li>",
"       <li>",
"        Oettle H, et al. Ann Oncol 2005; 16:1639.",
"       </li>",
"       <li>",
"        Stathopoulos GP, et al. Br J Cancer 2006; 95:587.",
"       </li>",
"       <li>",
"        Herrmann R, et al. J Clin Oncol 2007; 25:2212.",
"       </li>",
"       <li>",
"        Gemzar (gemcitabine hydrochloride). US FDA approvedmanufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 28, 2011).",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_56_36749=[""].join("\n");
var outline_f35_56_36749=null;
var title_f35_56_36750="BNP and survival ValHeFT";
var content_f35_56_36750=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Plasma BNP concentration predicts survival in patients with HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 423px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In an analysis from the Val-HeFT trial, patients with NYHA class II to III heart failure (HF) were stratified according to quartiles of plasma concentration of brain natriuretic peptide (BNP). The mortality rates at two years after randomization were significantly higher in higher quartiles of plasma BNP.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Anand IS, Fisher LD, Chiang YT, et al. Circulation 2003; 107:1278.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_56_36750=[""].join("\n");
var outline_f35_56_36750=null;
var title_f35_56_36751="Topical pain control in children";
var content_f35_56_36751=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 595px\">",
"   <div class=\"ttl\">",
"    Algorithm for topical anesthetic use* in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 575px; height: 490px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IV: intravenous; LP: lumbar puncture.",
"     <br>",
"      * For example: Lidocaine/prilocaine 2.5 percent/2.5 percent (EMLA&reg;); Liposomal lidocaine 4 percent (LMX",
"      <sub>",
"       4",
"      </sub>",
"      &reg;); Tetracaine gel (40 mg tetracaine per 1 g of gel, Ametop&reg;). Tetracaine gel is an ester-type local anesthetic that is not available in the USA.",
"      <br>",
"       &bull; For patients with an emergent need for a procedure or with non-intact skin, infiltrative anesthetic is suggested. For patients with an allergy to amide anesthetics, (see \"Allergic reactions to local anesthetics\").",
"       <br>",
"        &Delta; Methemoglobinemia is only a contraindication for lidocaine/prilocaine (EMLA&reg;). (See \"Clinical features, diagnosis, and treatment of methemoglobinemia\").",
"        <br>",
"         &loz; Topical anesthetic should be applied as soon as the need for a procedure is evident. (See \"Topical anesthetics in children\", section on Standing orders).",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Zempsky, WT, Cravero, JP, Committee on Pediatric Emergency Medicine, and Section on Anesthesiology and Pain Medicine. Relief of pain and anxiety in pediatric patients in emergency medical systems. Pediatrics 2004; 114:1348.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_56_36751=[""].join("\n");
var outline_f35_56_36751=null;
